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Cancer of the uterine cervix represents the second most common cancer in femnlcs 
worldwide and is a major cause of morbidity and mortality. In 2006, 9,710 women were 
diagnosed with cervical cancer and 3,700 women died from the disease in U.S.A 
Worldwide, morbidity and mortality rates are far higher with an incidence of 4,90,000 
new cases and 2,73,000 deaths occurring in 2005, according to the World Health 
Organization. About 80 percent cf these cases occur in developing countries. High-risk 
HPV infection is the primary risk factor for the development of cervical carcinoma. Over 
90% of cancers of the uterine cervix contain high-risk HPV DNA. 
The current hypothesis for induction of uterine cervical tumors by HPV is that during the 
course of viral infection, the HPV genome randomly becomes integrated into the host's 
genome. If the integration of th^viral genome results in disruption of the viral E2 gene. 
then there is a loss of its control over expression of viral oncoproteins E6 and E7. 
Uncontrolled expression of these two proteins is a consequence, and E6 and E7 interfere 
with functions of tumor suppressor proteins which control both the cell cycle and 
apoptosis, resulting in initiation of pre-cancerous lesions and cancer. E6 protein binds to 
p53 via the E6-Ap protein (a host cell ubiquitin ligase) and facilitates the degradation of 
p53 through the ubiquitin proteasome pathway. This dramatically decreases the half-life 
of the p53 tumor suppressor protein in infected cells, and p53-mediated regulation of the 
cell cycle is lost. In addition to the loss of p53 protein, the overexpression of E6 and E7 
proteins facilitates uncontrolled proliferation of the infected cell through the activation of 
cellular cyclins E and A. E7 protein also interferes with the functions of the cellular 
tumor suppressor protein retinoblastoma (pRB). Viral E7 protein binds to pRb and 
inhibits the interaction of pRB with E2F and other factors associated with the cell cycle. 
High risk E6 and E7 proteins are usually coexpressed within infected cells. By 
simultaneous disruption of the functions of the functions of key cellular tumor 
suppressors p53 and pRb, high-risk HPV E6 and E7 proteins immortalize and transform 
human cells, setting the stage for cancer progression. 
The standard first line treatment for invasive cervical cancer is usually cisplalin (Platinol) 
and 5-fluorouracil (5-FU, Adrucil, Efude.x) used in combination and in addition to 
radiation. Recurrent and late stage cervical cancers are often treated with a combination 
of platinum, bleomycin, methotrexate, and 5-FU. Chemotherapy is administered 
intravenously, through injection, or in pill form and side effects often accompany 
treatment and may be severe; which can include nausea, vomiting, diarrhea, and 
leukopenia (low white blood cell count). Most of these side effects are a result of drug 
toxicity to healthy tissues such as skin, hair follicles, and epithelial cells that line the 
digestive tract and patient tumo's can develop resistance to these therapies as well. 
Hence, there is a need to develop alternate, safer, less toxic, and more specific therapies 
for uterine cervical cancer. 
Some of the most successful currently used anticancer drugs are extracts or derivatives of 
compounds from plants or other natural products. These include the advance class of 
drugs known as taxanes (Paclit£.xel, Docetaxel) that come from the yew tree {Taxus 
baccata), and the vinca alkaloids (Vincristine, Vinblastine, Vinorelbinej which are 
derivatives from the periwinkle piant {Catharanthus roseus). These compounds affect the 
growth of all rapidly dividing cells, whether normal or malignant, and like other drugs, 
are associated with significant toxicity and side effects. Millions of research dollars each 
year go to the discc'very of new natural pioducts with limited side effects that may be 
used as effective antitumor agents. Some compounds that are currently being 
investigated are components of dietary plants. Epidemiological observations and 
laboratory studies, both in cell culture and animal models have indicated anticarcinogenic 
potential of garlic and its constituents, which has been traditionally used for varied 
human ailments around the world. 
Garlic {Alliitm sativum L.) is a widely consumed herb in foodstuffs and medicines. It has 
been reported to reduce chemically induced esophageal, skin, pulmonary, stomach, 
breast, uterine cervix, colon, mammary and lung tumor. The anticarcinogenic/ 
antitumorgenic effects of garlic and its organosulfur compounds have been attributed not 
only to the modulation of the antioxidation and/or drug-metabolizing enzyme (Phase I 
and II) system, but also to the reduction of cell proliferation and induction of apoptosis 
for tumor cells. Allicin, the major component present in freshly crushed garlic, is one of 
the most biologically active compounds of garlic. Allicin is formed from alliin by the 
action of allinase and gets metabolized rapidly into diallyl sulfide, diallyl disulfide, 
diallyl trisulfide, ajoene, S-allylmercaptocysteine, S-allylcysteine and vinyl dithiines. 
Allicin is readily permeable through phospholipid membranes aiding its biological 
activity, but its unstable nature raises the question whether all the effects of Allicin 
observed are due to Allicin itself or its metabolites. Indeed, its metabolites, .S'-all\l 
mercaptocysteine, diallyl sulfide, diallyl disulfide, diallyl trisulflde. ajoene and >S'-allyl 
cysteine have been shown to possess an anticancer activity, which varies depending on 
the agent and the experimental model. 
Earlier studies have shown that garlic-derived OSCs can suppress growth of cancer cells 
of different anatomical locations in association v/ith cell cycle arrest. Garlic-derived 
OSCs have also been shown to modulate a number of key elements in cellular signal 
transduction pathways linked to the apoptotic process. Therefore, the central aim of the 
current study was to investigate and evaluate the effect of Allicin, an organosulliir 
compound of garlic, on cervical cancer HeLa cell line and monocytes from cervical 
cancer patients. First of all, bearing in mind the previous reports of antiproliferative and 
apoptotic properties of Allicin on different cancer cell lines, various experiments were 
carried out to check the efficacy of Allicin to inhibit the proliferation of cervical cancer 
HeLa cells. In addition to this, anti-inflammatory property of Allicin was also verified by 
performing different experiments on monocytes isolated from the blood of cervical 
cancer patients. 
First, we investigated the effect af Allicin on HPV 18 positive cervical cancer HeLa cell 
line. Our results illustrated that Allicin strongly suppressed the proliferation of HeLa cells 
in a dose- and time-dependent manner. Furthermore, we also observed Allicin-induced 
cell cycle arrest in HeLa cells at GQ/GI phase along with a sub-Go/Gi population 
suggesting that certain amount of cells underwent apoptosis which was further confirmed 
by the result of FITC-Annexin V Assay. Thus, antiproliferative action of Allicin in HeLa 
cells could be attributed to cell cycle arrest and apoptosis. Therefore, the above combined 
results demonstrated that Allicin treatment caused a significant decrease in the percentage 
of viable cell along with a concurrent induction of apoptosis in cervical cancer HeLa 
cells; however, the percentage of apoptotic cells did not coincide with the percent of 
viable cells. This difference in cell viability and apoptosis could be due lo cell c)clc 
arrest at Go/Gi phase induced by Allicin. 
The mitochondrial apoptotic pathway (intrinsic pathway) is largely mediated through 
Bcl-2 family proteins, which include both proapoptotic members such as Bax, Bak and 
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BNIP3 that promote mitochondrial permeabihty and antiapoptotic members such as Bcl-2 
and Bcl-xL that inhibit their effects, or inhibit the mitochondrial release of cytochrome c. 
Another important component is the tumor suppressor protein p53, which simultaneously 
suppresses Bcl-2 and activates Bax. The ratio of EJax to Bcl-2 is critical to cell survival 
which determines whether a cell undergo apoptosis. In response to proapopioiic signals. 
Bax translocates to the mitochondria where it oligomerizcs into a heteromeric protein 
channel which releases apoptotic factors, such as cytochrome c. Cytochrome c leakage 
supports the formation of an apoptosome complex by binding to apoptotic protease 
activating factor-1 (Apaf-1), which activates the caspase-9 molecules (upon cleavage of 
the bound zymogen procaspases-9), which in turn activate caspase-3 to initiate apoptosis. 
Caspase-3 is one of the key executioners of apoptosis, being responsible either partially 
or totally for the proteolytic cleavage of many key proteins, such as the nuclear enzyme 
PARP, followed by DNA fragmentation. In the current study, considering the previous 
reports on garlic and its organosulfur compounds, we further explored the involvement of 
mitochondrial apoptotic pathway in Allicin-induced apoptosis in HeLa cells. Our 
Western blot results showed that Allicin induced mitochondrial release of cytochrome c. 
Moreover, Allicin treated HeLa cells also exhibited an augmented caspase-9 and -3 
activities which were found to be dose dependent. Likewise, Western blot results also 
showed cleavage and activation of procaspase-9 and -3 which further confirmed our 
finding of enhanced caspase-9 and -3 activities. Pretreating HeLa cells with caspase 
inhibitors Z-VAD-FMK, Z-DEVD-FMK (caspase-9 inhibitor) and Z-LEHD-FMK 
(caspase-3 inhibitor) completely abrogated Allicin-induced caspase activation and cell 
proliferation. Furthermore, we also demonstrated Allicin-induced PARP cleavage in 
HeLa cells and cleaved product of 89 KDa was found to be evident in Western blot. 
Similarly, results of Western blot analysis also revealed an upregulated Bax and 
downregulated Bcl-2 protein expressions in Allicin-treated HeLa cells. 
The mitochondrial apoptotic pathway (intrinsic pathway) is also regulated by the 
mitochondrial permieability transition pore (mPTP). Cyclosporin A (CsA) is an inhibitor 
of cyclophilin D and blocks the formation of the mPTP and prevents its opening which 
lead to inhibition of mitochondrial membrane depolarization and Bax translocation to 
mitochondria. This ultimately suppresses release of cytochrome c from mitochondria and 
IV 
in turn caspase activation whicli play important role in apoptosis. Therefore, in the 
current study, the effect of CsA pretreatment on Allicin-induced suppression of 
proliferation and apoptosis of HeLa cells was also investigated. Our results showed that 
CsA pretreatment of HeLa cells inhibited Allicin-induced growth suppression and coll 
death, corroborating the central role of mitochondria in the apoptotic process induced by 
Allicin. Furthermore, Allicin induced a cell cycle arrest at Go/Gi in HeLa cells. Upon 
CsA pretreatment, the percentages of cells at GQ/GI remain unchanged. So, it can be 
deduced from this result that the effect of Allicin on cell c>cle arrest was independent of 
its proapoptotic activity. 
Glutathione is the major regulator of the thiol-disulfide redox state of living cells. 
Alterations in cellular free thiols have already been described as a key event in the 
generation of apoptosis. Glutathione (GSH), cysteine and accessible free sultliydryl (-SH) 
groups of various proteins and peptides are rapidly oxidized by Allicin to their respective 
Allyl disulfide derivatives. In the present study, the effect of Allicin on cellular GSH 
content and total free thiol (-SH) content of cytosol and mitochondria was also examined. 
Our results showed that Allicin induced an initial drop in GSH levels that was followed 
by a regeneration process, occurring several hours after treatment. This may be due to 
decreased feedback inhibition of GSH biosynthetic enzyme such as y-glutamylcysieine 
synthetase (y-GCS) by GSH. In addition, Allicin also caused GSH depletion 
concomitantly in the cytosol and mitochondria in HeLa cells. The rate of free -SH 
depletion from the cytosol and the mitochondria was similar, indicating that Allicin 
penetrated the mitochondria and the cell membrane equally well and reacted with free -
SH in both compartments. Furthermore, in Buthionine sulfoximine (BSO)-pretreated 
cells, there was no recovery of GSH after its Allicin-induced depletion, as BSO is a direct 
inhibitor of y-GCS. Since BSO-induced depletion of GSH levels caused neither 
mitochondrial permeability transition nor apoptosis (no effect on cell survival), it is likely 
that BSO treatment depletes GSH mainly from the cytosol, whereas Allicin induced 
depletion of mitochondrial GSH trigger the apoptotic process. 
N-acetylcystein^'s (NAC) primary function in vivo is to supply cysteine necessary for 
GSH synthesis and replenishment. It can also reduce disulphide bonds in proteins and 
scavenge free radicals. In this study, we also investigated the effect of NAC pretreatment 
on Allicin-induced growth inhibition and apoptosis of HeLa cells. Our results showed 
that simultaneous treatment of HeLa cells with NAC and Allicin abrogated the 
antiproliferative and apoptotic activity of Allicin. Furthermore, the cell cycle arrest 
induced by Allicin at GQ/GI phase was also shown to be abolished by NAC. The results 
observed could be due to NAC's key role to provide cysteine for GSH synthesis and 
replenishment depleted by Allicin. 
HPV oncoproteins E6 and E7 can disturb cell cycle regulation and impede apoptosis by 
binding to two tumor suppressor proteins, p53 and pRb, respectively which results in 
cellular immortalization and transformation. In the current study, we also investigated the 
effect of Allicin on E6, E7 and p53 expression in HeLa cells. Strikingly, our results have 
revealed that Allicin strongly inhibited the expression of HPV 18 E6 and E7 oncoproteins 
in cervical cancer HeLa cells. This downregulation of E6 and E7 expression could result 
in cessation of cervical cancer cell growth. Furthermore, the expression of p53 tumor 
suppressor protein in Allicin treated HeLa cells was also found to be upregulated. In 
other words, Allicin could restore the function of p53 and disrupt the £6/p53 pathway 
which plays a vital role in cervical carcinogenesis. Since p53 simultaneously suppresses 
anti-apoptotic Bcl-2 and activates apoptotic Bax, its increased expression and restoration 
of function could also assist in programmed cell death induced by Allicin in cervical 
cancer cells. 
Monocytes play an important role in the initiation, development, and outcome of the 
immune response. Immune responses and inflammatory reactions mediated by monocytes 
are regulated not only positively by cellular recruitment, proliferation, and cross-talk, but 
also negatively by apoptosis of monocytes. So, in the present study, we further 
investigated the effect of A'licin on survival of monocytes isolated from cervical cancer 
patients. Strikingly, findings of the current study demonstrated that Allicin strongly 
induced apoptosis in monocytes of cervical cancer patients. Because the regulation of 
monocytic apoptosis has a great importance in the regulation of inflammation, this might 
be one of the mechanisms of Allicin's anti-inflammatory effects. 
Previous studies have shown that several proinflammatory cytokines (IL-la. IL-6, or 
TNF-a) stimulate proliferation of carcinoma cell lines derived from several different 
tissues including cervix. Thus, these proinflammatory cytokines might act as paracrine or 
autocrine growth factors in promoting malignant progression of cervical cancer. 
Surprisingly, results of the present study showed an augmented expression of 
proinflammatory cytokines TNF-a, IL-la and IL-6 in monocytes from cervical cancer 
patients. Furthermore, expressions of these proinflammatory cytokines in monocytes 
were shown to be suppressed by Allicin treatment. So, our above results indicated that 
suppression of proinflammatory cytokines such as TNF-a, IL-la and lL-6 by Allicin 
could alter the local microenvironment of cervical tumor leading to malignant 
progression. 
In summary, the combined results of the present study established that Allicin. an 
organosulfur compound of garlic {Allium sativum), has a potent antiproliferative and 
apoptotic properties against cervical cancer HeLa cell line. Allicin-induced growth 
inhibitory action in HeLa cells involved the cell cycle arrest and apoptosis involved the 
activation of caspase-9 and -3 as well as release of cytochrome c from mitochondria, 
downregulation of antiapoptotic BcI-2 and upregulation of apoptotic Bax and p53. 
Interestingly, Allicin also suppressed the expression of HPV E6 and E7 oncoproteins 
implicated in cervical carcinogenesis. In addition, Allicin also induced apoptosis and 
suppressed the augmented expression of proinflammatory cytokines TNF-a, IL-la and 
IL-6 in monocytes of cervical cancer patients. Thus, it could be concluded that in view ol' 
the above antiproliferative, apoptotic and anti-inflammatory properties. Allicin could be a 
promising chemotherapeutic agent in prevention of cervical cancer. 
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Cancer of the uterine cervix represents the second most common cancer in females 
worldwide and is a major cause of morbidity and mortality, in 2006, 9,710 women were 
diagnosed with cervical cancer and 3,700 women died from the disease in U.S.A. 
Worldwide, morbidity and mortality rates are far higher with an incidence of 4,90.000 
new cases and 2,73,000 deaths occurring in 2005, according to tlie World Health 
Organization. About 80 percent of these cases occur in developing countries. High-risk 
HPV infection is the primary risk factor for the development of cervical carcinoma. Over 
90% of cancers of the uterine cervix contain high-risk HPV DNA. 
The current hypothesis for induction of uterine cervical tumors by HPV is that during the 
course of viral infection, the HPV genome randomly becomes integrated into the host"s 
genome. If the integration of the viral genome results in disruption of the viral E2 gene, 
then there is a loss of its control over expression of viral oncoproteins E6 and E7. 
Uncontrolled expression of these two proteins is a consequence, and E6 and E7 interfere 
with functions of tumor suppressor proteins which control both the cell cycle and 
apoptosis, resulting in initiation of pre-cancerous lesions and cancer. E6 protein binds to 
p53 via the E6-Ap protein (a host cell ubiquitin ligase) and facilitates the degradation of 
p53 through the ubiquitin proteasome pathway. This dramatically decreases the half-life 
of the p53 tumor suppressor protein in infected cells, and p53-med!ated regulation of the 
cell cycle is lost. In addition to the loss of p53 protein, the overexpression of E6 and E7 
proteins facilitates uncontrolled proliferation of the infected cell through the activation of 
cellular cyclins E and A. E7 protein also interferes with the functions of the cellular 
tumor suppressor protein retinoblastoma (pRB). Viral E7 protein binds to pRb and 
inhibits the interaction of pRB with E2F and other factors associated with the cell cycle. 
High risk E6 and E7 proteins are usually coexpressed within infected cells. By 
simultaneous disruption of the functions of the functions of key ceWulav tumor 
suppressors p53 and pRb, high-risk HPV E6 and E7 proteins immortalize and transform 
human cells, setting the stage for cancer progression. 
The standard first line treatment for invasive cervical cancer is usually cisplatin (Platinol) 
and 5-fluorouracil (5-FU, Adrucil, Efudex) used in combination and in addition to 
radiation. Recurrent and late stage cervical cancers are often treated with a combination 
of platinum, bleomycin, methotrexate, and 5-FU. Chemotherapy is administered 
intravenously, through injection, or in pill form and side effects often accompany 
treatment and may be severe; which can include nausea, vomiting, diarrhea, and 
leukopenia (low white blood cell count). Most of these side effects are a result of drug 
toxicity to healthy tissues such as skin, hair follicles, and epithelial cells that line the 
digestive tract and patient tumors can develop resistance to these therapies as well. 
Hence, there is a need to develop alternate, safer, less toxic, and more specific therapies 
for uterine cervical cancer. 
Some of the most successful currently used anticancer drugs are extracts or derivatives of 
compounds from plants or other natural products. These include the advance class of 
drugs known as taxanes (Paclitaxel, Docetaxel) that come from the yew tree {Taxus 
baccata), and the vinca alkaloids (Vincristine, Vinblastine, Vinorelbine) which are 
derivatives from the periwinkle plant {Catharanthus roseiis). These compounds affect the 
growth of all rapidly dividing cells, whether normal or malignant, and like other drugs, 
are associated with significant toxicity and side effects. Millions of research dollars each 
year go to the discovery of new natural products with limited side effects that may be 
used as effective antitumor agents. Some compounds that are currently being 
investigated are components of dietary plants. Epidemiological observations and 
laboratory studies, both in cell culture and animal models have indicated anticarcinogenic 
potential of garlic and its constituents, which has been traditionally used for varied 
human ailments around the world. 
Garlic {Allium sativum L.) is a widely consumed herb in foodstuffs and medicines. It has 
been reported to reduce chemically induced esophageal, skin, pulmonary, stomach, 
breast, uterine cervix, colon, mammary and lung tumor. The anticarcinogenic/ 
antitumorgenic effects of garlic and its organosulfur compounds have been attributed not 
only to the modulation of the antioxidation and/or drug-metabolizing enzyme (Phase I 
and II) system, but also to the reduction of cell proliferation and induction of apoptosis 
for tumor cells. Allicin, the major component present in freshly crushed garlic, is one of 
the most biologically active compounds of garlic. Allicin is formed from alliin by the 
action of allinase and gets metabolized rapidly into diallyl sulfide, diallyl disulfide, 
diallyl trisulfide, ajoene, S-allylmercaptocysteine, S-allylcystcine and vinyl dithiincs. 
Allicin is readily permeable through phospholipid membranes aiding its biological 
activity, but its unstable nature raises the question whether all the effects of A1 lie in 
observed are due to Allicin itself or its metabolites. Indeed, its metabolites. .S'-allyl 
mercaptocysteine, diallyl sulfide, diallyl disulfide, diallyl trisulfide, ajoenc and .S'-allyl 
cysteine have been shown to possess an anticancer activity, which varies depending on 
the agent and the experimental model. 
Earlier studies have shown that garlic-derived OSCs can suppress growth of cancer cells 
of different anatomical locations in association with cell cycle arrest. Garlic-derived 
OSCs have also been shown to modulate a number of key elements in cellular signal 
transduction pathways linked to the apoptotic process. Therefore, the central aim of the 
current study was to investigate and evaluate the effect of Allicin, an organosulfur 
compound of garlic, on cervical cancer HeLa cell line and monocytes from cervical 
cancer patients. First of all, bearing in mind the previous reports of antiproliferative and 
apoptotic properties of Allicin on different cancer cell lines, various experiments were 
carried out to check the efficacy of Allicin to inhibit the proliferation of cervical cancer 
HeLa cells. In addition to this, anti-inflammatory property of Allicin was also veriiled by 
performing different experiments on monocytes isolated from the blood of cervical 
cancer patients. 
First, we investigated the effect of Allicin on HPV 18 positive cervical cancer HeLa cell 
line. Our results illustrated that Allicin strongly suppressed the proliferation of HeLa cells 
in a dose- and time-dependent manner. Furthermore, we also observed Allicin-induced 
cell cycle arrest in HeLa cells at Go/G| phase along with a sub-G(i/G| population 
suggesting that certain amount of cells underwent apoptosis which was further confirmed 
by the result of FITC-Annexin V Assay. Thus, antiproliferative action of Allicin in HeLa 
cells could be attributed to cell cycle arrest and apoptosis. Therefore, the above combined 
results demonstrated that Allicin treatment caused a significant decrease in the percentage 
of viable cell along with a concurrent induction of apoptosis in cervical cancer HeLa 
cells; however, the percentage of apoptotic cells did not coincide with the percent of 
viable cells. This difference in cell viability and apoptosis could be due lo cell c>clc 
arrest at GQ/G) phase induced by Allicin. 
The mitochondrial apoptotic pathway (intrinsic pathway) is largely mediated through 
Bcl-2 family proteins, which include both proapoptotic members such as Bax. Bak and 
III 
BNIP3 that promote mitochondrial permeability and antiapoptotic members such as Bcl-2 
and Bcl-xL that inhibit their effects, or inhibit the mitochondrial release of cytochrome c 
Another important component is the tumor suppressor protein p53. which simultaneously 
suppresses Bcl-2 and activates Bax. The ratio of Bax to Bcl-2 is critical to cell survival 
which determines whether a cell undergo apoptosis. In response to proapoplolic signals. 
Bax translocates to the mitochondria where it oligomerizes into a heleromeric protein 
channel which releases apoptotic factors, such as cytochrome c. Cytochrome c leakage 
supports the formation of an apoptosome complex by binding to apoptotic protease 
activating factor-1 (Apaf-1), which activates the caspase-9 molecules (upon cleavage of 
the bound zymogen procaspases-9), which in turn activate caspase-3 to initiate apoptosis. 
Caspase-3 is one of the key executioners of apoptosis, being responsible either partially 
or totally for the proteolytic cleavage of many key proteins, such as the nuclear enzyme 
PARP, followed by DNA fragmentation. In the current study, considering the previous 
reports on garlic and its organosulfur compounds, we further explored the involvement of 
mitochondrial apoptotic pathway in Allicin-induced apoptosis in HeLa cells. Our 
Western blot results showed that Allicin induced mitochondrial release of cytochrome c 
Moreover, Allicin treated HeLa cells also exhibited an augmented caspase-9 and -3 
activities which were found to be dose dependent. Likewise, Western blot results also 
showed cleavage and activation of procaspase-9 and -3 which further conllrmcd our 
finding of enhanced caspase-9 and -3 activities. Pretreating HeLa cells with caspase 
inhibitors Z-VAD-FMK, Z-DEVD-FMK (caspase-9 inhibitor) and Z-LEHD-FMK 
(caspasc-3 inhibitor) completely abrogated Allicin-induced caspase activation and cell 
proliferation. Furthermore, we also demonstrated Allicin-induced PARP cleavage in 
HeLa cells and cleaved product of 89 KDa was found to be evident in Western blot. 
Similarly, results of Western blot analysis also revealed an upregiilated Bax and 
downregulated Bcl-2 protein expressions in Allicin-treated HeLa cells. 
The mitochondrial apoptotic pathway (intrinsic pathway) is also regulated by the 
mitochondrial permeability transition pore (mPTP). Cyclosporin A (CsA) is an inhibitor 
of cyclophilin D and blocks the formation of the mPTP and prevents its opening which 
lead to inhibition of mitochondrial membrane depolarization and Bax translcKation to 
mitochondria. This ultimately suppresses release of cytochrome c from mitochondria and 
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in turn caspase activation which play important role in apoptosis. Therefore, in the 
current study, the effect of CsA pretreatment on Allicin-induced suppression of 
proliferation and apoptosis of HeLa cells was also investigated. Our results showed thai 
CsA pretreatment of HeLa cells inhibited Allicin-induced growth suppression and cell 
death, corroborating the central role of mitochondria in the apoptotic process induced by 
Ailicin. Furthermore, Allicin induced a cell cycle arrest at GQ/GI in HeLa cells. Upon 
CsA pretreatment, the percentages of cells at GQ/GI remain unchanged. So, it can be 
deduced from this result that the effect of Allicin on cell cycle arrest was independent of 
its proapoptotic activity. 
Glutathione is the major regulator of the thiol-disulfide redox state of living cells. 
Alterations in cellular free thiols have already been described as a key event in the 
generation of apoptosis. Glutathione (GSH), cysteine and accessible free sulfliydryl (-SH) 
groups of various proteins and peptides are rapidly oxidized by Allicin to their respective 
Allyl disulfide derivatives. In the present study, the effect of Allicin on cellular GSH 
content and total free thiol (-SH) content of cytosol and mitochondria was also examined. 
Our results showed that Allicin induced an initial drop in GSH levels that was followed 
by a regeneration process, occurring several hours after treatment. This may be due to 
decreased feedback inhibition of GSH biosynthetic enzyme such as y-glutamylcysteinc 
synthetase (y-GCS) by GSH. In addition, Allicin also caused GSH depletion 
concomitantly in the cytosol and mitochondria in HeLa ceils. The rate of free -SH 
depletion from the cytosol and the mitochondria was similar, indicating that Allicin 
penetrated the mitochondria and the cell membrane equally well and reacted with free -
SH in both compartments. Furthermore, in Buthionine sulfoximine (BSO)-preireatcd 
cells, there was no recovery of GSH after its Allicin-induced depletion, as BSO is a direct 
inhibitor of y-GCS. Since BSO-induced depletion of GSH levels caused neither 
mitochondrial permeability transition nor apoptosis (no effect on cell survival), it is likely 
that BSO treatment depletes GSH mainly from the cytosol, whereas Allicin induced 
depletion of mitochondrial GSH trigger the apoptotic process. 
N-acetylcysteine's (NAC) primary function in vivo is to supply cysteine necessary for 
GSH synthesis and replenishment. It can also reduce disulphide bonds in proteins and 
scavenge free radicals. In this study, we also investigated the effect of NAC pretreatment 
on Allicin-induced growth inhibition and apoptosis of HeLa cells. Our results showed 
that simultaneous treatment of HeLa ceils with NAC and Allicin abrogated the 
antiproliferative and apoptotic activity of Allicin. Furthermore, the cell cycle arrest 
induced by Allicin at GQ/GI phase was also shown to be abolished by NAC. The results 
observed could be due to NAC's key role to provide cysteine for GSH synthesis and 
replenishment depleted by Allicin. 
HPV oncoproteins E6 and E7 can disturb cell cycle regulation and impede apoptosis by 
binding to two tumor suppressor proteins, p53 and pRb, respectively which results in 
cellular immortalization and transformation. In the current study, we also investigated the 
effect of Allicin on E6, E7 and p53 expression in HeLa cells. Strikingly, our results have 
revealed that Allicin strongly inhibited the expression of HPV 18 E6 and E7 oncoproteins 
in cervical cancer HeLa cells. This downregulation of E6 and E7 expression could result 
in cessation of cervical cancer cell growth. Furthermore, the expression of p53 tumor 
suppressor protein in Allicin treated HeLa cells was also found to be upregulated. In 
other words, Allicin could restore the function of p53 and disrupt the E6/p53 pathway 
which plays a vital role in cervical carcinogenesis. Since p53 simultaneously suppresses 
anti-apoptotic Bcl-2 and activates apoptotic Bax, its increased expression and restoration 
of function could also assist in programmed cell death induced by Allicin in cervical 
cancer cells. 
Monocytes play an important role in the initiation, development, and outcome of the 
immune response. Immune responses and inflammatory reactions mediated by monocytes 
are regulated not only positively by cellular recruitment, proliferation, and cross-talk, but 
also negatively by apoptosis of monocytes. So, in the present study, we further 
investigated the effect of Allicin on survival of monocytes isolated from cervical cancer 
patients. Strikingly, findings of the current study demonstrated that Allicin strongly 
induced apoptosis in monocytes of cervical cancer patients. Because the regulation of 
monocytic apoptosis has a great importance in the regulation of inflammation, this might 
be one of the mechanisms of Allicin's anti-inflammatory effects. 
Previous studies have shown that several proinflammatory cytokines (IL-la. IL-6, or 
TNF-a) stimulate proliferation of carcinoma cell lines derived from several different 
tissues including cervix. Thus, these proinflammatory cytokines might act as paracrine nr 
VI 
autocrine growth factors in promoting malignant progression of cervical cancer. 
Surprisingly, results of the present study showed an augmented expression of 
proinflammatory cytokines TNF-a, IL-la and lL-6 in monocytes from cervical cancer 
patients. Furthermore, expressions of these proinflammatory cytokines in monocytes 
were shown to be suppressed by Allicin treatment. So, our above results indicated that 
suppression of proinflammatory cytokines such as TNF-a, IL-ia and lL-6 by Allicin 
could alter the local microenvironment of cervical tumor leading to malignant 
progression. 
In summary, the combined results of the present study established that Allicin, an 
organosulfur compound of garlic {Allium sativum), has a potent antiproliferative and 
apoptotic properties against cervical cancer HeLa cell line. Allicin-induced growth 
inhibitory action in HeLa cells involved the cell cycle arrest and apoptosis Involved the 
activation of caspase-9 and -3 as well as release of cytochrome c from mitochondria. 
downregulation of antiapoptotic Bcl-2 and upregulation of apoptotic Bax and p53. 
Interestingly, Allicin also suppressed the expression of HPV E6 and E7 oncoproteins 
implicated in cervical carcinogenesis. In addition, Allicin also induced apoptosis and 
suppressed the augmented expression of proinflammatory cytokines TNF-a, IL-la and 
IL-6 in monocytes of cervical cancer patients. Thus, it could be concluded that in view of 
the above antiproliferative, apoptotic and anti-inflammatory properties. Allicin could be a 
promising chemotherapeutic agent in prevention of cervical cancer. 
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Introdactton/ 
Cancer of the uterine cervix represents the second most common cancer in lemalcs 
worldwide and is a major cause of morbidity and mortality (Moore, 2006). In developing 
countries, cervical cancer is often the most common cancer in women and may constitute 
up to 25% of all female cancers (Burd, 2003, Waggoner, 2003). In 2006, 9.710 women 
were diagnosed with cervical cancer and 3,700 women died from the disease in U.S.A. 
(American Cancer Society, 2006). Worldwide, morbidity and mortality rates are far 
higher with an incidence of 4,90,000 new cases and 273,000 deaths occurring in 2005. 
according to the World Health Organization. About 80 percent of these cases occur in 
developing countries (Cox, 2006; WHO data. 2005). 
The association between Human papillomavirus (HPV) infection and cervical neoplasm 
was first demonstrated in the early 1980s by Harold zur Hansen (Gissmann and zur 
Hausen, 1980; de Villiers el al, 1981). HPVs are members of the Papillomaviridae 
family and are in the genus Papillomavirus which contains more than 100 types of the 
virus classified by genotype (de Villiers et al., 2004). Papillomaviruses infect the basal 
keratinocytes of squamous epithelium and may cause benign (noncancerous) tumors 
called warts, or papillomas, although some infections never produce clinical symptoms. 
All HPVs trigger proliferation of the cells they infect, but only a few types are associated 
with the risk of developing cancer. Based on their association with cervical cancer and 
precursor lesions, HPVs can be divided into high-risk, intermediate-risk, and low-risk 
subtypes. Low risk subtypes are associated with venereal warts (condyloma acuminate), 
whereas intermediate and high-risk subtypes are associated with cervical dysplasia and 
invasive carcinoma. High-risk HPV infection is the primary risk factor for ihc 
development of cervical carcinoma (zur Hausen, 1999). Over 90 percent of cancers of the 
uterine cervix contain high risk HPV DNA (zur Hausen, 2001). However, infection with 
high-risk HPV does not guarantee a patient will develop cervical cancer because most 
infections clear within 12-18 months, and there have been very rare instances where 
women have developed cervical cancers that are HPV-negative (Avrich ei uL. 2006). 
Cervical tumors can be resistant to traditional courses of chemotherapy and those patients 
who do respond positively to chemotherapy have tumors that can recur (Alexander cl uL, 
2005; Dreyere/ uL, 2005; Lindeque, 2005; Tewari and Monk, 2005). 
Human Papilloma Virus (HPV) Genome Structure 
HPV is a relatively small (55nm diameter) non-enveloped virus. The virus contains a 
double stranded, circular DNA genome containing -8000 base pairs (Fig. I). It has an 
icosahedral capsid composed of 72 capsomers, which contain at least two capsid proteins, 
LI and L2. The HPV genome can be divided into three regions, the noncoding long 
control region (LCR), or the upper regulatory region (URR), and the early (E) and late 
(L) gene region (protein encoding) (Zheng and Baker, 2006). The long control region of 
400 to 1,000 bp contains overlapping binding sites for many different transcriptional 
activators and repressors, including activating protein-1 (AP-1), and nuclear factor-1 
(NF-1). The LCR regulates transcription from the early and late regions, and therefore 
controls the production of viral proteins and particles (Bernard, 2002). The early region is 
downstream of the LCR and contains six open reading frames, El, E2 and E4-E7, and is 
involved in viral replication and oncogenesis. These encode all viral proteins except for 
the viral capsid proteins, which are encoded in the late region. The LI and L2 genes in 
the late region encode the major and minor capsid proteins, both of which are required 
late in the viral life cycle to encapsulate the virus. 
Life Cycle of Human Papilloma Virus (HPV) 
Papillomaviruses' primary host tissue is squamous epithelial tissues such as skin or the 
mucosal surfaces of the genital tract, anus, mouth, or upper respiratory tract (Doorbar, 
2005). Initial HPV infection requires access to cells in the basal layer by infectious 
particles, which for some HPV types are thought to require a mild abrasion or 
microtrauma in stratified epithelium (Fig. 2). For high-risk mucosal viruses, such as 
HPVI6, the formation of cervical lesions may be facilitated by the infection of columnar 
cells, which can subsequently form a basal layer of transformed stratified epithelium. The 
nature of the cell surface receptor used for viral attachment is not known, although 
heparin sulphate and stabilizing proteoglycans have been suggested to be epithelial cell 
receptors for HPV (Giroglou el al, 2001). Once in a host cell, the life cycle of HPV can 
be separated into two stages, i.e., nonproductive and productive. In the nonproductive 
stage, the virus maintains its genome as a low copy number episome by using the host's 
DNA replication machinery to synthesize its DNA in basal layer of the epithelium (Florcs 
etal, 1997). 
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Figure 1: Circular diagram of HPV-16 genome and open reading frames. The three 
separate regions of the HPV genome along with early genes E1-E7 and late genes LI and 
L 2 are shown (Adapted from zur Hansen, 1999). 
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Figure 2: The course of events that, over time, can lead to the development of 
precancerous and cancerous cervical tumors. Induction of cancerous tumors takes 
decades and is preceded by the development of early and late precancerous lesions called 
cervical intraepithelial neoplasias (CIN), which may regress. Persistent HPV infection is 
required for progression to carcinoma (Adapted from zur Hansen, 2002). 
The pattern of viral gene expression in these cells is not well defined, but it is generally 
believed that the viral El and E2 proteins are expressed in order to maintain the viral 
DNA as an episome (Wilson el al, 2002) and to facilitate the correct segregation of 
genomes during cell division (You et al, 2004). 
The productive stage of the viral life cycle occurs in the terminally differentiating 
suprabasal layers of the epithelium. In these cells, the virus switches to a rolling circle 
mode of DNA replication and amplifies its genome to higher copy number, expresses late 
genes encoding capsid proteins, and produces viral progeny (Flores ei al, 19^9). As a 
rule, in benign warts and pre-neoplastic lesions, the HPV genome is not integrated into 
the host cell genome (it is maintained in episomal form). However, in true neoplasia, it is 
wholly integrated into the host genome, although some authors have shown the 
coexistence of episomal and integrated forms in cervical cancer (Kristiansen et a!., 1994). 
The site at which the viral DNA is opened during this process of integration is fairly 
constant, and occurs within the E1/E2 open reading frame of the viral genome. The E2 
protein can function as either an activator or repressor of viral gene transcription 
depending upon the location of the E2-binding sites within the promoter region of the 
viral genome (Bernard et al., 1989; Phelps et al., 1987). However, as the E2 region of 
viral DNA normally represses the transcription of the E6 and E7 early viral genes, this 
interruption causes E6 and E7 protein overexpression (Finzer et al.. 2002). After all, 
while HPV integration means the end of the viral life cycle due to the functional 
inactivation of large parts of the viral genome, it leads to de-regulated expression of the 
viral oncogenes E6 and E7. 
Many experimental studies have investigated genomic HPV integration sites, and 
although integrated HPV genomes have been observed to show preferences for relatively 
few loci, no general integration hot spot has been identified. A recent review of 
integration sites confirmed that HPV integration sites are randomly distributed over the 
whole genome with a clear predilection for 'fragile' sites. No evidence supporting the 
targeted disruption or functional alteration of critical cellular genes by the integrated viral 
sequences has been unearthed. 
Molecular Pathophysiology of Cervical Cancer 
In normal epithelium, basal cells are sequestrated from the cell cycle following miyralion 
into the suprabasal cell layers and are committed to terminal differentiation. During MPV 
infection, E7 and E6 are expressed in these cells, and abolish cell cycle progression 
restraints and delay normal terminal differentiation (Sherman et al, 1997) (Fig. 3). The 
effects of E6 and E7 on p53 and pRB and on many other cellular proteins have been 
extensively investigated, and significant alterations in cell cycle regulation can be 
attributed to the biochemical interactions between these two viral oncogenes and their 
respective cellular binding partners (Munger et al, 2001) (Fig. 4). Moreover, recently it 
was demonstrated that the E6 and E7 cooperatively disturb the mechanisms oi' 
chromosome duplication and segregation during mitosis, and thereby induce severe 
chromosomal instability (Duensing and Munger, 2001). 
HPV E7 Oncoprotein 
The critical role of HPV E7 protein in the malignant transformation of cervical epithelial 
cells is attributed to its effects on pRb, a member of the "pocket protein" family, which 
also includes pl07 and pl30 (Vogelstein et al, 1993). The proliferation of normal human 
cells follows an orderly progression through the cell cycle under the influence of 
cyclin/cyclin dependent kinase (cdk) complexes. Each cyclin/cdk complex control a 
specific cell cycle transition, the key downstreairi targets of the Gi phase cyclin/cdk 
complexes are members of the pRb family, i.e.. Rb. pi07. and pi03. During Gi 
progression, Rb is sequentially phosphorylated by cyclin Dl/cdk4 and 6 and cyclin 
E/cdk2 complexes, whereas hypophosphorylated pRB represents the active foi"m and 
inhibits S phase entry, thus the sequential phosphorylation of Rb inhibits the repressor 
activity of pRb. The repressor activities of pRB and of the related pocket proteins pi 07 
and pi 30 are mediated by members of the E2F family of transcription factors. In Go/Gi 
hypophosphorylated pRB is bound to E2F. Since pRB encodes a transcriptional repressor 
domain, pRB/E2F complexes function as transcriptional repressors. Following 
phosphorylation by cdk in Gi, pRB/E2F complexes dissociate and E2F acts as a 
transcriptional activator, which results in S phase entry (Weinberg, 1995). 
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Figure 3: Processes involved in HPV-induced carcinogenesis 
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Figure 4: Stimulation of cell-cycle progression by high-risk HPV types 
HPV infection leads to deregulation of the cell cycle. Regulation of protein expression in uninfected 
epithelium is shown in (A). In the presence of high-risk HPV (B), the regulation of proteins necessary 
for cell proliferation is liltered, allowing HPV to stimulate S-phase entry in the upper epithelial layers. 
(A) Uninfected epithelium. The expression of proteins necessary for cell-cycle progression is 
controlled by pRB, which in non-cycling cells associates with members of the E2F transcription factor 
family (centre). In the presence of growth factors, cyclin D/Cdk4/6 is activated, which leads to Rb 
phosphorylation and tlie release of the transcription factor E2F, wdiich drives the expression of 
proteins involved in S-phase progression, pi 6 regulates the levels of active cyclin D/Cdk in the cell, 
providing a feedback mechanism that regulates the levels of MCM, PCNA (proliferating-cell nuclear 
antigen) and cyclin E. fil4 , whose expression is directly linked to that of pl6, regulates the activity 
of the MDM (murine double minute) ubiquitin ligase, which maintains p53 at a level below that 
required for cell cycle arrest and/or apoptosis. (B) HPV-infected epithelium. In cervical epithelium 
infected by high-risk HPV types, progression through the cell cycle is not dependent on external 
growth factors, but is stimulated by the E7 protein, which binds and degrades pRB and facilitates E2F-
mediated expression of cellular proteins necessary for S-phase entry. Although pI6 levels rise, normal 
feedback is by-passed, as HPV-mediated cell proliferation is not dependent on cyclin D/Cdk4/6. The 
rise in the level of pi4 , which occurs in the absence of pl6-mediated feedback, leads to the 
inhibition of MDM function and an increase in the level of p53. This is countered by E6, which 
associates with the E6AP ubiquitin ligase in order to stimulate the degradation of the p53 protein and 
prevent growth arrest and/or apoptosis. In low-grade cervical disease, where E7 levels are carefully 
regulated, it is thought that E7-mediated cell proliferation can sometimes be inhibited as a result of 
association with p21 and cyclin E/Cdk. The high levels of E7 found in cervical cancer cells are 
thought to overcome this block by binding and inactivating the Cdk inhibitor p21 (Adapted from 
Doorbar, 2006). 
However, the virally encoded protein, E7, binds to tiypophosphorylated pRb and 
displaces the E2F transcription factor from pRb. Thus, binding to Rb by E7 is essentially 
for E7-induced cells transformation, because E7 proteins, which are associated with HPV 
strains with a low cervical cancer risk, show little or no affinity for pRb. As for the 
E7/pRB interaction, E7 targets pRb for ubiquitin-mediated degradation by the 
proteasome (Boyer et al, 1996). 
Moreover, it was suggested that the cellular transformation activity of E7 tightly 
correlates with its ability to degrade pRB (Jones and Miinger, 1997). It appears that pRB 
degradation, not solely binding, is important ibr the E7-induced inactivation of pRb 
(Gonzalezes/, 2001). 
In addition to regulation by phosphorylation and dephosphorylation, cdl<s are regulated 
by a group of functionally related proteins called cdk inhibitors. In differentiating 
epithelial cells, high levels of cdk inhibitors (p2r'''' and p27'^ '''') can lead to the formation 
of inactive complexes consists of E7, cyclinE/cdk2 and either p21 or p27. As a result, it 
appears that during HPV infection, the ability of E7 to stimulate S-phase entry is limited 
to a subset of cells with low levels of p21/p27, or to cells which express high enough 
levels of E7 to subvert the block to S-phase entry. However, recent studies suggest that 
E7 can also interfere with the activity of the cyclin dependent kinase inhibitors p21'^ '''' 
and p27'^ '''' and thus override normal G| checkpoint control (Jones e( al, 1997; Zerfass-
Thome et al, 1996). In addition, to cyclin/cdk complexes and cdk inhibitors, E7 can also 
associate with other proteins involved in cell proliferation, including histonc deacetylases 
(Antinore et al, 1996) and components of the AP-1 transcription complex (Longworth 
and Laimins, 2004), through p21 upregulation. 
HPV E6 Oncoprotein 
Although, E7 protein can independently immortalize various human cell types in tissue 
culture, efficiency is increased when E7 and E6 are coexpressed (Munger ci al. 1989). 
Thus, E6 protein is believed to complement the role of E7 protein, and prevent apoptotic 
induction in response to unscheduled S-phase entry mediated by E7. However, the 
importance of HPV E6 in cancer appears to be primarily due to its effects on the cellular 
tumor suppressor gene, p53. The most commonly found alterations to p53 in cancers, 
such as, colon, breast, and lung cancer, are deletion, insertion, and point mutation (Barlek 
et al, 1990; Rodrigues et al, 1990; Takahashi el al, 1991). The p53 gene negatively 
regulates the cell cycle and "loss of function" mutation in p53 is required for tumor 
formation (Levine et al, 1991). Up to 99% of invasive cervical carcinomas have been 
found to contain HPV 16 or 18 DNA and in these few are found Vv'ithout evidence ol' 
HPVp53 mutations (Crookera/, 1992). 
Normally p53 is transiently upregulated after DNA damage, which leads lo cell c>clc 
arrest in the Gl phase and apoptosis. This arrest allows time for DNA repair, and if repair 
is not possible, cells are committed to apoptotic death. P53 acts through downstream 
regulators, such as p2l, which leads to cdk inhibition and the eventual blockade of Rb 
gene phosphorylation, thus preventing cell cycle progression. However, virally encoded 
E6 binds to a cellular ubiquitin/protein ligase, E6-AP, and simultaneously to p53, which 
results in the ubiquitination of p53 and its subsequent proteolytic degradation (Ferenczy 
et al, 2002). Other consequences are presently emerging from the E6/E6-AP interaction; 
potentially important is the recent observation of E6-AP-mediated ubiquitination and 
degradation of the Src family tyrosine kinase BIk (Oda et al, 1999). It is conceivable that 
the presence of E6 partially blocks this degradation and thereby stabilizes the respective 
kinase and stimulates mitotic activity (Oda et al, 1999). This could explain, in part, 
growth-stimulatory functions of the E6 protein of high-risk HPVs. 
E6 proteins of high oncogenic risk HPVs, i.e., HPV 16 and 18, have a higher affinii\ for 
p53 than lower oncogenic risk types (HPV 6 and 11) (Crook et al. 1991; Lechner et al, 
1994). Moreover, although the association between E6 and p53, and the inactivation of 
p53-mediated growth suppression and/or apoptosis have been well documented, this 
association can also lead to apoptosis via changes in the expressional levels of Bax and 
Bcl-2 family members (Selvakumaran et al, 1994). Consequently, the presence of r:6 is 
considered to predispose the development of HPV associated cancers, by allowing the 
accumulation of chance errors in host cell DNA to go unchecked. Moreover, the E6 
protein of high-risk HPV types can also stimulate cell proliferation independently of E7 
through its C-terminal PDZ-ligand domain (Thomas et al, 2002).Both the p53 and Rb 
proteins interact with the double minute 2 gene (MDM2). P53 acts as a iranscripiioiial 
activator of MDM2, whereas MDM2 acts in an autoregulatory fashion by providing 
negative feedback to p53 transcription. MDM2 can also interact with Rb and restrain lis 
action. 
Other Oncogenes Involved in Pathogenesis of Cervical Cancer 
Although, the over-expressions of E6 and E7 appear pivotal in the development of 
cancer, their expressing is not enough either for the immortalization of cultured human 
cells, or for malignant conversion. Rather, other specific genetic abnormalities are 
important during cervical carcinogenesis and the aggressiveness of cervical tumors. In 
addition to p53 and Rb, the ras family genes (K-ras, H-ras and N-ras) and c-myc 
oncogene might also have a role in the pathogenesis of cervical cancer (Baker et uL, 
1998; Bourhis et al, 1990; Dokianakis et al, 1998; Garzetti et ai. 1998: Riou et al.. 
1987; Brenna et al, 2002). Each of these genes has been reported to be overexpressed in 
cervical cancer and several of them have been associated with a poor prognosis. 
Epigenetic Changes 
In recent years the importance of epigenetic changes in inactivation of a tumor suppressor 
gene and the establishment of the malignant phenotype has been illuminated. In 
malignancies, some tumor suppressor genes are not transcribed because their promoter 
regions are methylated. Of the hypermethylation events studied in association with 
carcinogenesis, promoter CpG island hypermethylation has been frequently investigated 
in many human cancers, including cervical cancer (Esteller et al.. 2001: Muller ei al.. 
1998; Virmani et al., 2001; Yang et al., 2004; Kang et al., 2005). Dong et al., (2001) 
showed that promoter hypermethylation of at least one of the genes pi 6, DAPK, MGMT, 
APC, HIC-1, and E-cadherin occurred in 79% of cervical cancer tissues and in none of 
normal cervical tissues from several hysterectomy specimens. Virmani et al., (2001) 
detected aberrant methylation of at least one of the genes pl6, RARP, FHIT, GSTPI, 
MGMT, and hMLHl in many cervical cancer tissue samples. 
Co-Factors of Cervical Cancer 
It has been well established that a persistent infection in combination with high-risk MPV 
is the main risk factor of cervical cancer. Subclinical, clinical, and latent HPV infections 
are considered the most common sexually transmitted infections. The prevalence of HPV 
infection among sexually active young women is in the range of 5-40% (Ho et al., 1998; 
lARC Working Group, 1995; Melkert et al., 1991). Further, most HPV infections are 
transient and it is estimated tliat newly diagnosed HPV infections cleared within 12-18 
months in approximately 80% of women, as the humoral immune system is brought lo 
bear on the virus. Even low-grade precancerous lesions do not always progress into high 
grade lesions. Instead, a cytotoxic T cell response is elicited against HPV-infectcd 
keratinocytes in the majority of cases. This suggests that other factors are involved in the 
carcinogenesis of cervical cancer. Smoking, high parity, and the long-term use of oral 
contraceptives are considered proven co-factors. 
Smoking 
Smoking has long been associated with cervical cancer risk (Castellsague and Munoz, 
2003). A recent review of the relation between smoking and cervical cancer found 
consistent associations (Szarewski and Cuzick, 1998, Deacon et al., 2000; Hildesheim ci 
al., 2001; Plummer et al, 2003). Interestingly, a multi-center case-control study of 
cervical adenocarcinoma reported a negative association between smoking and cervical 
adenocarcinoma and a positive association between smoking and the risk of squamous 
cell carcinoma (Lacey Jr. et a/., 2001). 
Sexually Transmitted Diseases 
Herpes Simplex Virus -2 (HSV-2) has been found to be carcinogenic in both in vitro and 
in vivo studies. It was hypothesized that HSV-2 and HPV may act synergistically with 
HSV-2 to initiate mutations and carcinogenesis in HPV-infected cervical cells (de 
Sanjose, 1994; Zur Hausen, 1982). A consistent but modest association between the 
presence of serum IgG antibodies to Chlamydia trachomaiis and cervical cancer has been 
reported in epidemiological studies (de Sanjose el al., 1994; Dillner el al., 1994). In a 
lACR rnulticenter study, C. trachomatis seroposilivity increased the risk for cervical 
cancer among HPV-positive women by 2.1-fold (Smith et al., 2002). Numerous studies 
have addressed the association between HIV and cervical neoplasia (Boyle and Smith. 
1999; Jay et al., 2000; Conley et al., 2002; Ellerbrock et al., 2000; Moscicki el al.. 2000: 
Ferenczy et al., 2003), and the Center for Disease Control and Prevention included 
invasive cervical cancer in its definition of AIDS. 
Oral Contraceptives 
Steroid contraceptive hormones have been identified to be a cofactor of 1 IPV-rclated 
cervical carcinogenesis in many epidemiological studies. However, although some 
epidemiologic studies liave produced inconsistent results, the majority of studies have 
found that prolonged used of these agents increases the risk of cervical cancer (Moreno el 
al, 2002; Castellsague and Munoz, 2003; Smith el ciL, 2003; Moodley el al., 2003). 
Evasion of Cell-Mediated Immunity by HPV 
Human papilloma viruses have evolved several mechanisms to evade effective cellular 
immune responses (Frazer et al., 1999). First, they have evolved mechanisms to limit the 
extent to which viral antigens are exposed to immunologic recognition. They delay 
expression of abundant viral proteins (the capsid proteins encoded by the late viral genes) 
until the terminal differentiation stage of squamous epithelium, an anatomically 
superficial location where immunocompetent cells would have less access to them. In 
contrast, in the basal epithelium, where the early genes (such as E6 and E7) are 
expressed, the level of protein expression is low and confined to a nuclear location, thus 
potentially limiting an effective immune response again.st the cells in which the virus is 
actively replicating. Second, viral proteins such as E7 may modulate immune responses 
and the over expression of E7 protein may inhibit the antigen presenting function of 
dendritic cells in the epithelium (Barnard and McMillan, 1999; Rudolf el al., 2000: 
Garrido et al., 2000). Third, keratinocytes may be relatively less susceptible to cytotoxic 
T lymphocyte-mediated lysis than other infected cells and may even present antigen in a 
tolerogenic manner (Brady et al., 2000). Fourth, Keratinocytes infected by HPV can 
modify the immune response in several ways: through the secretion of various cytokines 
(IL-la, IL-6, IL-8, TNF-a, TGF-P) and soluble receptors for TNF-a, or through the 
production of Th2 cytokines (IL-4 and 10) in squamous carcinomas, configuring an 
evasion mechanism against the T-cell mediated immune response (Woodworth and 
Simpson, 1993; Malejczyk e/a/., 1996; K\m el al., 1995). 
Role of Proinflammatory Cytokines in Cervical Cancer 
The anti-tumor immune response has been reported to be regulated by several factors. 
which includes cytokines produced by tumor and other cells of lumor SUDIIUI. Ii seems 
likely that the local cytokine microenvironment, acting on tumor cell or on the adjacent 
cells, can either block or facilitate tumor growth, and that proinflammatory cytokines 
strongly influence the immunologic state. Various cytokines have been implicated in the 
pathogenesis of cervical cancer, among which interleukin-6 (lL-6) has received particular 
attention because it is a central proinflammatory cytokine involved in female genital 
infection and is abundant in the microenvironment of cervical cancer (Tartour cl al.. 
1994; Richter et al., 1999). Viral infection and exposure to proinflammatory cytokines 
such as IL-la and tumor necrosis factor-a can stimulate lL-6 gene expression b} the 
keratinocytes (Iglesias et al., 1995). IL-6 expression in tumor tissues is high and 
correlates with the severity of cervical cancer (Tartour el ai, 1994; Wei e! al., 2001). 
Also, IL-6 may contribute to a local immunosuppressive effect that protects the lumor 
cells from the host immune system (Tilg et al., 1997). Previous studies have shown that 
several proinflammatory cytokines (IL-la, IL-6, or TNF-a) stimulate proliferation of 
carcinoma cell lines derived from several different tissues including cervix (Ito et al., 
1993; Wu etal., 1993; Sugarman et al., 1986; Lewis e/a/., 1987, Wei el al., 2003). Thus, 
these proinflammatory cytokines might act as paracrine or autocrine growth factors in 
promoting malignant progression of cervical cancer. 
Current Treatments for Cervical Cancer 
Treatment options for HPV positive uterine cervical tumors vary with the stage of disease 
at diagnosis, the health of the patient, and desire for bearing children, but in all cases 
involves surgical removal of the malignant tumor (Moore, 2006). The standard first line 
treatment for invasive cervical cancer is usually cisplatin (Platinol) and 5-fluorouraciI (5-
FU, Adrucil, Efudex) used in combination and in addition to radiation. Recurrent and late 
stage cervical cancers are often treated with a combination of platinum, bleomycin, 
methotrexate, and 5-FU (DuPont and Monk, 2006). Chemotherapy is administered 
intravenously, through injection, or in pill form. Side effects often accompan}' treatment 
and may be severe; they can include nausea, vomiting, diarrhea, and leukopenia (low 
white blood cell count). Most of these side effects are a result of drug toxicity to healthy 
tissues such as skin, hair follicles, and epithelial cells that line the digestive tract (Stewart 
and Viswanathan, 2006). Patient tumors can develop resistance to these therapies as well 
(Muggia et al., 2004). Hence, there is the need to develop alternate, safer, less toxic, and 
more specific therapies for uterine cervical cancer. 
Garlic {Allium sativum) as an Anticancer Agent 
Experimental and epidemiological studies over the past few decades have provided ample 
evidences in support of associations between plant food intake and reduced cancer risk. 
Many phytochemicals are proven to have anticancer activities and many are in use for 
cancer therapeutics. Among them garlic (Allium sativum) has been of much interest, 
mostly due to the epidemiological reports which linked increased garlic consumption 
with reduced prevalence of many human diseases. Health benefits o^ Allium vegetables 
including garlic have been noted throughout recorded history, dating back to 1400 BC 
(Rivlin, 2001). The known medicinal benefits of garlic and other Allium vegetables and 
their constituent organosulfur compounds (OSCs) include lowering of serum cholesterol 
level, inhibition of platelet aggregation and increased fibrinolysis (Agarwal. 1996: 
Rahman, 2001), stimulation of immune function through activation of macrophages and 
induction of T-cell proliferation (Lau e( al., 1991; Lamm and Riggs, 2000), reduction of 
blood glucose level (Sheela et al., 1995; Augusti and Sheela, 1996), radioprotection 
(Singh et al., 1995), improvement of memory and learning deficit (Moriguchi et al., 
1996; Nishiyama et al., 1997), protection against microbial, viral and fungal infections 
(Cellini et al, 1996; Avato et al, 1997; Guo et al, 1993), and anticancer effects (Milner, 
2001; Thomson and AH, 2003). initial evidence for the anticancer effect of Allium 
vegetables was provided by population-based observational studies (You et al, 1989; 
Steinmetz et al, 1994; Hsing et al, 2002). 
Preclinical animal studies have indicated that OSC analogues are highly effective in 
affording protection against cancer induced by a variety of chemical carcinogens 
(Belman, 1983; Sparnins et al, 1986; Wargovich et al, 1988; Reddy et al. 1993; Suzui 
et al, 1997). Elucidation of the mechanisms by which OSCs may offer protection against 
cancer has been a passionate subject of research for the past 20 years. 
Chemical Constituents of Garlic 
Chemical analyses have indicated that garlic bulbs, leaf, shoot, flower and roots are the 
source of many compounds having medicinal properties with varied pharmacological 
functions (Ross, 1999). Fresh garlic contains water (65%), carbohydrates (28% mainly 
fructans), proteins (2% mainly allinase), fiber (1.5%), and fat, as well as essential amino 
acids (1.2''/o) (arginine, alanine, cystine, glutamic acid, aspartic acid, glycine, histidinc. 
isoleucine, leucine, phenylalanine, proline, serine, threonine, tryptophan, valine, tyrosine 
etc.), vitamins (P-carotene, ascorbic acid, biotin, thiamin, riboflavin, niacin, nicotinic acid 
etc), minerals (Al, Fe, Mg, Co, Cu, Mn, Ni, P, K, Na, Sn, Zn, Sc, Cy etc.), organosulfur 
compounds (Alliin, Allicin, Z-ajoene, diallylsulfide (DAS), diallyldisultlde (DADS). 
diallyltrisulfide (DATS), methylallydisulfide (MADS), methylallylsullide (MAS), 
methylallyltrisulfide (MATS), methylpropyldisulfide (MPDS), dimethyltrisulilde 
(DMTS), dimethyldisulfide (DMDS), allylpropyldisumde (APDS), S-(2-carbox)-
propyl)-glLitathioii, S-allylmercaptocysteine (SAMC), S-allylcysteine (SAC) and many 
other chemical compounds (ferulic acid, caffeic acid, p-coumaric acid, quercelin, 
sativosides, scordines, scordinines, degalactotigonin, gitonin, dithiins, dithiane ihione, 
thiazole) etc.) (Abdullah et al, 1988; Ejaz et ai, 2003; Li, 2000). 
The sulfur chemistry of garlic is fairly well understood (Block, 1985). The main .sulfur 
compound in intact garlic is y-glutamyl-i'-alk (en)yl-Z-cysteine, which is hydrolyzed and 
oxidized to yield Alliin (Block, 1985) (Fig. 5). Alliin accumulates naturally during 
storage of the bulbs at cool temperature and is the odorless precursor of the organosulfur 
compounds (OSC) believed to be responsible for the anticancer effect of garlic (Belman. 
1983; Sparnins et al., 1986; Wargovich et ai, 1988; Reddy et al., 1993; Suzui et ai. 
1997). Processing of garlic bulbs (crushing, cutting or chewing) releases a vacuolar 
enzyme alliinase that acts on alliin to give rise to extremely unstable and odoriferous 
compounds, including Allicin (Fig. 6). Allicin and other thiosulfinates decompose to oil-
soluble OSC, including DAS, DADS, DATS, dithiins and ajoene (4.5.9-trithiadodeca-
1,6,1 l-triene-9-oxide) ( Block, 1985) (Fig. 6, 7). Further transformation of organosulfur 
compounds can occur after interaction with free sulfliydryl groups, including those 
present in cysteine, glutathione, or proteins, producing S-allylcysteine, S-
allylmercaptocysteine, S-(2-carboxy-propyl)-glutathion etc. (Weisberger and Pensky. 
1958; Gilbert, 1990) (Fig. 7). 
Mechanism of Cancer Prevention 
Several mechanisms have been proposed to explain the cancer-preventive effects of 
Allium vegetables and related OSCs. These include inhibition of mutagenesis by 
inhibiting the metabolism, inhibition of DlNA adduct formation, free-radical scavenging, 
and effects on cell proliferation and tumor growth. Although there are evidences 
supporting these mechanisms for OSCs, they are still speculative, and further research is 
needed to support causality between such properties and the cancer preventive activity in 
experimental animals. 
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Modulation of Phase I Detoxification Enzymes 
Carcinogenic activity of many environmental pollutants is often dependent on their 
activation by cytochrome P450-dependent monooxygenases. OSCs derived from garlic 
have been studied for the ability to inhibit experimental cancer in various animal models. 
primarily througli alteration of expressions of cytochrome P450 (CYP) enzymes (Phase 1 
detoxification enzymes). The suppression of vinyl carbamate (VC) and N-
nitrosodimethylamine (NDMA)-induced mutagenesis in Salmonella typhi murium TAIOO 
by diallyl sulfide (DAS) has been reported to be correlated with their inhibition of 
CYP2E1-mediated o-nitrophenol hydroxylation and NOMA N-demethylation (Surh et 
al, 1995). DAS also acts as a competitive inhibitor of N-dimethylnitrosamine 
demethylase activity (Brady et al, 1988). It also decreased the activity of CYP2E1 in a 
time- and dose-dependent manner and induced the activities of CYP2B1 and pentoxy-
and ethoxyresorufin dealkylases in hepatic microsomes (Brady et al.. 1991). DAS, 
DADS, and AMS also decreased p-nitrophenol hydroxylase activity and CYP2E! protein 
concentration in rat liver (Reicks and Crankshavv, 1996). DADS increases the activities of 
several monooxygenases and transferases in intestine and liver and also the protein levels 
of epoxide hydrolase and CYP2B1/2 (Haber et al, 1995). Garlic oil induced the 
expression of CYP2B1 and decreased the expression of CYP2E1 (Sheen et al. 1999). 
The modulation of hepatic drug-metabolizing enzymes in rats treated with dimethyl 
sulfide (DMS), methylpropyl disulfide (MPDS), dipropyl sulfide (DPS), dipropyl 
disulfide (DPDS) and DADS induced ethoxyresorufin 0-deethylase, methoxyresorufin 
0-demethylase and mostly pentoxyresorufin 0-depentylase and decreased 
nitrosodimethylamine N-demethylase and erythromycin N-demethylase. These 
modifications of enzyme activities were accompanied by an increase of CYP2B1, 2 and a 
decrease of CYP2E1 (Siess et al., 1997). Collectively, modulation of carcinogen 
activation may be one of the mechanisms by which garlic constituents ma\' offer 
protection against chemically induced cancers. 
Induction of Phase II Detoxification Enzymes 
Experimental evidence exists to suggest that garlic constituents may function as a double-
edge sword in the prevention of chemically induced cancers by inhibiting carcinogen 
activation and enhancing detoxification of activated carcinogenic intci-mediatcs through 
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the induction of Phase II enzymes, including glutathione S-transferases (GST) and 
quinone reductase (Sparnins et al., 1988; Hu et al., 1996; Hu and Singh, 1997; Hu el uL, 
1997). Wattenberg and colleagues showed that prevention of BP-induced forestomach 
and lung cancer in mice by garlic OSCs was correlated with elevation of hepatic and 
target organ total GST activity (Sparnins el al., 1988). The activity of mammary and liver 
GST was increased by the addition of garlic powder to the diet of rats (Liu el al.. 1992). 
Previous studies have shown that DAS, DADS and DATS administration to A/J mice 
results in induced expression of Alpha (mGSTA3-3, mGSTAl-2, mGSTA4-4). Mu 
(mGSTMl-1) and Pi class GST (mGSTPI-1) in the liver, lung and forestomach (llu et 
al., 1996; Hu and Singh, 1997; Hu et al., 1997). However, OSC-mediated prevention of 
BP induced forestomach tumorigenesis, but not lung neoplasia, in A/J mice is most 
closely correlated with the induction of mGSTPl-1 (Hu el al., 1996; Hu and Singh, 
1997). 
Garlic organosulfides DAS, DADS, DPS and DPDS induced the expression of 
NAD(P)H: quinone oxidoreductase (NQO) enzyme, implicated in the detoxification of 
activated quinone metabolite of BP, in the forestomach and/or lung of A/J mice (Singh el 
al., 1998). Subsequently, Kong and colleagues showed a positive correlation between 
OSC-mediated induction of Phase II enzymes, activation of antioxidant response element 
and accumulation of transcription factor nuclear factor E2-related factor 2 in HcpG2 
hepatoma cells (Chen et al., 2004). DADS increased the activities of phase II 
detoxification enzymes quinone reductase (QR), glutathione transferase (GST), and 
uridine diphosphate (UDP)-glucuronosyl transferase in forestomach, glandular stomach, 
duodenum, jejunum, ileum, caecum, colon, liver, kidney, spleen, heart, lungs and urinary 
bladder of rats and suggested that such enzyme induction contributed to the protective 
activity of garlic against gastrointestinal tract (GIT) cancers (Munday and Munday, 
1999). Thus, it is reasonable to conclude that the induction of Phase II enzymes, 
especially GST, represents another potential mechanism to explain OSC-mediated 
prevention of chemically induced cancers. 
Inhibition of DNA Addiict Formation 
DNA adducts are believed to be an initial step in carcinogenesis. The anticarcinogcnic 
action of garlic can be attributed to its role in preventing DNA-carcinogen adducl 
formation and activation of carcinogen (Liu et ai, 1992). In rat mammary gland, different 
garlic preparations decreased the occurrence of dimethylbenz[a]anthracene (DMBA)-
DNA adducts in vivo and the amounts of total and individual adducts correlated 
positively with mammary tumor incidence (Amagase and Milner, 1993). DNA adducts 
induced by incubation of human bladder tumor cells with N-acetyl-Z-aminotluorene (2-
AF) were inhibited by DAS and DADS (Chung et al., 2004). Further, a water extract of 
raw garlic and SAC, but not DAS, significantly inhibited benzo(a)pyrene [B(a)l']-DNA 
adduct formation in simulated human peripheral blood lymphocytes in vitro (Hageman ci 
al., 1997). Shenoy and Choughuley showed that onion and garlic juices inhibited the 
nitrosation reactions in vitro in a dose-dependent manner (Shenoy and Choughuley, 
1992). Production of N-nitrosomorpholine (NMOR), a known liver carcinogen, has been 
reported to be reduced by water extracts of garlic and deodorized garlic powder (Dion ef 
ai, 1997). The occurrence of 7-methyldeoxyguanosine (7-MedG) and 06-
methyldeoxyguanosine (06-MedG) was decreased in rat liver when garlic powder was 
added to their diet containing amino pyrine and sodium nitrite (Lin el ai, 1994). 
Free Radical Scavenging 
Free radicals have been related to several age-related diseases, including cancer 
(Weisburger, 2001). Garlic possesses strong antioxidant activity and it is due to its 
organosulfur compounds (Shobana and Naidu, 2000). Alliin metabolite Allicin has been 
shown to be responsible for the oxygen radical scavenging property of garlic (Siegers et 
ai, 1999). It was also shown to prevent lipid peroxidation in liver homogenates (Prasad 
et al., 1995). The protective effect of pretreatment with garlic and tomato against N-
methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced genotoxicity and oxidative stress 
was observed in Swiss mice (Kumaraguruparan et ai, 2005). Garlic and onion oils 
stimulated the activity of glutathione peroxidase (GPx) and inhibited the ratio of 
reduced/oxidized glutathione produced by 12-0-tetradecanoyl-phorbol-l3-acetate (TPA) 
in epidermal cells (Perchellet et al., 1986). GPx activity was also increased in animal 
tissues by DAS administration against B(a)P-induced genotoxicity in mouse forestomach. 
DAS and DADS also increased the activity of glutathione reductase, and garlic oil 
increased the activity of superoxide dismutase (SOD) (Gudi and Singh, 1991). Similarly, 
DAS and garlic homogenates decreased catalasc (CAT) in the livers of rats and mice 
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(Sheen et al., 1996). Aged garlic extract (AGE), SAC, and SAMC exhibited radical 
scavenging activity in both chemiluminescence and l,l-diphenyl-2-picr}lhydraz\ I 
(DPPH) assays against t-butyl hydroperoxide-induced ROS in liver microsomal fraction 
(Imai et al., 1994). DAS, DADS, and AMS showed selective actions on different markers 
in tests for their ability to react with carbon tetrachloride (CCI4) generated free radicals 
(Fanelh' et al., 1998). Aged garlic extract containing both water and lipid soluble 
organosulfur components including S-allylcysteine (SAC) and S-allylmercaptocysteine 
(SAMC) is reported to have antioxidant action by enhancing cellular antioxidant enzymes 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) (Borek. 
2001). SAC and SAMC also increased the synthesis of glutathione (GSH) in human 
prostate cancer cells (Pinto et al., 1997). 
Inhibition of Cell Cycle Progression 
Cell cycle consists of a series of events involving growth stimulus, replication and 
division of a eukaryotic ceil (Molinari, 2000; Murray, 2004). Cellular stresses may 
activate signal transduction pathways, referred to as checkpoints, which lead to cell cycle 
arrest (Molinari, 2000; Murray, 2004). The cell cycle checkpoints ensure completion of 
phase specific events and protect against genomic instability or, in cases where the 
damage is too severe, switch the ceil fate to programmed cell death (Molinari, 2000; 
Murray, 2004). Many anticancer treatments initially cause perturbations in cell cycle 
progression and the interrupted phase depends on the genetic background of the cell as 
well as the mode of action of a given treatment. Studies have shown that garlic-derived 
OSC can suppress growth of cancer cells of different anatomical locations in association 
with cell cycle arrest, mainly in the G2/M phase of the cell cycle. 
Milner and colleagues were the first to show that DADS treatment caused dose-
dependent and time dependent accumulation of human colon cancer cells in the G:/M 
phase of the cell cycle (Knowles and Milner, 1998; Knowles and Milner, 2000). The 
DADS-mediated G2/M phase cell cycle arrest in human colon cancer cells was 
accompanied by a decrease in the kinase activity of the Cdkl/ cyclin Bl complex. 
reduction in complex formation between Cdkl and cyclin 81, and a decrease in Cdc25C 
protein level (Knowles and Milner, 2000). Similar effects have been reported in other 
cellular systems with other organosulfur compounds (OSCs) (Tan e/ al., 2004; 
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Arunkumar el al., 2006; Wu et ai, 2004; Xiao el ciL, 2005; F4ernian-Antosievvicz and 
Singh, 2005; Herman-Antosiewicz, 2007; Antosiewicz, 2006). For instance, DADS (20 
j-imoI/L, 12 h) caused inactivating phosphorylation of Cdkl in HL-60 cells (Tan e/ uL. 
2004) or decreased Cdkl level in PC-3 human prostate cancer cells in a dose-dependent 
manner (Arunkumar et al, 2006). DATS was much more effective than either DADS or 
DAS in causing G2/M phase cell cycle arrest (Xiao el al., 2005). These results further 
support the notion that even a subtle change in OSC structure (the oligosulfide chain 
length) could have a significant impact on its biological activity. Interestingly, a normal 
prostate epithelial cell line PrEC was resistant to growth inhibition and cell cycle arrest 
by DATS (Xiao et ai, 2005). The DATS-induced G2/M phase cell cycle arrest in PC-3 
cells was associated with increased Tyrl5 phosphorylation of Cdkl, inhibition of 
Cdkl/cyclin Bl activity, increased inhibitory phosphorylation of Cdc25C at Ser216. and 
downregulation of total Cdc25C protein level (Xiao et al., 2005). The DATS-mediated 
hyperphosphorylaticn and decline in protein level of Cdc25C were abrogated in the 
presence of anti-oxidants, suggesting a redox-sensitive mechanism for these effects (Xiao 
et al., 2005). Recent studies have revealed that DATS-mediated cell cycle arrest, at least 
in human prostate cancer cells, is linked to c-Jun N-termina! kinase (JNK)-dependent 
generation of reactive oxygen species (ROS) (Antosiewicz, 2006). 
Several studies show that OSCs affect the microtubule network in cancer cells that might 
initiate mitotic block or apoptosis. For example, treatment of SW480 human colon cancer 
cells or NIH3T3 mouse fibroblasts with 150 )imol/L water-soluble SAMC caused rapid 
microtubule depolymerization and cytoskeleton disruption in interphase cells (Xiao et al., 
2003). DATS, but not DADS or DAS, has been shown to induce mitotic arrest in HC"T-
15 and DLD-1 human colon cancer cells in association with disruption of the microtubule 
network in interphase cells and inhibition of spindle formation in mitotic cells (Hosono ct 
ai, 2005). This study further revealed DATS-mediated oxidative modification of tubulin-
P at residues Cysl2 and Cys354 (Hosono et al., 2005). Another oil-soluble garlic 
compound, Z-ajoene, caused G2/M phase cell cycle arrest and disruption of the 
microtubule network in normal marsupial kidney cells and inhibited tubulin 
polymerization in vitro (Li et al., 2002). A few reports have also shown that garlic-
derived OSCs arrest cancer cells in phases other than G2/M. The DADS mediated 
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suppression of human nosopharyngeal carcinoma cell growth correlated with S phase 
arrest (Zhang et al., 2006). Allitridi, synthetic DATS, was shown to arrest human gastric 
cancer BGC823 cells in the Gi phase and was accompanied by a decrease in cyclin Dl 
level and an increase in p27 protein level (Lan et al., 2003). Nevertheless, inhibition of 
ceil cycle progression appears to be a common cellular response to many structurally 
diverse OSCs. 
Induction of Programmed Cell Death (Apoptosis) 
Apoptosis (also known as programmed cell death) is a tightly controlled and 
evolutionarily conserved process of cellular suicide critical to normal embryonic 
development'and maintenance of tissue homeostasis. Dysregulation of programmed cell 
death underlies numerous pathological conditions including cancer and, therefore, 
apoptosis is a valid target in cancer therapy and prevention (Kaufmann, 2000; Ghobrial et 
ai, 2005). Garlic-derived OSCs have been shown to modulate a number of key elements 
in cellular signal transduction pathways linked to the apoptotic process. The majority of 
garlic-derived compounds activate the so called intrinsic or mitochondria-mediated 
pathway in the execution of apoptosis, which involves loss of mitochondrial membrane 
potential and release of apoptogenic molecules from the mitochondria to the cytosol 
(Hengartner, 2000; Thornberry and Lazebnick, 1998). Activation of the intrinsic 
apoptotic pathway is regulated by the Bcl-2 family of anti-apoptotic (eg. Bcl-2 and Bcl-
xL) and proapoptotic (eg. Bax and Bak) proteins (Chao and Korsmeyer, 1998). Garlic-
derived OSCs are believed to trigger apoptosis by modulating the levels of Bcl-2 
proteins. For example, DAS or DADS treatment increased the ratio of Bax/Bcl-2 in SH-
SY5Y neuroblastoma cells, as well as in H460 and H1299 lung cancer cells compared 
with untreated controls (Karmakar et al., 2007; Hong et al., 2000). A time-dependent 
upregulation of Bax protein level and concomitant downregulation of Bcl-xL protein 
level was observed in DADS treated MDA-lVlB-231 breast cancer cell line (Nakagawa el 
al., 2001). The Z-ajoene-induced apoptosis in HL-60 cells was associated with caspase-
mediated cleavage of Bcl-2 (Li el al., 2002). 
A previous study has shown that DATS is a more potent inducer of apoptosis in PC-3 and 
DU145 prostate cancer cells than DAS or DADS (Xiao et ai, 2004). The DATS induced 
apoptosis in prostate cancer cells correlates with a decrease in Bcl-2 level as well as with 
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hyperphosphoryiation of this protein, wiiich reduces Bcl-2/Bax interaction and activates 
the mitochondrial pathway of apoptosis (Xiao et al., 2004). The DATS-induced apoptosis 
in LNCai' ceils correlated with a modest increase in protein levels of pro-apoptotic Bcl-2 
family members Bax and Bak (Kim et al, 2007). The DATS-mediated 
hyperphosphoryiation of Bcl-2 in PC-3 and DU145 cells is caused by activation of .INK 
and, to a lesser extent, extracellular signal-regulated kinase V2 (ERKl/2) (Xiao el uL, 
2004). Overexpression of Bcl-2 in PC-3 cells conferred statistically significant protection 
against DATS-induced apoptosis (Xiao et al., 2004). On the other hand, ectopic 
expression of Bcl-2 failed to protect against DATS-mediated cell death in LNCaP human 
prostate cancer cells (Kim et al, 2007). Furthermore, a recent study showed that DATS-
mediated inhibition of PC-3 xenograft growth in nude mice correlated not only with 
increased apoptosis but also with induction of Bax and Bak proteins in the tumor tissue 
(Xiao et al, 2006). 
A previous study has shown that the DATS-induced apoptosis in human prostate cancer 
cells was, at least in part, regulated by the Akt-Bad pathway (Xiao el al, 2006). One of 
the pro-survival functions of Akt (also known as protein kinase B) is to phosphorylate 
Bad, which causes cytoplasmic sequestration of Bad and consequently protection against 
interaction with anti-apoptotic Bcl-2 family members. DATS treatment markedly reduced 
Akt activity in PC-3 and DU145 cells and consequently lowered the phosphorylation of 
Bad at Serl55 and Serl36, which diminished complex formation between Bad and 
cytosolic 14-3-3p (Xiao et al, 2006). Overexpression of constitutively active Akt in PC-3 
cells conferred significant protection against DATS-induced apoptosis (Xiao et al, 
2006). 
Experimental evidence exists to support a critical role of ROS as an intermediary of 
OSC-induced apoptosis. For instance, DADS-induced apoptosis in HL-60 cells is 
correlated with ROS generation (Kwon et al, 2002). The DADS-induced ROS formation 
in SH-SY5Y neuroblastoma cells is evident as early as 15 min after treatment and is 
accompanied by oxidation of cellular lipids and proteins (Filomeni et al, 2003). ROS 
generation in DADS treated cells was associated with activation of JNK (Filomeni et al, 
2003). Overexpression of Cu, Zn-superoxide dismutase or pretreatment with spin 
trapping molecule 5,5'-dimethyl-l-pyrroline //oxide offered protection against DADS-
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induced ROS generation, oxidative damage of cellular macromolecules and apoptosis in 
SH-SY5Y cells (Filomeni et al., 2003). 
A few studies have suggested that apoptosis induction by OSC might result from an 
increase in free intracellular calcium (Karmakar el al., 2007; Sundaram and Milner, 1996; 
Sundaram and Milner, 1996; Park el al., 2002; Sakamoto el al.. 1997). Park ei al. 
reported DADS-mediated increase in intracellular calcium level which was followed by 
an increase in hydrogen peroxide level and caspase-3 activation (Park el al.. 2002). 
Recently, it has been shown that both DAS and DADS cause an increase in calcium level 
in SH-SY5Y cells, which leads to activation of a non-caspase cysteine protease calpain 
which can contribute to cell death by inducing mitochondria-mediated apoptosis 
independently of caspases (Karmakar el al., 2007). 
Some of the studie;? cited above have compared apoptotic responses to OSC in cancer 
cells versus normal cells. Strikingly, malignant cells appear to be more sensitive to OSC-
mediated apoptosis than normal non-transformed cells. For example, viability of primary 
neurons was minimally affected by treatment with 50 or 100 f.unol/1 DAS or DADS, 
whereas the neuroblastoma of SH-SY5Y cells treated with these concentrations of DAS 
or DADS exhibited a marked reduction in cell viability (Karmakar et al.. 2007). 
Similarly, the viability of a normal prostate epithelial line PrEC was not affected by 
DATS treatment even at concentrations that are highly cytotoxic to prostate cancer cells 
(Xiao et al., 2005; Kim et al., 2007). Finally, Z-ajoene has been shown to cause apoptosis 
in human leukemia cells, but not in peripheral mononuclear blood cells of healthy donors 
(Dirsch et al., 1998). The mechanism behind the differential sensitivity of cancer cells 
and normal cells to apoptosis induction by OSCs remains to be elucidated. 
Histone Modificatiion 
OSCs may affect cancer cell proliferation through modification of histone acel_\ lalion 
and, thus, regulation of gene expression. It has been reported that treatment of DS19 
mouse erythroleukemia and K562 human leukemia cells with DADS increases 
acetylation of histones H4 and H3 (Lea et al., 1999). DADS and its metabolite, allyl 
mercaptan, inhibited histone deacetylases in rat hepatoma and human breast cancer cells 
and it has been suggested that histone acetylation may mediate the differentiation process 
of erythroleukemia cells (Lea et al., 1999). Growth inhibitory effects of Allicin, SAMC 
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and SAC on DS19 cells and SAMC on Caco-2 human colon and T47D human breast 
cancer cells are correlated with increased histone acetylation (Lea et al.^ 2002). The 
DADS-induced accumulation of Caco-2 and HT-29 colon tumor cells in the G;/M phase 
of the cell cycle is correlated with inhibition of histone deacetylase, hyperacetylation of 
H3 and H4 histones, and iipregulation of p21 mRNA and protein level (Druesne el al. 
2004; Druesne et al, 2004). 
Inhibition of Angiogenesis and Metastasis by Garlic Constituents 
Recent studies using cellular and animal models indicate that garlic extract and its 
components are able to affect tumor angiogenesis and metastasis. The formation of new 
blood vessels is necessary for the growth of solid tumors because evidence exists to 
suggest that tumor growth beyond 1 mm in diameter is restricted by angiogenesis 
(Folkman, 2003). A study by Matsuura el al. showed that aged garlic extract (AGE) 
suppressed proliferation of transformed human and rat endothelial cell lines and reduced 
the invasiveness of the endothelial cells by about 20%-30% (Matsuura el al, 2006). 
Additional tests indicated that AGE increased the adhesion of the endothelial cells to 
collagen and fibronectin in a dose-dependent manner; thus, reducing their motility 
(Matsuura et al, 2006). In another study, Xiao ei al examined the effects of DAS, DADS 
and DATS on human umbilical vein endothelial cell (HUVEC) viability and have shown 
that DATS is the most potent of the three analogs in reducing the viability of IIUVHC 
(Xiao et al, 2006). Alliin was shown to significantly reduce VEGF and fibroblast growtli 
factor-2 (FGF-2)-induced tube formation and angiogenesis in HUVEC (Mousa and 
Mousa, 2005). A recent study showed that DADS and DAS not only inhibited endothelial 
cell proliferation and migration, but also reduced matrix metalloproteinases 2 and 9 
(Thejass and Kuttan, 2007). Based on the reviewed studies it can be concluded that 
components of garlic extract (in combination or alone) present a great potential as anti-
angiogenic and anti-metastatic agents. 
Modulation of P-glycoprotein Mediated Multidrug Resistance 
Multidrug resistance (MDR) mediated by the over-expression of drug efflux protein P-
glycoprotein (P-gp) is one of the major obstacles to successful cancer chemotherapy. 
Garlic OSCs have been shown recently to modulate the P-gp mediated multidrug 
resistance. DAS (8.75x10'-^  M) decreased the induced levels of P-gp in K562 leukemic 
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resistant cells back to the normal levels (Arora et ai, 2004). in another study, it was 
shown that OSCs present in a garlic-rich diet might alter chemotherapeutic treatments 
using P-gp substrates in renal brush-border membranes (Demeule cl a/.. 2004). In a 
recent study, effects of dietary phytochemicals on P-gp function were investigated using 
human IMDR carcinoma KB-C2 cells and the fluorescent P-gp substrates daunorubicin 
and rhodamine 123. DAS and DATS were shown to be capable of modulating the effect 
of P-gp overexpression (Nabekura et al., 2005). 
In summary, research over the past 20 years has revealed that garlic derived OSCs can 
not only inhibit chemically induced cancers but can also suppress growth of cancer cells 
in culture and in vivo. The garlic compounds appear to target multiple pathways, 
including the cell cycle machinery, the intrinsic pathway for apoptotic cell death and 
angiogenic pathway, which may all contribute to their anticancer activities. 
Apoptosis (Programmed Cell Death) 
Apoptosis, or programmed cell death (PCD), is an evolutionarily conserved mechanism 
for the selective removal of aging, damaged or otherwise unwanted cells (Thorburn. 
2004; Lawen, 2003; Abe et al., 2000; Strasser et al., 2000; Peter and Krammer, 1998). Il 
is an essential component of many normal physiological processes such as 
embryogenesis, normal tissue development, and the immune response (Vaux and 
Korsmeyer, 1999). Thus, regulation of apoptosis is critical for tissue homeostasis and its 
deregulation can lead to a variety of pathological conditions including carcinogenesis and 
chemoresistance (Sheikh and Huang, 2004; Ozoren and El-Deiry, 2003; Green and Evan. 
2002;Zornige/a/., 2001; Daniel e/o/., 2001; Thompson, 1995). 
Apoptosis is mediated primarily through the activation of specific proteases called 
caspases (cysteinyl, aspartate-specific proteases) (Algeciras-Schimnich et al., 2002: 
Ozoren and El-Deiry, 2003; Salvesen and Dixit, 1997; Stegh and Peter, 2001; Thorburn. 
2004). Caspases are effectors of cell suicide and cleave multiple substrates, leading to 
biochemical and morphological changes that are characteristic of apoptotic cells (Abe ci 
al., 2000; Slrasscr et al., 2000). These alterations include: mitochondrial outer membrane 
permcabilization; cell membrane remodeling and blebbing; exposure of 
phosphatidyiserine (PS) at the external surface of the cell; cell shrinkage wiih 
cytoskeletal rearrangements; nuclear condensation; and DNA fragmcnlalion (Ashkena/i 
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and Dixit, 1999; Green and Evan, 2002; Lavven, 2003; Peter and Krammer, 2003; 
Schulze-Osthoff e/ al., 1998; Thorburn, 2004). These morphological changes culminate 
in the formation of apoptotic bodies that are normally eliminated by phagocytosis (Gcske 
and Gerschenson, 2001; Wallach, 1997). 
In mammalian systems, the extrinsic death receptor pathway and the intrinsic 
mitochondrial pathway are the two major signaling systems that result in the activation of 
the executioner/effector caspases and the consequent demise of the cell (Abe ci a/., 2000; 
Ozoren and EI-Deiry, 2003; Peter and Krammer, 2003; Strasser et al., 2000; Thorburn, 
2004) (Fig. 8). In many cell types, including cancer cells, activation of the extrinsic 
pathway also engages the mitochondrial pathway for full execution of cell death (Jaattela. 
2004; Kroemer, 2003; Thorburn, 2004). Thus, many apoptotic signals merge at the 
mitochondria, and thus mitochondria have been termed "gatekeepers" of the apoptotic 
machinery (Jaattela, 2004; Kroemer, 2003; Thorburn, 2004). As gatekeepers, the proteins 
comprising the intrinsic mitochondrial pathway are the major mediators of the cytotoxic 
effects of many chemotherapeutic agents and radiation therapy (Brenner et uL, 2003; 
Costantini et al., 2000; Debatin et al., 2002; Hersey and Zhang, 2003). Cancer cells oiten 
evade this apoptosis and develop chemoresistance and radioresistance. Indeed, disruption 
of the mitochondrial apoptotic machinery has been observed in many tumors (Danie! ci 
al., 2001; Morisaki and Katano, 2003). It is also likely that disruption of the 
mitochondrial machinery or mutations in the mitochondrial DNA could play a role in 
cancer initiation. Because of the central role of mitochondria in these processes, various 
components of the mitochondrial machinery can be targets for novel therapeutic 
strategies. 
The Mitochondrial Pathway of Apoptosis 
Mitochondria are thought to be the primary organelles involved in mediating most 
apoptotic pathways in mammalian cells (Green and Kroemer, 2004; Kroemer, 2003; 
Ravagnan et al., 2002; Sorice et al, 2004; Zamzami and Kroemer, 2001). Mitochondria 
are engaged via the intrinsic pathway of cell death, which can be initiated by a variety of 
stress stimuli, including ultraviolet (UV) radiation, y-irradiation, heat, DNA damage, the 
actions of some oncoproteins and tumor suppressor genes (i.e. p53). viral virulence 
factors, and most chemotherapeutic agents (Fig. 8) (Kroemer, 2003). These diverse forms 
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of stress are sensed by multiple cytosolic or intraorganellar molecules. Transduction of 
these signals to tlie mitochondria ultimately results in alterations of the outer 
mitochondrial membrane (OM) (Esposti et al, 2003; Green and Kroemer. 2004; Kuvvana 
et al., 2002; Zamzami and Kroemer, 2001). These changes in the OM then lead to 
increased permeability to proteins that normally reside between the OM and the inner 
mitochondrial membrane (IM), enabling these proteins to escape the mitochondria and 
diffuse into the cytosol. 
The mitochondrial pathway of apoptosis can also be activated in response to death 
ligands. In a majority of cells (type II cells), including tumor cells, extracellular death 
signals engage the miitochondria in a way that is equivalent to the intrinsic pathway (Abe 
et al, 2000; Algeciras-Schimnich et al., 2002; Ozoren and EI-Deiry, 2002; Peter and 
Krammer, 1998). In these cells, signals originating from the death ligand-induced 
activation of caspass-8 and caspase-10 bifurcate into two arms, one of which directly 
engages mitochondria via a sequence of events causing activation of the effector caspases 
(i.e. caspase-3). The second arm promotes the cleavage of non-caspase substrates, such as 
Bid, inducing changes in the mitochondrial OM and the release of apoptogenic factors 
and activation of caspase-9, which then cooperates with the less-efficient activation of 
caspase-8 in these cells. 
The Release of Proapoptotic Factors 
Mitochondria contain and release many soluble proteins that are involved in the apoptotic 
cascade (Fig. 9) (Daniel et al., 2001; Debatin et al., 2002; Green and Kroemer, 2004; 
Reed, 2004). The variety of mitochondrial proteins participating in this pathway indicates 
the pivotal role of these organelles in determining cellular fates. Bcl-2 family members 
control apoptosis by regulating the permeabilization of the mitochondrial membrane 
(Chao and Korsmeyer, 1998; Cory el al., 2003; Daniel et al., 2001). The release of 
mitochondrial proteins, including cytochrome c, apoptosis-inducing factor (/\1F). second 
mitochondria-derived activator of caspases (Smac/Diablo), high-temperature requirement 
A2 (HtrA2/0mi), and endonuclease G, is believed to play a pivotal role in inducing 
programmed cell ccath (PCD) (Martinou and Green, 2001: Zamzami and Kroemer. 
2001). 
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Figure 9: Schematic representation of mitochondrial membrane permeabilization. 
Mitochondrial membnine permeabilization is regulated by an elegant balance of opposing 
actions of proapoptotic and antiapoptotic Bcl-2 family members. Bax, Bad, and Bak 
promote the release of cytochrome c and AIF through the formation of transmembrane 
chamiels across the mitochondrial outer membrane, while Bcl-2 and Bcl-XL delay this 
release and abort the apoptotic response, leading to cell survival. Besides the release of 
mitochondrial proapoptotic components, the loss of mitochondrial membrane integrity 
results in the loss of many essential biochemical cellular functions such as ATP synthesis 
and results in the generation of reactive oxygen species (ROS). The increased levels of 
ROS are directly linked to the oxidation of lipids, proteins, and nucleic acids. 
Cytochrome C 
Cytochrome c (Cyt c), a small (13 kDa) nuclear encoded mitochondrial protein, was the 
first protein identified as being released from mitochondria upon apoptosis. It is 
considered a key regulator of apoptosis because once it is released from the 
mitochondrial intermembrane space (IMS), the cell is irreversibly committed to death 
(Green and Evan, 2002; Kluck et al, 1997; Zhivotovsky et al., 1998a; Zhivotovsky ei uL, 
1998b). The release of cytochrome c to the cytosol is considered among the major steps 
in the intrinsic death pathway (Kluck et a/., 1997; "Newmeyer and Ferguson-Miller, 2003; 
Zhivotovsky et al, 1998a). Once it escapes to the cytosol, it is captured by ihe apoptosis 
protease activating factor (APAF-1), a 130 kDa adaptor protein (Soengas et al, 1999; 
Zou et al, 1999). Prior to binding Cyt c, APAF-1 is virtually inactive. Once bound to Cyt 
c, the APAF-1 monomer goes through a cytochrome c-induced conformational change 
that promotes its activation. Further oligomerization occurs, resulting in a cartwheel-
shaped heptameric structure containing seven Cyt c/APAF-1 complexes. This larger 
multiprotein complex is termed the apoptosome (Acehan et al, 2002; Adrain el al, 2001; 
Adrain et al, 1999; Srinivasula et al, 1999). Pro-caspase-9 is recruited to the 
apoptosome through its CARD domain, promoting its cleavage and converting it to an 
active protease (Adrain et al, 1999). Consequently, caspase-9 dissociates from the 
complex and goes on to activate effector caspases (3, 6, and 7) which collectively 
orchestrate the execution of apoptosis (Slee et al, 1999; Srinivasula et al, 1999; Zou ct 
al, 1999). 
Apoptosis-Inducing Factor 
The precursor of the protein AlF is synthesized in the cytosol and imported into 
mitochondria (Susin et al, 1999). It contains an N-terminal mitochondrial localization 
sequence (MLS) which is cleaved upon its mitochondrial translocation to form the mature 
57 kDa AlF (Susin et al, 1999). Under apoptosis-inducing conditions, AlF translocates 
through the permeabilized mitochondrial outer membrane to the cytosol (Cande el al, 
2002; Susin et al, 1999). Subsequently, AlF is transported to the nucleus where it 
induces ATP-independent nuclear chromatin condensation, as well as large-scale DNA 
fragmentation (Cande et al, 2002; Susin et al, 1999). 
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Smac/Diablo 
Second mitochondria-derived activator of caspases (Smac) is a 22 l<Da mitocliondrial 
protein also known as direct lAP-associated binding protein witli low pi (Diablo). 
Inhibitors of apoptosis (lAP) family members have the ability to interact and inhibit the 
enzymatic activity of caspases through their baculovirus inhibitor repeat (BIR) functional 
motif (Deveraux and Reed, 1999; Miller, 1999). The Smac/Diablo precursor is 
synthesized in the cytosol, then imported to the mitochondria where it is cleaved and 
activated. A mature form of Smac/Diablo is released to the cytosol under apoptotic 
conditions. Unlike cytochrome c, which directly activates APAF-I and caspase-9, 
Smac/Diablo binds to the BIR domains of multiple lAP members, antagonizing them and 
promoting indirect caspase activation (Ekert el ai, 2001; Srinivasula ci a!.. 1999: 
Verhagen and Vaux, 2002). 
HtrA2/0mi 
HtrA2, also referred to as Omi, is a mitochondrial protein that belongs to the family of 
serine proteases. This proapoptotic protein is expressed as a 50 kDa precursor that is 
cleaved at the N-terminal, upon translocation to the mitochondria, to generate the active 
36 kDa protein (Hegde et a/., 2002; Martins et ai, 2002; Suzuki et ai, 2001; Verhagen 
and Vaux, 2002). Similar to cytochrome c and Smac/Diablo, mature HtrA2/0mi localizes 
to the IMS (Hegde et ai, 2002; Suzuki et al, 2004). Its release to the cytosol is 
stimulated by apoptotic triggers. Upon its release, HtrA2/0mi binds directly to the BIR 
domain of lAPs and inhibits their caspase-inhibitory activity (Suzuki et uL. 2001). 
Endonuclease G 
As with most mitochondrial proteins, Endonuclease G is expressed as a precursor in the 
cytosol. Upon its translocation to the mitochondria, the 33 kDa protein is cleaved to a 28 
kDa mature form (Cote and Ruiz-Carrillo, 1993). During apoptosis, endonuclease G is 
released from the mitochondrial IMS and translocates to the nucleus, where it causes 
oligonucleosomal DNA fragmentation (Li et al, 2001; van Loo et al. 2001). 
Endonuclease G release appears to be dependent on caspase activation downstream of 
mitochondria (Arnoult el al, 2003). 
35 
Mitochondrial Proteins and Caspase Activation 
Among the various proteins that leak out of mitochondria, a few, such as cytochrome c, 
play a major role in promoting caspase activation. (Kluck el al., 1999; Saeiens el al., 
2004) These apoptogenic factors are released in a hierarchical manner during cell death. 
Upon activation of the intrinsic pathway, cytochrome c, Htr2A/0mi and Smac/ Diablo 
are released first, vv'ith similar kinetics (Saeiens et al., 2004). The subsequent release of 
AIF and endonuclease G (Arnoult et al, 2003; Penninger and Kroemer, 2003) is 
associated with more severe damage to both the outer and inner membranes. Notably, 
cytochrome c has been shown to be directly involved in the mediation of cell death, as it 
is indispensable for the activation of Apaf-1 and subsequent Ibrmation of the apoptosome 
(Arnoult et al, 2003). 
The apoptosome itself is a platform for recruiting and facilitating the autocatalytic 
activation of pro-caspase-9, the apical caspase of the intrinsic pathway of apoptosis 
(Adams and Cory, 2002; Baliga and Kumar, 2003; Cain et al, 2002; Chinnaiyan, 1999; 
Hill et al, 2003; Salvesen and Renatus, 2002; Shi, 2002). The activation of caspase-9 
leads to the local accumulation of zymogens, promoting an autocatalytic process of 
downstream caspase activation (Adams and Cory, 2002;Baliga and Kumar, 2003; Cain c! 
al., 2002; Chinnaiyan, 1999; Hill et al, 2003; Salvesen and Renatus, 2002; Shi, 2002). 
However, the apoptosome requires additional regulatory factors, including Smac/Diablo, 
for full activation of the caspase cascade. Smac/Diablo interacts with several lAPs to 
release them from their inhibitory interaction with pro-caspase-9 and other caspases 
(Adams and Cory, 2002; Baliga and Kumar, 2003; Cain et al, 2002; Shi, 2002). 
Smac/Diablo is also present in the mitochondria, where it is directly attached to the OM 
and is released upon alterations in the OM permeability (Cain et al, 2002; Saeiens el al. 
2004). 
The BcI-2 Family of Proteins and Regulation of the Mitochondrial 
Pathway to Cell Death 
The process of mitochondrial release of proapoptotic factors such as cytochrome c is 
elegantly regulated through members of the Bcl-2 family (Antonsson el al, 1997: Cory et 
al, 2003; Danial and Korsmeyer, 2004; Green and Kroemer, 2004; Schendel el al, 1997) 
(Fig. 9). In mammals, the antiapoptotic members of this family include l3cl-2, Bcl-XL, 
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and Bcl-W, while the proapoptotic members include Bax, Bak, Bad, Bik, Bim, and Bid. 
The proapoptotic family members are further classified based on domain sequence 
homology into two groups: one that contains multiple BH domains and one that contains 
only the BH3 domain (Cheng et al., 2001; Fiers et al., 1999; Kuwana and Newmeyer, 
2003; Wei et al, 2001). The fate of the cell depends to a great degree on the precious 
balance of function between these proapoptotic and antiapoptotic Bcl-2 proteins. Studies 
have shown that Bax, Bad, and Bak promote the release of AIF and cytochrome c, while 
Bcl-2 and Bcl-XL delay the release and abort the apoptotic response, promoting cell 
survival (Cory and Adams, 2002; Yang et al, 1997), 
It is believed that Bcl-2 family members regulate the apoptotic response by controlling 
mitochondrial membrane permeabilization (MMP) (Green and Kroemer, 2004). The 
proapoptotic proteins Bax and Bak have been shown to contribute to the formation of 
transmembrane channels across the mitochondrial OM, leading to the escape of A IPs 
(Dejean et al., 2005; Korsmeyer et al, 2000; Kuwana et al, 2002; Nechushtan et al, 
2001; Wei et al, 2001). Bcl-2, Bcl-W, and Bcl-XL are, on the other hand, believed to 
prevent pore formation and to inhibit the release of cytochrome c from the mitochondria 
(Kluck et al, 1997; Yang et al, 1997). Moreover, heterodimerization of Bax or Bad with 
Bcl-2 or Bcl-XL is thought to inhibit their protective effect. 
Bid is a potent proapoptotic protein that is normally located in the cytosol, but also 
shuttles through the surfaces of intracellular membranes due to its lipid-interacting 
capacity. Bid plays an important role in the mitochondrial pathway to apoptosis as it has 
been identified as the link between the death receptor signal and the release of 
cytochrome c. Activated caspase-8 engages the intrinsic apoptotic pathway through the 
truncation of Bid (Li et al, 1998; Luo et al, 1998). Upon death signaling, activated 
caspase-8 cleaves Bid (26 kDa) into two fragments: a C-terminus fragment (15 kDa) and 
an N-terminus fragment (II kDa) (Luo et al, 1998). The 15 kDa fragment, which 
contains the BH3 domain, is termed truncated Bid or tBid. This functional fragment 
translocates to the mitochondria where it interacts with several proteins through its BH3 
domain (Wang et al, 1996). There are two modes of Bid proapoptotic action. (I) In the 
BH3-dependent mode, Bid interacts with the antiapoptotic Bcl-XL through its BII3 
domain and prevents the formation of the Bcl-XL/Apafl antiapoptotic complex. (2) In 
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the BH3-independent mode, after truncation, Bid is proposed to form selective channels 
similar to BAX through its structural motifs (Chou et ai, 1999; McDonnell et ai, 1999). 
Moreover, tBid has been shown to induce the oligomerization of Bax and Bak, resulting 
in MAC formation and the subsequent release of proapoptotic cytochrome c (Eskes el ai, 
2000; Wei et ai, 2000). 
The mitochondrial receptor for caspase-cleaved Bid is thought to be cardiolipin (CL), a 
mitochondrial lipid (Esposti et al., 2003; Kuwana et al., 2002; Newmeyer and Ferguson-
Miller, 2003; Sorice et al., 2004). CL is a glycerophospholipid that is synthesized and 
localized in the inner membrane of the mitochondria, making it one of its major 
constituents (Khosravi-Far and Esposti, 2004; McMillin and Dowhan, 2002; Schlame et 
al., 2000; Wright et al., 2004). This dimeric molecule apparently plays a significant role 
in controlling the mitochondrial membrane structure and function. It has been proposed 
that upon apoptotic stimulation, CL contributes to the apoptotic signal through the 
recruitment of cytosolic proteins such as tBid to the mitochondrial membrane. 
Additionally, it is thought that CL is involved in altering MMP, leading to the subsequent 
release of proapoptotic factors (Lutteretal., 2000). 
Targeting Mitochondria in Cancer Therapy 
As mitochondria are gatekeepers of apoptotic signals, targeting mitochondria to induce 
apoptosis of malignant cells is an important therapeutic strategy. In the past several years, 
extensive research has focused on screening for chemical compounds, small molecules 
and peptides that could target the mitochondria. Therapeutic tactics have included 
strategies that involve the Bcl-2 family proteins, activation of PTPs, the respiratory chain, 
mitochondrial DNA depletion, and selective targeting of ROS-stressed malignant cells, as 
well as targeting inhibitors of apoptosis such as lAPs (Dias and Bailly, 2005). Targeting 
the antiapoptotic members of the Bcl-2 family, namely Bcl-2 and Bcl-XL, and targeting 
the PTP are among the most studied mechanisms (Dias and Bailly, 2005; O'Neill e/ al.. 
2004; Shangary and Johnson, 2003; Walensky, 2006). The induction of proapoptotic 
protein release through increased PTP formation and opening has been explored in the 
recent years as a possible mechanism for cancer treatment. As a chemotherapeutic 
approach, this method involves perturbation of the mitochondrial membrane through 
direct targeting of the components of the membrane permeability transition pore complex 
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(PTPC) (Brenner et al, 2003;Costantini et al., 2000; Debatin et al., 2002; Fantin and 
Leder, 2006; Galluzzi et al., 2006; Khosravi-Far and Esposti, 2004; Morisaki and Katano, 
2003; Reed, 2004). 
In summary, the intrinsic and extrinsic death pathways leading to changes in 
mitochondrial permeability, the components of the PTPC, including members of the BcJ-
2 family, apoptogenic factors and their regulators, and mutations in mtDNA have been 
studied extensively in the past for their contributions to cancer progression or resistance 
to therapy. These constitute an extensive list of targets that could induce apoptosis, some 
with possible specificity for cancer cells. Therapeutic agents against many of these 
targets, including Bcl-2 family members and components of the PTP, are currently at 
various stages in the development pipeline. The ultimate goal of these studies is to 
generate novel mitotoxic agents that can selectively induce apoptosis of cancer cells and 
reduce the possibility of resistance. 
Role of Glutathione (GSH) in Maintaining Cellular Redox Environment 
Glutathione (GSH) is a tripeptide produced naturally in the body, with an intracellular 
concentration of 1-10 mM in mammalian cells. It is the most abundant non-protein 
molecule in the cell and has a number of physiological roles. GSH is synthesized 
intracellularly from its constituent amino acids: glutamic acid, cysteine and glycine via 
two sequential ATP-consuming steps, which are catalysed by y-gli-itamylcysteine 
synthetase (y-GCS) and GSH synthetase (Fig. 10). 
Under normal conditions, the majority of GSH exists in reduced form (0.5 to 10 mM) 
(Kosower and Kosower, 1978). Oxidation of the reduced GSH to form oxidized 
glutathione (GSSG) is carried out either by direct interaction with free radicals or, more 
often, when GSH acts as a cofactor for antioxidant enzymes such as glutathione 
peroxidases (GPx) during the reduction of H202 and phospholipid hydroperoxide 
glutathione peroxidases. Also, GSSG is formed when glutathione transhydrogenase 
(glutaredoxin reductase) uses GSH to reduce the disulfide bond in glutarcdoxin, the 
downstream action of which leads to the formation of deoxyribonucleotides (via the 
activation of ribonucleotide reductase) (Holmgren, 1989). However, highly efficient 
NADPH-dependent reduction of GSSG by glutathione reductase is able to maintain the 
intracellular concentration of GSSG at very low levels of around 5 to 50 mlVI (Kosower 
and Kosower, 1978). The ratio of the GSSG/GSH couple can serve as an important 
indicator of the cellular redox environment (Schafer and Buettner, 2001). Glutahione S-
transferases (GST) catalyse the conjugation of GSH with many exogenous as well as 
endogenous electrophilic substrates. GSTs are a family of phase II detoxification 
enzymes, which have broad substrate specificity. The human GSTs consist of six classes, 
namely alpha (a), mu (JJ), pi (n), theta (9), zeta © and omega (w), each of which is 
divided into one or more isoforms. The expression levels of different isoforms of GSTs 
are reported to be tissue specific (Salinas and Wong, 1999). GSTs are present 
predominantly in hepatic cells and other mammalian cells and tissues, such as 
erythrocytes and in the intestine. GST catalyses the conjugation of GSH with endogenous 
compounds such as the lipid peroxidation product, 4-hydroxy-2-nonenal, estrogens and 
cholesterol-5,6-oxide and with xenobiotics including environmental carcinogens such as 
benzo(a)pyrene 7,8-dihydrodiol-9,10-epoxide (BPDE) and acrolein, pesticides such as 
DDT and a number of drugs which include cisplatin and acetaminophen (Eaton and 
Bammler, 1999). 
GSH, which is transported to the cell membrane, becomes a substrate for membrane-
bound y-glutamyl transpeptidase (Griffith et al., 1978). y-glutamyl transpeptidase and 
dipeptidase catalyse the extracellular breakdown of GSH (Fig. 10). The y-glutamyl 
transpeptidase catalyses cleavage of the gamma linkage between glutamate and cysteine 
in an ATP-dependent manner, which generates cysteinylglycine. Cysteinylglycine is 
subsequently cleaved by dipeptidase to yield free cysteine and glycine (Fig. 10). 
The transportation of GSH is a very important aspect of GSH metabolism. Intracellular 
GSH concentrations vary between 0.5 and lOmM; however, only micromolar 
concentrations of GSH are found in blood plasma. The ability of many cells to transport 
GSH into the extracellular compartment may help in the transfer of cysteine, a limiting 
amino acid in glutathione synthesis de novo, between cells via the y-glutamyl cycle 
(Dickinson and Forman, 2002). In addition, GSH may protect the cell membrane b\ 
reducing harmful compounds such as highly reactive oxygen species in the cellular 
environment and facilitating the transport of molecules such as disulfides (Deiieke and 
Fanburg, 1989). 
40 
Plasma 
GSH 
Extracel lular space 
Giy Cys 
Endoplasmatic 
reticulum Mitochondria 
Cytosol; 
Figure 10: Glutatlliione biochemistry and intracellular pools. Some molecular 
mechanisms where ( JSH plays a key regulatory role are indicated within mitochondria, 
nucleus, and the endoplasmic reticulum, aa, amino acids; x, molecules that bind GSH 
forming conjugates; FRs, free radicals; (1) GGT; (2) y-glutamyl amino acid (y-Glu-aa) 
transporter; (3) dipeptidases; (4) Cyst(e)ine transporters; (5) y-Glu-cyclotransferase; (6) 
5-oxoprolinase; (7) GCS; (8) GSHS; (9) GPx; (10) GR; (11) transhydrogenases; (12) 
GSTs. 
Functions of Glutathione 
GSH has several different, yet vital, physiological roles, highlighted by its abundance 
within cells. It is the major cellular antioxidant and is crucial in maintaining the balance 
between oxidation and antioxidation. GSH is also important in cellular detoxification, 
and is required in many aspects of the immune response. 
Antioxidation 
Oxygen radical stress is caused as a byproduct of aerobic metabolism within all aerobic 
organisms. Highly active intermediates are formed, namely hydrogen peroxide and 
superoxide, which promote oxygen radical production, which in turn leads to cellular 
damage (Halliwell, 1994). GSH is the major endogenous soluble antioxidant in 
mammalian cells. It provides protection against oxidative stress through serving as a 
substrate for the antioxidant enzymes GSH peroxidase and phospholipid hydroperoxide 
GSH peroxidase (Takebe et ah, 2002) that convert peroxides into less harmful fatty acids, 
water and GSH disulfide. It is also able to protect cells against oxidative stress by non-
enzymatic scavenging of free radicals. Reduced GSH can directly scavenge radicals and 
peroxides via mixed disulfide formation, or upon oxidization to GSSG. This is able to 
prevent harmful effects on tissues associated with peroxidation of cell membrane lipids 
(Toborek and Hennig, 1994). There is evidence that a variety of oxygen radical stresses 
can result in GSSG formation and depletion of GSH in the short term (Deneke and 
Fanburg, 1989). 
Cells are very sensitive to signals via changes in their environment. A vast number of 
cellular processes are affected by the redox state of the cell, in which GSH has a pivotal 
role, with many signaling molecules being activated by GSH redox status, either directly, 
or indirectly through interaction with free radicals. Molecules activated in this way 
include activator protein-1 (AP-1), responsible for the expression of a number of genes 
including those for many cytokines, TGF-(3 and collagenase, activator protein-2 (AP-2), 
c-jun N-terminal kinase (JNK), stress-activated protein kinase (SAPK), protein kinase C 
(PKC) and tyrosine kinase (Janssen et al, 1993; Hayes and McLillen, 1999). These 
molecules are involved in a wide range of cellular pathways such as cellular prolileralion, 
differentiation and morphogenesis. A decrease in GSH level is also able to stimulate NF-
KB activation. In this way, GSH is able to regulate indirectly the expression of genes ihal 
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contain the NF-KB binding site in tiieir promoter including numerous cytol<.ines, receptors 
for cytokines and cell adhesion molecules. This activation is blocked by antioxidants 
such as the GSH precursor N-acetyl L-cysteine and other thiol compounds (Fernandez el 
al, 1999). 
Immunomodulation 
GSH is required in many stages of the immune response, httracellular GSH has been 
shown to modulate not only T-cell function, including the binding, internalization, and 
degradation of interleukin-2 (Liang et al, 1989), but also DNA synthesis (Suthanthiran ct 
a/., 1990). GSH a.nd other sulfhydryl compounds can also enhance cytotoxic T-cell 
activation, proliferation and differentiation (Multhoff e/ al, 1995). Studies have shown 
not only that in vivo administration of GSH can activate cytotoxic T-cells, but also that 
depletion of intracellular GSH can inhibit the activation of lymphocytes, suppressing 
their cytotoxic functions and increasing susceptibility of the ceil to radiation damage 
(Drogee/a/., 1994). 
Detoxification 
Cells are constantly being exposed to damaging chemical substances (toxins) including 
environmental pollutants, smoke, heavy metals and drug metabolites. There are many 
mechanisms for detoxification, including phase 1 reactions, which are primarily catalysed 
by cytochrome P-450, hydrolysis or reduction, and phase II reactions, which involve the 
conjugation of toxins to an endogenous chemical. Conjugation to GSH is the major 
Phase 11 reaction in mammalian species, and is particularly important in the 
detoxification of electrophilic substances such as epoxides, alkenes, halides and heavy 
metals (Kaplowitz el al, 1985). The liver, kidney and lungs have the highest exposure to 
toxins and are therefore richest in GSH. GST is able to catalyse nucleophilic substitution 
to form GSH conjugates (Salinas and Wong, 1999). GSH conjugates can then be 
eliminated via an ATP-dependent GS-X pump (Ishikawa, 1992). 
Prooxidation 
In an interesting paradox, the interaction of GSH with metal ions can also lead to an 
overall 'oxidizing' effect, by the generation of superoxide anions from the transfer of 
electrons from the metal ions to molecular oxygen (Pompella el al, 2003). Cleavage of 
the y-glutamyl bond in GSH by membrane-bound y-glutamyl tranferase (GGT) increases 
its ability to reduce metals, and it has been shown that GGT/GSH-mediated prooxidant 
reactions can lead to oxidative modification of a number of molecular targets. This may 
represent a novel mechanism for modulation of cellular signal transduction (Paolicchi ci 
al, 2002). 
Role of Glutathione In Cancer 
GSH metabolism has a complicated role in both cancer and antineoplastic therapy. While 
GSH is important in the detoxification of carcinogens, its elevated slate in many types of 
tumours may also increase resistance to chemo- and radiotherapy (Midander el al., 1982; 
Nguyen et al., 2001; Vukovic et al, 2000; Vukovic ei al, 2001). GSH levels have been 
shown to be elevated in a number of different human cancer tissues including, bone 
marrow (Joncourt et al, 1995), breast (Perry et al, 1993), colon (Redmond et al, 1991; 
Berger et al, 1994), larynx (Mulder et al, 1995) and lungs (Cook el al, 1991; Oberli-
Schrammli et al, 1994). Elevated levels of y-GCS have also been identified in different 
human cancer tissues including colon (Tatebe et al, 2002), lung (Soini ct al, 2001). 
breast (Seven et al, 1998), liver (Huang et al, 2001) and other types of cancers (iida et 
al, 1999). Many GSH-based therapeutic strategies have focused on lowering GSH levels 
in order to increase sensitivity of cells to ionizing radiation, and to decrease the resistance 
to many chemotherapeutic drugs (Chen et al, 1998). The development of inhibitors for 
specific molecules in the GSH synthesis/GST detoxification pathway may help to 
elucidate the complex role of GSH in cancer, provide better strategies in cancer 
prevention and enhance the effectiveness of current chemotherapeutic approaches. 
Aim of this Study 
The possibility that Allicin can suppress the proliferation of cervical cancer cells by 
inducing cell cycle arrest or apoptosis makes it a potential chemotherapeutic agent 
against cancer of the uterine cervix. The central hypothesis of this study is that Allicin 
suppresses the proliferation of cervical cancer cells by inducing cell cycle arrest, restores 
the function of p53 by upregulating its expression in HPV positive cervical carcinoma 
cells resulting in the activation of pro-apoptotic genes and apoptotic cascade and 
abrogates the functions of HPV E6 and E7 viral proteins by downregulating their 
expressions. The specific aims described below were investigated to test this hypothesis. 
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(1) The efficacy of the Allicin to induce cell cycle arrest and apoptosis in cervical cancer 
cell line was investigated. 
(2) The ability of Allicin to upregulate the expression of p53 in cervical cancer cell line 
was determined. 
(3) The possibility that Allicin could activate the pro-apoptotic genes and apoptotic 
cascade was also investigated. 
(4) The potential of Allicin to suppress or abrogate E6 and E7 protein function was also 
examined. 
(5) The effect of Allicin on the expressions of different proinflammatory c)tokines in 
monocytes from cervical cancer patients was also investigated. 
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Materials 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (iMTT). propidium iodide, 
RNase A, D,L-bLithionine S,R-sulfoximine (BSO), cyclosporin A (CsA). N-acetyl-L-
cysteine (NAC), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), metapJTosphorie acid. 
phenazine methosulfate (PMS), phenylinethylsulphonyl fluoride (PMSF), bovine serum 
albumin (BSA), Coomassie Brilliant Blue G-250, /?-Nitrophenyl phosphate. Triton X-
100, Tvveen-20, N,N,N'N'-Tetramethylethy]inediamine (TEMED) and diihiothreiolol 
(DTT) were from Sigma-Aldrich (St. Louis, IMO. USA). Trypan Blue dye was from 
Invitrogen (Carlsbad, CA, U.S.A). Reduced glutathione (GSH), Glutathione reductase 
and reduced p-nicotinamide adenine dinucleotide phosphate (NADPH) were from 
HiMedia Chemical Company, India, 
Allicin was obtained from LKT Laboratories, inc. U.S.A. Ficoll-Paque was purchased 
from Pharmacia, Piscataway, N.J., U.S.A. RPMI-1640 medium was from HiMedia, India. 
Fetal calf serum (FCS), antibacterial and anti fungal antibiotics were from Intergen. NY. 
U.S.A. The caspase substrates, DEVD-pNA (caspase-3 substrate) and LEHD-pNA 
(caspase-9 substrate) were from Sigma and inhibitors Z-VAD-FMK (general caspase 
inhibitor), Z-DEVD-FMK (caspase-3 inhibitor) and Z-LEHD-FMK (caspase-9 inhibitor) 
were from R&D Systems Inc. U.S.A. The anti-human primary antibodies against 
cytochrome c, Bcl-2, Bax, p53, HPV 18 E6 and E7 as well as HRP-conjugated anti-rabbit 
secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz. CA) and 
antibodies for cleaved caspase-3, cleaved caspase-9 and poly (ADP ribose) polymerase 
(PARP) were from Cell Signaling Technology (Beverly, MA). Protease inhibitors. 
aprotinin, pepstatin and leupeptin were purchased from Sigma, U.S.A. All other 
chemicals were of the highest analytical grade available. 
Methods 
Preparation of RPMI-1640 Medium 
Dehydrated RPMM640 medium of one unit vial (16.3 gm) (HiMedia, India), was 
suspended in 950 ml of tissue culture-grade water at room temperature with constanl. 
gentle stirring until the medium was completely dissolved. The container was I'inscd w ilh 
tissue culture grade water to remove all traces of powder and added to the above solution. 
3.7 gm sodium bicarbonate was added to the medium and stirred until dissolved. The 
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final volume was brought to 1000 ml with tissue culture grade water. The medium was 
sterilized immediately by filtering through a sterile membrane (liter with a porosii} of 
0.22 micron using positive pressure rather than vacuum to minimize the loss of carbon 
dioxide, and stored at 4°C until use. 
Cell Culture and Cell Viability Studies 
The human cervical cancer HeLa cells, obtained from National Centre for Cell Science 
(NCCS, Pune, India), were cultured in RPMI-1640 media supplemented with 10% heai-
inactivated FCS, 100 U/ml penicillin and 100 (ig/ml streptomycin sulfate at 37 °C in an 
atmosphere of 95% air and 5% CO2 under humidified conditions. 
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) is a water-soluble 
tetrazolium salt with a yellow color when prepared in aqueous solution. Dissolved MTT 
is reduced to an insoluble purple formazan by cleavage of the tetrazolium ring by 
mitochondrial dehydrogenase enzymes (Bruggisser et ai, 2002; Denizol and Lang, 1986; 
Green et al., 1984; Heeg et al., 1985; Mosmann, 1983). The precipitate can be dissolved 
in DMSO or other solvents. The increase in cell number corresponds to the increased 
amount of formazan and optical density detected by a multiple scanning 
spectrophotometric plate reader. A large number of samples can be measured with high 
precision and consistency simultaneously on a 96-well plate. 
Exponentially growing HeLa cells (5x10 /well) were seeded onto 96-vvell tlat-bottomcd 
plates and allowed to attach overnight. The cells were treated with 0,3. 0.6. 1.5 and 3 uM 
of Allicin for 24 and 48 h. 10|AI MTT (5 mg/ml) was added to each well and the plates 
were incubated for another 4 h at 37°C. DMSO was added to each well and thoroughly 
mixed to dissolve the purple crystals. The plates were read on a Qualisystems PR 601 
Elisa reader, using a wavelength of 570 nm and a reference wavelength of 450 nm. Cell 
viability was calculated as the percentage of MTT inhibition using the following formula: 
Survival (%) = (Mean experimental absorbance/ Mean control absorbance) x]00%. 
Trypan Blue Dye Exclusion Assay 
Effect of Allicin on HeLa cell proliferation was also determined by Trypan Blue dye 
exclusion assay as described previously (Xiao et al, 2004). Trypan Blue stains dead cells 
depending on loss of membrane integrity. It is normally excluded b}' intact cell 
membranes but if membranes are sufilciently damaged, trypan blue is able lo enter the 
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cells and binds to intracellular proteins. Dead cells can be recognized under microscope 
as they are stained blue. The cell viability can be determined by counting non-stained 
cells. 
1x10^  cervical cancer HeLa cells were grown in a 60 mm tissue culture dish for 24 hours 
at 37°C and 5% COj. After 24 hour of Allicin treatment (0.3-3 ^M). cells were detached 
using Trypsin-EDTA (Gibco, Grand Island, NY), collected and re-suspended in ihe 
medium used to grow the cells. The cells were counted by a Thoma hemocylomeler 
(Shanghai, China) using 0.2% Trypan Blue dye (Invitrogen, Carlsbad, CA). A non-
treated sample was prepared as a control. The percentage of cell viability or survival was 
calculated by comparing the sum of non-stained cells from treated samples with the sum 
from the untreated control. 
Cell Cycle Analysis 
Flow cytometry measures characteristics of a group of cells passing through a sensing 
point using laser as a light source which then produces scattered light and emitted 
fluorescence. Physical characteristics including cell size, shape, internal complexit}' and 
cell components labeled by fluorophore can be detected. Cell cycle analysis can be 
obtained by flow cytometry via measuring the amount of DNA in cells and then 
calculating the percentage of cells in different subpopulations. For this, cells are stained 
with propidium iodide (PI) which intercalates into the major groove of double-stranded 
DNA and forms a highly fluorescent complex that can be excited at 488 nm with 
emission of 600 nm. While passing through the system, the fluorescent complex produces 
fluorescence, and the intensity measured by the detector is proportional to the amount of 
DNA in the cell. Since in different (GQ/GI, S, G2/M) phases, the cell contains dilfeienl 
amount of DNA, the percentage of cells in each subpopulation can be determined b\' the 
flow cytometric histogram. Moreover, apoptotic cells are represented by a sub Go/Gi 
population seen to the left of the GQ/GI peak (Lecoeur, 2002). 
Cell cycle analysis of Allicin-treated HeLa cells was performed with ethanol lixed cells 
using the intercalating DNA fluorochrome, propidium iodide (PI) as described earlier 
(Xiao el al., 2004; Singh et ai, 2004). HeLa cells (IxlO '^ cells) were cultured in a 35 mm 
tissue culture dish for 24 hours at 37°C and 5% CO2 and treated with Allicin (0.6. 1.5 and 
3 |LiM) for another 24 hours. Cells were harvested, washed with PBS by centriliigalion al 
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600g for 5 mill, fixed in 80% chilled ethanoi and stored at 4°C till cell cycle analysis. 
Cells were washed with PBS after removing ethanoi and treated with RNasc A (200 
l-ig/ml) for 30 min at 37°C. Subsequently cells were stained with PI (25 ^g/ml) for 15 inin 
at room temperature. Cell cycle was analyzed using Becton Dickinson FACS Calibur 
(Becton Dickinson, San Jose, CA). 
FITC-Annexin V Assay 
Perturbations in the cellular membrane occur during the early stages of apoplosis and 
lead to a redistribution of phosphatidylserine (PS) from inside to outside of the cell 
membrane (Vermeulen et al., 2005; Ashe and Berry, 2003). This change can be detected 
by fluorescein-conjugated Anne.xin V, which is a 35-36 kDa Ca'^ dependent 
phospholipid-binding protein that has a high affinity for PS and selectively binds to it. 
During the process of necrosis, the plasma membrane loses its integrity, and the Annexin 
V can also bind to the inner face, so Propidium Iodide (PI) which is excluded from intact 
cells is added to distinguish apoptotic cells with intact plasma membrane and those 
undergoing necrosis with leaky membrane. 
FlTC-labeled Annexin V apoptosis detection kit was obtained from Becton Dickenson 
(San .lose, CA, USA). Briefly, txlO^cervical cancer HeLa cells were grown in a 35 mm 
tissue culture dish, treated with 1.5 and 3 ^M Allicin for 24 h, harvested and washed with 
PBS. Subsequently, cells were resuspended in 100 \.\.\ binding buffer (10 inM 
HEPES/'NaOH, pH 7,4, 10 mM NaCl, 2.5 mM CaCN) and stained with 5 i^l FITC-
Annexin V and 10 |-il PI (50 |-ig/ml). After 15 min at room temperature 400 |.il of binding 
buffer were added to each sample and analyzed by flow cytometry. The percentage of 
Annexin V-positive and negative cells were estimated by applying appropriate gales and 
using regional statistics analysis facility provided in the CellQuest Software (Becton 
Dickenson, San .lose, CA, USA). Our definition of cellular status was as follows: 
unstained cells were classified as 'viable', cells stained for Annexin V only were "early 
apoptotic", cells stained for both Annexin V and P! were 'late apoptotic'. and cells 
stained for PI only were 'necrotic'. Apoptotic cells w'erc the sum of early and late 
apoptotic cells. 
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Protein Quantitation 
Amount of protein in cell lysates was quantitated bj' the methods of Bradford (1976) and 
Smith e/fl/. (1985). 
Bradford Method 
Use of Coomassie G-250 Dye in a colorimetric reagent for the detection and quantitation 
of total protein was first described by Dr. Marion Bradford (1976). In the acidic 
environment of the reagent, protein binds to the Coomassie dye. Detailed studies indicate 
that the free dye can exist in four different ionic forms for which the pKa values are 1.15. 
1.82, and 12.4 (Chial et ai, 1993). Of the three charged forms of the d;,'e that 
predominate in the acidic assay reagent solution, the more cationic red and green forms 
have absorbance maxima at 470 nm and 650 nm, respectively. In contrast, the more 
anionic blue form of the dye, which binds to protein, has an absorbance maximum at 590 
nm. Thus, the quantity of protein can be estimated by determining the amount of dye in 
the blue ionic form. This is usually achieved by measuring the absorbance of the solution 
at 595 nm. This method is subject to less interference by common reagents and non-
protein components of biological samples. 
The dye was prepared by dissolving 100 mg of Coomassie Brilliant Blue G-250 in 50 ml 
of 95% ethanol and then 100 ml of 85% (v/v) orthophosphoric acid was added in it. The 
resulting solution was diluted to a final volume of 1.0 litre and filtered through Whatman 
No. 1 filter paper to remove undissolved particles. 
To 100 fil ofdifferent dilutions of total cell lysate(l, !;!0, 1:100, 1:1000) was added 2.0 
ml of dye solution. The contents were mixed thoroughly by vortexing and the absorbance 
was read at 595 nm after 5 minutes against a reagent blank. A calibration curve was 
constructed using dilutions of a stock solution of 1 mg/ml of bovine serum albumin 
(BSA). 
Bicinclioninic Acid (BCA) Assay 
The bicinchoninic acid (BCA) assay, first described by Smith ci ai, combines the well-
known reduction of Cu^ "^  to Cu"^  by protein in an alkaline medium with the highly 
sensitive and selective colorimetric detection of the cuprous cation (Cu ) by 
bicinchoninic acid (Smith cl al., 1985). The first step is the chelation of copper with 
protein in an alkaline environment to form a blue colored complex. In the second step of 
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the color development reaction, BCA reagent, a highly sensitive and selective 
colorimetric detection reagent reacts with the cuprous cation (Cu^) that was formed in 
step 1. The purple colored reaction product is formed by the chelation of two molecules 
of BCA reagent with one cuprous ion. The BCA-Cu"^  complex is watcr-soUihlL' and 
exhibits a strong linear absorbance at 562 nm with increasing protein concentrations. In 
particular, this assay is not affected by a range of detergents and denaturing agents such 
as urea and guanidinium chloride. 
Reagents prepared for BCA assay were (1) Reagent A; sodium bicinchoninale (0.1 g). 
Na2C03.H20 (2.0 g), sodium tartrate dihydrate (0.16 g). NaOH (0.4 g) and NaHCO; 
(0.95 g) were dissolved in water and volume made up to !00 ml. pi I was adjusted to 
11.25 with NaHCOa or NaOH. (2) Reagent B: CUSO4.5H2O (0.4 g) was dissolved in 10 
ml of water. Standard working reagent (SWR) was prepared by mixing 100 volume of 
regent A with 2 volume of reagent B. 
To a 100 )il of different dilutions of cell lysate(l, 1:10, 1:100, 1:1000) was added 2 ml of 
standard working reagent. The contents were incubated at 60°C for 30 min and then 
cooled to room temperature. The absorbance was read at 562 nm against a reagent blank. 
A calibration curve was constructed using dilutions of a stock solution of 1 mg/ml of 
bovine serum albumin (BSA). 
Caspase Activity Assay 
The downstream signals during apoptosis are transmitted via caspases which are 
synthesized as inactive proenzymes and their activation during apoptosis results in 
cleavage at specific aspartate cleavage sites (Cohen, 1997; Thornberry et ciL. 1997). 
While initiator caspases-9 undergoes autocatalytic activation, executioner pro-caspase-3 
is processed by initiator caspase. Caspase-3 functions as an perpetrator which regulates 
various components responsible for morphological changes including cell shi-inkagc. 
membrane blebbing, nuclear condensation and DNA fragmentation and eventually leads 
to cell death (Ashe and Berry, 2003; AInemri, 1997; Coffey el ai, 2001; Hnari c/ a/.. 
1998; Nagata, 2000). 
Caspase activities were determined by the method described earlier (Slicn cf a/.. 2007). 
The assay is based on the ability of the active enzyme to cleave the chromophore from 
the enzyme substrate, LEHD-pNA (Leu-Glu-His-Asp-/>nitroanilide for caspasc-9) and 
DEVD-pNA (Asp-Glu-Val-Asp-p nitroanilide for caspase-3). IxlO'' Hcl.a cells wca-
grovvn in a 60 mm tissue culture dish for 24 h at 37°C and 5% CO; and treated wiili 
Allicin (0.3-3 [xM) for another 24 or 48 h. Cells were collected and washed with PBS and 
suspended in 50 i^l of cold lysis buffer (50 mM Tris-HCI, 150 mM NaCl. I mM EGTA. 1 
mM EDTA, 20 mM NaF, 100 mM Na3V04, 0.5% NP-40, 1% Triton X-100. I mM 
PMSF, 5 |ig/ml aprotinin, 5 jag/ml pepstatin and 5 |ig/ml leupeptin). incubated on ice lor 
to min, and centrifuged for I min in at 10,000 g. Protein concentration (as determined by 
Bradford and BCA assay) was adjusted with the cell lysis buffer. Equivalent amounts of 
cell lysates were incubated with peptide substrate (DEVD-pNA or LEHD-pNA) in assay 
buffer (100 mM NaCI, 50 mM HEPES, 10 mM DTT, I mM EDTA. 10% glycerol. 0.1% 
CHAPS, pH 7.4) for 2 h at 37"C. The release of chromophore/?-nitroaniline (y -^NA). after 
its cleavage by caspases from the labeled caspase-specific substrates, was measured 
spectrophotometrically at 405 nm. 
Polyacrylamide Gel Electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis was performed under denaturing conditions as 
described by Laemmli (Laemmli, 1970). One-dimensional gel electrophoresis under 
denaturing conditions (i.e. in the presence of SDS) separates proteins based on molecular 
size as they move through a polyacrylamide gel matrix toward the anode. The 
polyacrylamide gel is cast as a separating gel (sometimes called resolving or running gel) 
topped by a stacking gel and secured in an electrophoresis apparatus. After sample 
proteins are solubilized by boiling in the presence of SDS, an aliquot of the protein 
solution is applied to a gel lane, and the individual proteins are separated 
electrophoretically. Dithiothreitol (DTT) is added during .solubilization to reduce 
disulilde bonds. 
Reagents and Solutions 
(a) 30% Acrylamide Mix: A stock solution of 30%) aery lam ide was prepared by 
dissolving 29.2 gm of acrylamide and 0.8 gm of N.N'-methylenebisacrylaniidc in a total 
volume of 100 ml. The solution was filtered through a 0.45-|.un filter and stored at 4"C in 
dark brown bottle. 
(b) Separating Gel Buffer (1.5 M Iris pH 8.8): A stock solution was prepared by 
dissolving 18.17 gm Tris base in distilled water, pi I adjusted to 8.8 with 1 N IICI and (he 
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final volume brought to 100 ml with distilled water. The solution was filtered through a 
0.45-[un filter and stored at 4°C. 
(c) Stacking Gel Buffer (1.0 M Tris pH 6.8): 12.1 1 gm Tris base was dissolved in 
distilled water, pH adjusted to 6.8 with 1 N HCl and the final volume adjusted lo iOU ml 
with distilled water. The solution was filtered through a 0.45-|.un filter and stored at 4"'C. 
(d) 5x Electrophoresis Buffer 
15.1 gTris base (0.125 M final), 72.0 g glycine (0.96 M final) and 5.0 g SDS (0.5% linal) 
were dissolved in distilled water and the volume adjusted to 1000 ml. The stock was 
diluted to Ix for working solution. 
(e) 6x Sample Buffer 
3.0 ml glycerol (30% final), I g SDS (10% final), 0.93 g DTT (0.6 M final) and 1.0 mg 
bromophenol blue (0.01% final) were dissolved in 6 ml of 1.0 M Tris-Cl. pH 6.8 and 
volume was adjusted to 10 ml if required. 
Procedure 
The glass plates (18 cm x 16 cm) were soaked in chromic acid and thoroughly washed 
with tap water follov/ed by a final rinse with distilled water and ethanol. The plates were 
dried and sealed with 1% Agarose using 1.5 mm thick spacers. The reagents were mixed 
and poured between the glass plates, a well-forming comb was inserted immediatel) and 
the gel was left to polymerize at room temperature. After ensuring complete 
polymerization, the protein samples (50 )ig) in one-fourth volume of sample buffer were 
electrophoresed at 80 volts at room temperature. 
Recipe for 12% Separating Gel (15 ml) 
Separating Gel (12%) 15 ml 
Distilled water (H2O) 5.0 ml 
30% Acrylamide Mix 6.0 ml 
1.5 M Tris (pH 8.8) 3.8 ml 
10% Sodium dodecyl sulfate (SDS) 150 jal 
10% Ammonium persulfate (APS) 150 |al 
TEMED 6 pi 
Recipe for 5% Stacking Gel (5 ml) 
Stacking Gel (5%) 5 ml 
Distilled water (H2O) 3.4 ml 
30%AcrylamideMix 830 ul 
I.OMTns(pH6.8) 630^1 
10% Sodium dodecyl sulfate (SDS) 50 ^ il 
10% Ammonium persulfate (APS) 50 ^ il 
TEMED 5 ul 
Western Blot Analysis 
Western Blot Analysis was performed by the method described previously (Xiao c/ ul.. 
2003; Singh et ah, 2004; Nakagawa et al., 2005; Hsu et a!., 2006). IxlO' HeLa cells were 
grown in a 60 mm tissue culture dish for 24 h at 37°C and 5%o CO2 and treated with 
Allicin (1.5 and 3 ]xM) for another 24 h. Cells were collected and cell lysaies were 
prepared in lysis buffer A (50 mM Tris-HCl, 150 mM NaCl, 1 mM EGTA, I mM EDTA. 
20 mM NaF, 100 mM Na3V04, 0.5% NP-40, 1% Triton X-100, 1 mM PMSF. 5 ^g/ml 
aprotinin, 5 ^g/ml pepstatin and 5 |ig/ml leupeptin) and lysis buffer B (250 mM sucrose. 
20 mM HEPES-KOH buffer, pH 7.5, 10 mM KCI, 1.5 mM MgCb, I mM EDTA. i mM 
EGTA, I mM DTT, 5 |ag/ml aprotinin, 5 |ig/ml pepstatin and 5 jjg/ml leupeptin). L.ysis 
buffer A was used to analyze caspase-9, -3, Bax, BcI-2, PARP, p53. E6 and E7 proteins 
and lysis buffer B was used to analyze cytochrome c release in cytosol (Xiao ci al.. 2003; 
Hsu el al., 2006; Nakagawa et al., 2005). After centrifugation (10,000g. 30 min, 4°C), 
equivalent amount of protein (50 |ig) in the supernatant was resolved by SDS-PAGE 
(12%)) and transferred electrophoretically to polyvinylidene difluoride (PVDF) 
membranes. After the membrane was blocked in Tris-buffered saline (TBS) containing 
0.05% Tween-20 (TBST) and 5% non-fat powdered milk, it was incubated overnight 
with primary anti-human antibodies (against cytochrome c, caspase-9. -3, Bax. Bcl-2. 
PARP, p53, E6 and E7) at 4"C. After washing three times with TBS for 10 min each, the 
membrane was again incubated with Horseradish Peroxidase (HRP)-labcled sccondar\ 
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antibody for 1 h. The membrane was washed again and detection performed using the 
chromogenic substrate 3,3'-diaminobenzidine (DAB). 
Assay for Cellular Glutathione (GSH) Content 
Glutathione was measured according to the method described by Anderson (Anderson. 
1985). HeLa cells, treated with Allicin, were collected (600 g, 7 min, 4°C) and washed 
with PBS. After protein precipitation with 5% metaphosphoric acid (0.2-0.3 ml/5xlO'' 
cells) by centrifugation (10,000g, for 30 min), the supernatant was used for GSII 
quantitation, and the pellet, dissolved in 0.2-0.3 ml of 0.5 M NaOH, was used for protein 
determination. Samples (40 |.il) were neutralized with 2 M triethanolamine (10 |.il) in a 
96-well plate. The reaction was started by adding 200 fil per well of 0.4 U/ml Glutathione 
reductase enzyme in 143 mM phosphate buffer pH 7.5 containing 0.3 mM reduced 
nicotinamide adenine dinucleotide phosphate, 0.6 mM DTNB and 6.25 niM l-DTA. The 
initial rate of 5-thio-2-nitrobenzoic acid formation was monitored. Similarly, effect of 
pretreatment of BSO (100 \M, 24 h) on the GSH content of HeLa cells, treated with or 
without Allicin, was also determined. 
Assay for Total Free Thiol or Sulfhydryl (-SH) Content 
Mitochondria were prepared from cultured cells (5xlO'') as described elsewhere 
(Grinberg et al, 2005). HeLa cells, treated with Allicin, were harvested and washed with 
PBS (600 g, 7 min). Cell pellets were suspended in 0.5 ml cold HEPES isotonic 
mitochondrial buffer (HIM) buffer (200 mM Mannitol, 70 mM Sucrose. I mM EGTA, 10 
mM HEPES-KOH buffer, pH 7.5) containing protease inhibitors, incubated 30 min on ice 
and homogenized by multiple passages through a 25-gauge needle (5/8 in.). Nuclei and 
unbroken cells were removed (1300 g, 8 min at 4°C). Protein and free Sll were 
determined in the cytosol (supernatant) (10,000 g, 30 min at 4°C) and in the 
mitochondria-enriched fraction (pellet, dissolved in HIM buffer containing 1% Triton X-
100). Protein assay was done with the method of Bradford (1970) and Smith ci al (1985). 
Total free -SH contents in cell extracts or in cytosolic and mitochondrial liaciions (50 [il) 
were determined v^ ith DTNB in a 96-vvell plate. Samples were acidilied with 5% 
metaphosphoric acid (50 (.il/well) to stabilize the reduced slate and neutralized with 2 M 
triethanolamine (50 |.il/well). DTNB (50 |.il of 1 mM solution in 50 mM phosphate buffer 
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pM 7.2 containing 2 mM CDTA) was added. After 10 min of incubalion. the ab.sorbaiicc 
was measured at 4!2 nm using an ELISA reader. 
Prcparution of Peripheral Blood IMoiioiiiiclear Cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) from blood of healthy donors and cervical 
cancer patients with similar age and stage of cancer (n=15) attending O, P. 1). of .1. N, 
Medical College arid Hospitals, AVIU, Aligarh were isolated b\ density gratheiii 
sedimentation on Fieoll-Paque separation medium as described earlier (Hasan ci nL. 
2006). PBMCs thus obtained were washed thrice and suspended (5xU/'cclls/uell) in 12-
well tissue culture plates (Costar Corp. Cambridge, MA) in complele RP\'I1-I64U 
medium, and were subsequently incubated at 37°C, 5% CO; for 1-2 h for adherence. 
Non-adherent cells were washed away with RPMI medium and adherent monoc)lcs weie 
rested for overnight in RPMI-1640 medium lia\ing 2% serum at 37°C, 5% CO:. 
Tumor Necrosis Factor-a (TNF-a), lutcrletikin-lr/. (IL-lu) and Interleiikin-() (lL-6) 
Immunoassays 
The concentration of TNF-a, IL-la and lL-6 in monoc\'tic culture supernales were 
determined by Quantikine Human TNF-a, IL-lu and lL-6 Immunoassay Kits (R&D 
Systems, Inc., Minneapolis, MN, USA) according to manufacturer's instruction. This 
assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for TNF-a, IL-lu or IL-6 has been pre-coated onto a microplaie. 
Standards and culture supernates are pipetted into the wells and any TNF-u. IL-la or II,-
6 present is bound by the immobilized antibody. After washing awa\ any unbound 
substances, an enzyme-linked polyclonal antibody specific for TNF-«, 11,-h/ or II.-6 is 
added to the wells. Following a wash to remove any unbound antibody-en7,\nie reagent, a 
substrate solution is added to the wells and color develops in proportion to the anioiini of 
TNF-a, IL-la or IL-6 bound in the initial step. The color dexelopment is stopped and iho 
intensity of the color is measured. 
Statistical Analysis 
Statistical significance of difference in measured variables between control and treated 
groups was determined b}' paired l-test or one-wa\- ANOVA. Statistical significance was 
determined at the 0.001 level. 
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The present study involves tlie investigations for tiie effect of AMicin. an organosulfur 
compound of garlic, on cervical cancer llcLa cell line and monocles Iroin ccr\ ical 
cancer patients. First of all, keeping in mind the previous reports of antiproiifcralive and 
apoptotic properties of Allicin on different cancer cell lines, various experiments were 
carried out to check the efficacy of Allicin to inhibit the proliferation of cervical cancer 
HeLa cells. In addition to this, anti-inflammatory property of Allicin was also verified by 
performing different experiments on monocytes isolated from the blood of cervical 
cancer patients. The results obtained are described below. 
Allicin Inhibited Proliferation of Cervical Cancer IIcLa Cells 
Cervical cancer HeLa cells (S.xKVcells/well) were incubated with increasing 
concentrations of Allicin (0.3 to 3 uM) for grov^ing time periods up to 48 h and their 
viability was detennined by the iVlTT and Trypan blue dye exclusion assa}s. Our results 
have shown that Allicin inhibited proliferation of HeLa cells in a concentration and time 
dependent manner. A low magnitude of inhibition of cell proliferation, of about 14.79','o 
(p<0.001) and 24.82 % (p<0.001) compared to control, was observed in the presence of 
0.3 and 0.6 ^M Allicin respectively after 24 h of treatment (Fig. 11). In the presence of 
1.5 pM Allicin, HeLa cells exhibited about 47.35% (p<0.001) inhibition of proliferation 
after 24 h. At 3 |:iM allicin, after 24 h, the rate of inhibition reached 56.57*)o (pO.OOlj 
(Fig. 11). At the dose of 0.3 |uM Allicin, a small amount of inhibition of prolil'eration 
(27.89%) was observed after 48 h of treatment (Fig. 12). Allicin, at the dose of 0.6 uVl. 
1.5 pM and 3 p.M, showed marked inhibition of proliferation of about 41.53% (p<0.()OI). 
59.89% (p<0.00!) and 68.66% (p<0.00l) respectively after 48 h of treatment (Fig. 12). 
Similarly, we confirmed our above results with Trypan blue dye exclusion assax. A low 
magnitude of inhibition of cell proliferation, of about 12.62% (p<0.001) and 24.53"'o 
(p<0.001), were observed after 24 h of treatment in the presence of 0.3 and 0.6 uM 
Allicin respectively (Fig. 13). In the presence of 1.5 pM allicin, HeLa cells exhibited 
about 44.61% (p<0.001) inhibition of proliferation after 24 h. Al 3 uM allicin. aficr 24 h. 
(he rale of inhibition reached 53.84% (p<O.OOI) (Fig. 13). At the do.se of 0.3 uM Allicin. 
a small amount of inhibition of proliferation (21.68%) was observed aller 48 h of 
treatment (Fig. 14). 
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Figure 11: Dose dependent inhibition of growth of cervical cancer HeLa cells treated 
with Allicin (0.3-3 fiM) for 24 hour assessed by MTT assay: NT denotes no treatment 
(Control). Data represent mean ± S.E.M. of three independent experiments. p<0.001 was 
considered significant. 
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Figure 12: Dose dependent inhibition of growth of cervical cancer HeLa cells treated 
with Allicin (0.3-3 fiM) for 48 hour assessed by MTT assay: NT denotes no treatment 
(Control). Data represent mean ± S.E.M. of three independent experiments. p<0.001 was 
considered significant. 
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Figure 13: Dose dependent inhibition of growth of cervical cancer HeLa cells treated 
with Allicin (0.3-3 fiM) for 24 hour assessed by Trypan Blue dye exclusion assay: NT 
denotes not treated (Control). Data represent mean ± S.E.M. of three independent 
experiments. p<0.001 was considered significant. 
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Figure 14: Dose dependent inhibition of growth of cervical cancer HeLa cells treated 
with Allicin (0.3-3 jiiM) for 48 hour assessed by Trypan Blue dye exclusion assay: NT 
denotes no treatment (Control). Data represent mean ± S.E.M. of three independent 
experiments. p<0.001 was considered significant. 
Allicin, at the dose of 0.6 ^iM, 1.5 i^M and 3 ).iM, showed marked inhibition of 
proliferation of about 36.51% (p<0.001), 54.69% (p<0.00i) and 65.59% (pcO.OOl) 
respectively after 48 h of treatment (Fig. 14). These results indicated that Allicin 
inhibited cell growth in HeLa cells as a function of dose and lime. Inhibilion of cell 
proliferation could be the result of the induction of cell cycle arrest or apoplosis. 
Therefore, we hypothesized that Allicin induced inhibition of cell proliferation was due 
to alterations in cell cycle control and programmed cell death. 
Allicin Induced Cell Cycle Arrest in Cervical Cancer HcLa Cells 
To determine whether suppression of cell proliferation by Allicin results IVoiii inhibition 
of cell cycle progression, HeLa cells were treated with 1.5 and 3 \.iW\ Allicin for 24 lioui's 
and subjected to How cytometric analysis of DNA fluorescence in propidium iodide (PI) 
stained cells. Allicin treatment over 24 h caused a significant ceil cycle arrest in llel.a 
cells at Go/Gi phase (Fig. 15). The percentage of Go/Gi cells started to increase when the 
Allicin concentration was 1.5 f,iM. Until 3 |uM, cells at Go/G| reached over 1.56 fold of 
that of the control (Fig. 15). With increasing Allicin concentration, the percentage of cells 
at S and G2/M phase decreased and i! seems that most of the cells at G(i/Gi came from 
these phases. McLa cells treated with 1.5 |JM allicin resulted in a reduction in the S (from 
26.3%o to 20.3%) and G2/M fractions (32.5% to 28.1%)) and these were associated 
primarily with accumulation of cells in the GQ/GI phase (41.2%) to 5l.6"/o) (Pig.16). A 
further increase in allicin concentration to 3 ^M resulted in a more pronounced reduction 
in the S (from 26.3% to 18.2%) and G2/M fractions (32.5% to 17.3%) with a concomiiani 
increase in the percentage of cells in the GQ/GI (41.2% to 64.5%) (Fig. 17). Furthermore, a 
sub-Gu/Gi population was also observed along with Go/Gi phase arrest in MeLa cells 
incubated with 1.5 and 3 \xM Allicin suggesting that certain amount of cells underwent 
apoptosis after 24 h of treatment. Since, in addition to cell cycle arrest, the growth 
inhibition induced by Allicin treatment could also be due to programmed cell death, 
hence, we investigated whether Allicin induced apoptosis in I IcLa cells. 
Alliciii-Iiuluccd Apoptosis in Ccr\ ical Cancer HcLa Cells 
To determine whelher the loss of viability in HeLa cells induced b\' Allicin was due lo 
apoptosis, MeLa cells were treated with 1.5 and 3 |LtiVI Allicin for 24 hours and 
phosphatidylserine (PS) externalization was measured by lluorescence activated cell 
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Figure 15: Cell cycle analysis of Allicin-treated HeLa cells: Cells were treated with 
0.6, 1.5 and 3 ^M Ailicin for 24 hour and stained with propidium iodide in the presence 
of RNase A as described in Materials and Methods. Cell cycle analysis was carried out 
with a flow cytometer. The data shown here are from a representative experiment 
repeated three times with almost similar results. 
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Figure 16: Cell cycle analysis of Allicin-treated HeLa cells: Cells were treated with 1.5 
i^M Allicin for 24 hour and stained with propidium iodide in the presence of RNase A as 
described in Materials and Methods. Cell cycle analysis was carried out witli a flow 
cytometer. NT denotes no treatment (Control). The data shown here are from a 
representative experiment repeated three times with almost similar results. 
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Figure 17: Cell cycle analysis of Allicin-treated HeLa cells: Cells were treated with 3 
\iM Allicin for 24 hour and stained with propidium iodide in the presence of RNase A as 
described in Materials and Methods. Cell cycle analysis was carried out with a flow 
cytometer. NT denotes no treatment (Control). The data shown here are from a 
representative experiment repeated three times with almost similar results. 
sorting (FACS) after Annexin-V FITC/PI staining. Our results showed tliai Alliciii 
induced significant amount of apoptosis in ! leLa cells of about 17.1% and 3 1.4% alter 24 
h of treatment with 1.5 and 3 )iM Aliicin respectively (Fig. 18, 19). Moreover, the 
percentage of apoptotic cells did not coincide with the percent of viable cells, which 
could be due to a cell cycle arrest at GQ/GI phase, in order to explore the mechanism(s) 
by which Aliicin induces apoptosis, we investigated the alterations in the expression of 
selected proteins that are involved in the complex processes of apoptosis. 
Altered Bax and Bcl-2 Expressions in Aliicin treated HcLa Cells 
The mitochondrial apoptotic pathway (intrinsic pathway) is largely mediated through 
Bcl-2 family proteins, which include both proapoptotic members such as Bax and Bak 
that promote mitochondrial permeability and antiapoptotic members such as Bcl-2 and 
Bcl-xL that inhibit their effects, or inhibit the mitochondrial release of c)'tochrome c 
(Korsmeyer et al, 1993; Antonsson et al., 1997). The ratio of the proapoptotic Bax and 
antiapoptotic Bcl-2 is critically balanced during cell proliferation such that an increase in 
the levels of Bax or a decrease in the level of Bcl-2 can shift the ratio and trigger a signal 
initiating apoptosis. We hypothesized that Aliicin induces apoptosis in lieLa cells 
through mitochondrial pathway. Therefore, we investigated the effect of Aliicin on 
protein expression of Bax and Bcl-2 by Western blot analysis which was carried out after 
treating HeLa cells with 1.5 and 3 (aM Aliicin for 24 h. Our Western blot results showed 
an upregulated Bax expression and a downregulated Bcl-2 expression in Aliicin treated 
HeLa cells (Fig. 20). Thus, an increased Bax/Bcl-2 ratio in HeLa cells treated with 
Aliicin indicated the initiation of apoptosis. 
Allicin-Induced Cytochrome c Release from Mitochondria 
Cytochrome c is a component of the electron transport chain in mitochondria and plays 
an important role in initiation of apoptosis. In response to pro-apoptotic signals. Bax 
translocates to the mitochondria where it oligomerizes into a heteromeric protein channel. 
This putative Bax channel inserts into the outer mitochondrial membrane and releases 
apoptotic factors, such as cytochrome c (Wolter el al. 1997). This release of cytochrome 
c in turn activates initiator caspase-9, a cysteine protease. Caspase-9 further activates 
executioner caspase-3 and -7, which are responsible for destroying the cell from within. 
Therefore, we investigated whether there was a release of cytochrome c in the cytosol of 
66 
NT 1.5 ^M 3^M 
o u 
c 
a> 
u 
<n (I) 
h. o 
3 
E L 
> 
c 
'x 
0) 
c 
c 
< 
6 
t 
Early 
apopfotic 
'0 
Viable j ( ? 
Ml 
Late 
apoptotic 
Necrotic 
Propidium iodide Fluorescence 
Figure 18: FITC-Annexin V Assay for Measurement of Apoptosis in AUicin-treated 
HeLa Cells: HeLa cells were treated with 1.5 and 3 l^M of Allicin for 24 hour and 
stained with FITC-Ajinexin V and Propidium Iodide. Percent apoptosis was measured 
using a Flow cytometer. The data shown here are from a representative experiment 
repeated three times with almost similar results. 
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Figure 19: Percent Apoptosis in Allicin-treated HeLa cells: Cells were treated with 
1.5 and 3 pM Allicin for 24 hour and stained with FITC-Annexin V and propidium iodide 
as described in Materials and Methods. Percent apoptosis was determined by a flow 
cytometer. NT denotes no treatment (Control). Data represent mean ± S.E.M of three 
independent experiments. 
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Figure 20: Modulation of Bax and Bcl-2 Levels in Allicin-treated HeLa Cells: HeLa 
cells were treated with 1.5 and 3 fiM of Allicin for 24 hour. Protein (50 )j,g) from total 
cell lysates was subjected to SDS-PAGE and Western blotting using Bax and Bcl-2 
antibodies. 
HeLa cells treated with Allicin. For that reason, HeLa cells were treated with 1.5 and 3 
^M Allicin for 24 h and release of cytochrome c was analyzed by Western blotting. Our 
result showed an increased amount of cytochrome c in the cytosol of HeLa cells treated 
with Allicin after 24 h (Fig. 21). Thus, the release of cytochrome c from mitochondria of 
HeLa cells treated with Allicin indicated the initiation of the apoptotic cascade induced 
by the said compound. 
Allicin-Induced Activation of Caspases during Apoptosis 
The downstream signals during apoptosis are transmitted via caspases, which, upon 
conversion from pro to active forms, mediate the proteolytic cleavage of many key 
proteins, such as the nuclear enzyme PARP, followed by DNA fragmentation (Enari el 
al., 1998; Nagata, 2000). We were keen to know whether caspases play some role in the 
apoptosis of HeLa cells induced by Allicin. Therefore, we determined the caspase 
activities in HeLa cells treated with Allicin. As described previously, the cell growth 
inhibition by Allicin was strongly dose and time dependent; we examined the dose and 
time dependence of caspase activation as well. HeLa cells were treated with different 
doses of Allicin (0.3-3 |iM) for 24 and 48 h. Cytosolic proteins were extracted and 
assayed for caspase activities by incubation with a chromogenic substrate. LEHD-pNA 
(for caspase-9) or DEVD-pNA (for caspase-3). Our results showed a significant induction 
of caspase-9 and -3 activities in HeLa cells after treatment of Allicin at 1.5 and 3 piVl 
concentrations (p<O.0OI) (Fig. 22, 23). Insignificant amount of caspase-9 and -3 activities 
were observed at 0.3 and 0.6 |iM concentration of Allicin after 24 and 48 h of treatment 
(Fig. 22, 23). Thus, the caspase activities in Allicin treated HeLa cells were found to be 
dose and time dependent and maximal at the dose of 3 |iM Allicin after 24 and 48 h of 
treatment. Furthermore, we confirmed our above results by Western blot anal}sis of 
capase-9 and -3 in total cell lysate of HeLa cells prepared after 24 h of treatment w ith 1.5 
and 3 j.iM of Allicin. Our western blot results showed that treatment of HeLa cells with 
Allicin led to cleavage and activation of initiator caspase-9 which was evident after 24 h 
of treatment (Fig. 24), The activation of initiator caspase-9 resulted in cleavage and 
activation of downstream effector caspase-3 which was also marked after 24 h of 
treatment with 1.5 and 3 pM Allicin (Fig. 25). Thus, activation of caspase-9 and -3 in 
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Figure 21: Mitochondrial Release of Cytochrome c by Allicin-treated HeLa Cells: 
HeLa cells were treated with 1.5 and 3 jiM of AUicin for 24 hour. Protein (50 ^g) from 
cytosolic cell lysate was subjected to SDS-PAGE and Western blotting using cytochrome 
c antibody. 
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Figure 22: Dose and time dependent activation of caspase-9 in Allicin-treated HeLa 
cells: HeLa cells were treated with different concentrations of Allicin (0.3-3 [xM) for 24 
and 48 h. Cells were harvested and lysed in lysis buffer. Enzymatic activity of caspase-9 
was determined by incubation of 50 \ig of total protein with substrate LEHD-pNA for 2 h 
at 37 °C. The release of p-NA was monitored spectrophotometrically at 405 nm. NT 
denotes no treatment (Control). Data represent mean ± S.E.M. of three independent 
experiments. p<0.001 was considered significant. 
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Figure 23: Dose and time dependent activation of caspase-3 in Ailicin-treated HeLa 
cells; HeLa cells were treated with different concentrations of Allicin (0.3-3 fiM) for 24 
and 48 h. Cells were harvested and lysed in lysis buffer. Enzymatic activity of caspase-3 
was determined by incubation of 50 ^g of total protein with substrate DEVD-pNA for 2 h 
at 37 °C. The release of p-NA was monitored spectrophotometrically at 405 nm. NT 
denotes no treatment (Control). Data represent mean ± S.E.M. of three independent 
experiments. p<0.001 was considered significant. 
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Figure 24: Cleavage and Activation of Caspase-9 in Allicin-treated HeLa Cells: 
HeLa cells were treated with 1.5 and 3 ^M of Allicin for 24 hour. Protein (50 [xg) from 
total cell lysates was subjected to SDS-PAGE and Western blotting using cleaved 
caspase-9 antibody. 
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Figure 25: Cleavage and Activation of Caspase-3 in Allicin-treated HeLa Cells: 
HeLa cells were treated with 1.5 and 3 [iM of Allicin for 24 hour. Protein (50 jig) from 
total cell lysates was subjected to SDS-PAGE and Western blotting using cleaved 
caspase-3 antibody. 
HeLa cells treated with Allicin clearly indicated the involvement of intrinsic or 
mitochondrial pathway during Allicin-induced programmed cell death. 
Caspase Inhibitors Abrogated Apoptosis Induced by Allicin 
The above results clearly indicate that caspase-9 and -3 proteases arc activated in 
response to the apoptosis induced by Allicin. To determine whether the activation of 
caspase-9 and -3 is required for the induction of cell death by Allicin, HeLa cells were 
pretreated with cell permeable caspase inhibitors, Z-LEHD-FMK (caspase-9 inhibitor). 
Z-DEVD-FMK (caspase-3 inhibitor) or Z-VAD-FMK (general caspase inhibitor). 
followed by Allicin (3|aM) for 24 h and subsequently caspase activities and cell 
viabilities were measured. Our results showed that pretreatment of Z-LEHD-FMK and Z-
DEVD-FMK abolished caspase-9 and caspase-3 activities respectively in HeLa cells 
induced by Allicin (p<0.001) and respective caspase activities were found to be similar to 
the control value (no significant difference) (Fig. 26, 27). Similarly, Z-LEHD-FMK, Z-
DEVD-FMK and Z-VAD-FMK also abrogated the cell growth inhibition and in turn 
apoptosis in HeLa cells induced by Allicin (p<O.OOI) and the respective cell viabilities 
were found to be similar to the control value (no significant difference) (Fig. 28, 29, 30). 
Thus, the above combined results showed that the activation of caspases is a crucial event 
during Allicin-induced apoptosis in HeLa cells. 
Allicin-induced Cleavage of Poly (ADP-Ribose) Polymerase (PARP) during 
Apoptosis 
Caspase-3 plays an important role in apoptosis as an executioner caspase and mediates 
the cleavage of Poly (ADP-Ribose) Polymerase (PARP), a nuclear enzyme involved in 
DNA repair. Therefore by Western blot analysis, we then determined whether there is a 
PARP cleavage in HeLa cells after 24 h of treatment with 1.5 and 3 jiM Allicin. Our 
results revealed PARP cleavage in Allicin treated HeLa cells and its cleaved product of 
89 KDa was obvious in the Western blot (Fig. 31). Thus, the induction of caspase-9 and -
3 activities and cleavage of PARP is a specific biochemical event, brought about b\ 
Allicin during apoptosis. 
Cyclosporin A (CsA) Suppressed the Cytotoxic Effect of Allicin on the Cell Viability 
Mitochondrial permeability transition (mPT) is an increase in the permeability of ihc 
mitochondrial membranes to molecules of less than 1.5 KDa and results from opening of 
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Figure 26: Suppression of Ailicin-induced caspase-9 activation by caspase-9 
inhibitor (Z-LEHD-FMK): HeLa cells were pretreated for 2 h with caspase-9 inhibitor 
(Z-LEHD-FMK) and then treated with 3 nM of Allicin for 24 hour. Cells were harvested 
and lysed in lysis buffer. Enzymatic activity of caspase-3 was determined by incubation 
of 50 ng of total protein with substrate LEHD-pNA for 2 h at 37 °C. The release ofp-NA 
was monitored spectrophotometrically at 405 nm. Data represent mean ± S.E.M. of three 
independent experiments. p<0.001 was considered significant. 
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Figure 27: Suppression of AUicin-induced caspase-3 activation by caspase-3 
inhibitor (Z-DEVD-FMK): HeLa cells were pretreated for 2 h with caspase-3 inhibitor 
(Z-DEVD-FMK) and then treated with 3 jiM of Allicin for 24 hour. Cells were harvested 
and lysed in lysis buffer. Enzymatic activity of caspase-3 was detennined by incubation 
of 50 Jig of total protein with substrate DEVD-pNA for 2 h at 37 °C. The release of p-NA 
was monitored spectrophotometrically at 405 nm. Data represent mean ± S.E.M. of three 
independent experiments. p<0.001 was considered significant. 
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Figure 28: Abrogation of Allicin-induced growth suppression of HeLa cells by 
caspase-9 inhibitor (2>LEHD-FMK): HeLa cells were pretreated for 2 h with caspase-9 
inhibitor (Z-LEIID-FMK) followed by 3 \iM of Allicin for 24 hour and cell viability was 
determined by MTT assay. Data represent mean ± S.E.M. of tiiree independent 
experiments. p<0.001 was considered significant. 
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Figure 29: Abrogation of Allicin-induced growth suppression of HeLa cells by 
caspase-3 inhibitor (Z-DEVB-FMK): HeLa cells were pretreated for 2 h with caspase-3 
inhibitor (Z-DEVD-FMK) followed by 3 fiM of Allicin for 24 hour and cell viability was 
determined by MTT assay. Data represent mean ± S.E.M. of three independent 
experiments. p<0.001 was considered significant. 
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Figure 30: Abrogation of Allicin-induced growth suppression of HeLa cells by 
general caspase inhibitor (Zl-VAD-FMK): HeLa cells were pretreated for 2 h with 
general caspase inhibitor (Z-VAD-FMK) followed by 3 \iM of Allicin for 24 hour and 
cell viability was determined by MTT assay. Data represent mean ± S.E.M. of three 
independent experiments. p<0.001 was considered significant. 
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Figure 31: PARP Cleavage in Allicin-treated HeLa Cells: HeLa cells were treated 
with 1.5 and 3 |iM of AUicin for 24 hour. Protein (50 )ig) from total cell lysates was 
subjected to SDS-PAGE and Western blotting using PARP antibody. 
protein pores called mitochondrial permeability transition pores (mPTP) which arc 
formed in the membranes of mitochondria under certain pathological conditions (pro-
apoptotic stimuli) which can lead to mitochondrial swelling and play an imporlanl role in 
apoptosis (Zamzami and Kroemer, 2001). mPTP opening also acts as an initiating event 
to trigger Bax translocation to mitochondria, ultimately leading to cytochrome c- release 
and caspase activation (Precht et al, 2005). The role of mPTPs in the cytotoxicity of 
Allicin was gained by using Cyclosporin A (CsA), an inhibitor of Cyclophilin D which is 
a structural part of mPTP. Cyclosporin A blocks the formation of the mPTP and prevents 
its opening which could lead to abrogation of mitochondrial membrane depolarization 
and Bax translocation to mitochondria. This ultimately suppresses release of cytochrome 
c from mitochondria and thus caspase activation which play important role in apoptosis. 
We hypothesized that Allicin-induced cytochrome c release in cytosol from mitochondria 
took place after Bax translocation to mitochondria and it could be suppressed by blocking 
mPTPs with CsA. Thus in other words, CsA could block the antiproliferative and 
apoptotic effect of Allicin. Accordingly, we investigated the effect of pretreatment of 
CsA on Allicin treated HeLa cells. HeLa cells were pre-incubated with 5 ).iiVl CsA for 1 h 
and then treated with allicin (1.5 and 3 f^ M) for 24 h. Our results have shown that CsA 
inhibited the detrimental effects of allicin on cell viability as determined by the MTT 
assay. Cell viabilities were found to be 51.21% and 40.35% when HeLa cells were 
treated alone with 1.5 and 3 inM Allicin respectively but pretreatment with CsA (5 ).iM) 
significantly ameliorated the growth suppressive effect of Allicin and cell viabilities 
increased to 74.31% and 65.14% respectively, compared to control (p<0.001) (Fig. 32. 
33). There was no significant difference between nontreated and CsA-treated cells. No 
significant difference was found between CsA alone and CsA followed by Allicin treated 
cells. Thus, the effect of pretreatment of CsA on HeLa cells suggested the involvement of 
mPTPs in Allicin-induced apoptosis. 
Cyclosporin A (CsA) Suppressed Allicin-induced Apoptosis 
Since CsA prevents the mPTPs from opening and thus inhibiting cytochrome c release, 
we hypothesized that it could also suppress the Allicin-induced apoptosis. Fluorescence 
activated cell sorting (FACS) analysis of HeLa cells treated with 3 |.iM Allicin for 24 h 
showed that 31.79% of the cells were apoptotic, whereas CsA pretreatment reduced the 
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Figure 32: Effect of pretreatment of Cyclosporin A (CsA) on cell viability of Allicin-
treated HeLa cells: Cells were treated with 1.5 ^M Allicin for 24 h pretreated with 5 
^M CsA and cell viability was measured by the MTT assay. NT denotes no treatment 
(Control). Data represent mean ± S.E.M. of three independent experiments. p<0.001 was 
considered significant. 
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Figure 33: Effect of pretreatment of Cyclosporin A (CsA) on cell viability of Allicin-
treated HeLa cells: Cells were treated with 3 nM Allicin for 24 h pretreated with 5 ^M 
CsA and cell viability was measured by the MTT assay. NT denotes no treatment 
(Control). Data represent mean ± S.E.M. of three independent experiments. p<0.001 was 
considered significant. 
apoptotic fraction to 15.53% (p<0.001) (Fig. 34). The fraction of HeLa cells at the GM/(M. 
S and G2/IVI phase were 41.2%, 26.3% 32.5% respectively for nontreated cells and 
42.4%, 27.3% and 30.3% respectively for cells treated with CsA only (the difference was 
not significant). Cell cycle arrest at GQ/GI in Allicin-treated cells with or without CsA 
pretreatment was found to be 64.5% and 65.1%, respectively (the difference was not 
significant) (Fig. 35). Thus it is obvious from this result that CsA suppressed only 
Allicin-induced apoptosis and did not affect cell cycle distribution altered by Allicin. 
Allicin-Induced Intracellular Glutathione (GSH) Depletion 
Glutathione is the major regulator of the thiol-disulfide redox state of living cells 
(Gilbert, 1990; Powis, 1995; Sies, 1999; Moran et al., 2001). Allicin has been shown to 
react with sulfliydryl (-SH) containing molecules e.g. GSH (Rabinkov el al., 1998). 
Reduction in intracellular GSH levels has been associated with apoptotic cell death in 
various cell types (Liu et al., 1998; Singh et al.. 1998; Meister, 1995; Lash. 2006), 
Therefore, we set out to investigate whether a decrease in the GSH level in the Allicin-
treated HeLa cells can account for the strong cell growth inhibitory and apoptotic activity 
of this compound. Accordingly, GSH level was measured in HeLa cells treated with 
Allicin (1.5 and 3 |.iM) after different time intervals (0-24 h) and the effect of Allicin 
treatment on GSH levels was compared with that on cell proliferation. Our results 
showed that treatment of HeLa cells with 1.5 and 3 [iM Allicin resulted in a drop in GSH 
concentration to 46'/'o and 37.71% of the control level respectively, within 4 h (p<0.00l) 
(Fig. 36, 37). This decrease was transient and was followed by a rapid recovery of the 
basal GSH level within 24 h. This is in accordance with a previous report, where GSII-
Allicin conjugate (^-allylmercaptoglutathione) is formed immediately after Allicin 
penetration in red blood cells (Miron et al., 2000). Minimal GSH level was also measured 
in HeLa cells after treatment with different concentrations of Allicin (0.3-3 (^ iM) for 4 h. 
The minimal GSH level was found to be 81.91%, 64.79%, 46% and 37.71% of the 
control value (without treatment) when HeLa cells w-ere treated with 0.3, 0.6, 1.5 and 3.0 
x^M Allicin respectively. Hence, the extent of the Allicin-induced decrease in GSI I level 
in HeLa cells and the growth inhibition induced by this compound demonstrated similai-
concentration dependence (Fig. 38). 
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Figure 34: Effect of Cyclosporin A (CsA) on AUicin-induced apoptosis in HeLa cells: 
Cells with or without CsA pretreatment (5 \M) were incubated in absence or presence of 
3 \M Allicin for 24 hour and stained with FITC-Annexin V and propidium iodide as 
described in Materials and Methods. Percent apoptosis was determined by a flow 
cytometer. NT denotes no treatment (Control). Data represent mean ± S.E.M of tliree 
independent experiments. p<0.001 was considered significant. 
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Figure 35: Effect of Cyclosporin A (CsA) on cell cycle distribution of Allicin-treated 
HeLa cells: Cells with or without CsA pretreatment (5 i^M) were incubated in absence or 
presence of Allicin (3 yM) for 24 hour and stained with propidium iodide in the presence 
of RNase A as described in Materials and Methods. NT denotes no treatment (Control). 
The data shown here are from a representative experiment repeated three times with 
almost similar results. 
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Figure 36: Effect of Ailicin on Glutathione (GSH) content of HeLa cells: Cells were 
treated with 1.5 jtM Ailicin and at each time point cells were harvested and washed twice 
with PBS. Cell pellets were extracted with 5% raetaphosphoric acid and analyzed for 
GSH content and protein concentration. Data represent mean ± S.E.M of three 
independent experiments. p<0.001 was considered significant. 
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Figure 37: Effect of Allicin on Glutathione (GSH) content of HeLa cells: Cells were 
treated with 3 |iM AlJicin and at each time point cells were harvested and washed twice 
with PBS. Cell pellets were extracted with 5% metaphosphoric acid and analyzed for 
GSH content and protein concentration. Data represent mean ± S.E.M of three 
independent experiments. p<0.001 was considered significant. 
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Figure 38: Minimal Glutathione (GSH) level in AUicin-treated HeLa cells: Cells 
were treated with Aliicin (0.3-3 ^M) for 4 hour (maximum GSH depletion time point), 
harvested and washed twice with PBS. Cell pellets were extracted with 5% 
metaphosphoric acid and analyzed for GSH content and protein concentration. NT 
denotes no treatment (Control). Data represent mean ± S.E.M of tliree independent 
experiments. p<0.001 was considered significant. 
Allicin-Induced Depletion of Free Sulfliydryl (-SH) Contents of Cytosol and 
Mitochondria 
We further investigated tlie effect of Allicin on total free sulfliydryl (-SH) contents of 
cytosol and mitochondria of HeLa cells. Accordingly, total free sulfliydryl (-Sl-i) contents 
were measured in the cytosolic and mitochondrial fractions of Hel.a cells treated with 
Allicin (3 i^M) after different time intervals (0-8 h). The decrease in free -SH in the 
cytosol (Fig. 39) was accompanied by a decrease of free -SH in the mitochondria (Fig, 
40). Since mitochondrial GSH is supplied from the cytoplasm and upon Allicin treatment 
it was depleted in both cellular compartments, it could followed by a substantial decrease 
in the cell-reducing potential. Consequently, depolarization of the mitocliondrial 
membrane could occur and trigger a chain of apoptotic events leading to cell death. 
Buthionine sulfoximine (BSO) Irreversibly Augmented Allicin-Induced 
Intracellular Glutathione (GSH) Depletion 
DL-Buthionine-(S,R)-sulfoximine (BSO) is a selective inhibitor of y-glutam)l cysteine 
synthetase (y-GCS), an enzyrne in the glutathione biosynthetic path\va>'. We 
hypothesized that Allicin-induced GSH depletion could not be recovered to basal level in 
HeLa cells pretreated with BSO and thus cells could become more susceptible to undergo 
apoptosis. Accordingly, we first investigated the effect of pretreatment of BSO in Allicin 
treated HeLa cells. When HeLa cells were treated only with 100 fiM BSO for 24 h. the 
GSH level was found to be decreased to 32.37% (p<0.00l) of the control value (without 
BSO treated cells) (Fig. 41). Moreover, Allicin (1.5 and 3 )iM) applied to HeLa cells 
pretreated with 100 |iM BSO for 24 h caused an additional GSH decrease to 15.5% 
(p<0.00l) and 11.91% (p<0.00l) of GSH of only BSO treated cells respectively (Fig. 
42). Here, there was no recovery of GSH as in the case of HeLa cells treated with Allicin 
alone. 
Buthionine Sulfoximine (BSO) Enhanced the Allicin-Induced Cell Cro>\th 
Inhibition 
We also investigated whether BSO altered the Aliicin-induced cell growth suppression 
besides augmenting Aliicin-induced GSH depletion in HeLa cells. Hence. llcLa cells 
were pretreated with 100 fiM BSO followed by 1.5 and 3 |iM Allicin for 24 h and their 
viability was deterrained by MTT assay. HeLa cells pretreated with BSO followed by 1.5 
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Figure 39; Effect of Allicin on free Thiol (-SH) content of cytosolic fraction of HeLa 
cells: Cells were treated with Allicin (3 ^M) and at different time intervals, cells were 
harvested and washed twice with PBS. Cell ifractionation was done and total free -SH and 
protein concentration were determined. Data represent mean ± S.E.M of tliree 
independent experiments. p<0.001 was considered significant. 
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Figure 40: Effect of Allicin on free Thiol (-SH) content of mitochondrial fraction of 
HeLa cells: Cells were treated with Allicin (3 \iM) and at different time intervals, cells 
were harvested and washed twice with PBS. Cell fractionation was done and total free-
SH and protein concentration were determined as described earlier. Data represent mean 
± S.E.M of three independent experiments. p<0.001 was considered significant. 
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Figure 41: Time dependent decrease of Glutathione (GSH) level in Allicin-treated 
HeLa cells pretreated with Buthionine sulfoximine (BSO): Cells were pretreated with 
or without 100 ^nM BSO for 24 hour and further treated with 1.5 iM Allicin. At each time 
point, cells were han.'ested and washed twice with PBS. Cell pellets were extracted with 
5% metaphosphoric acid and analyzed for GSH content and protein concentration. Data 
represent mean ± S.E.M of three independent experiments. p<0.001 was considered 
significant. 
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Figure 42: Time dependent decrease of Glutathione (GSH) level in Allicin-treated 
HeLa cells pretreated with Buthionine sulfoximine (BSO): Cells were pretreated with 
or without 100 pM BSO for 24 hour and further treated with 3 jiM Allicin. At each time 
point, cells were harvested and washed twice with PBS. Cell pellets were extracted with 
5% metaphosphoric acid and analyzed for GSH content and protein concentration. Data 
represent mean ± S.E.M of three independent experiments. p<0.001 was considered 
significant. 
and 3 (iM Allicin showed a further decrease in viability to 31.47% and 23.18';o 
respectively in comparison to only Allicin treated cells (50.13% and 41.24%) 
respectively) (p<0.001) (Fig. 43). HeLa cells treated only with BSO showed no 
significant difference in viability (95.21%o) compared to control (98.14%) (Fig. 44). Thus 
it is clear from this result that an irreversible depletion in GSH content caused due to 
BSO pretreatment further sensitized Allicin treated HeLa cells to undertake death. 
N-acetylcysteine (NAC) Abolished Allicin-Induced Inhibition of Cell Proliferation 
Our above results have already shown that Allicin treatment transiently reduced the GSH 
level and inturn altered the redox balance of HeLa cells which could sensitize them to 
undergo apoptosis. Since N-acetylcysteine (NAC) is a cysteine prodrug which 
replenishes intracellular GSH level; therefore, we investigated whether NAG treatment 
could abrogate the Allicin-induced inhibition of cell proliferation, cell cycle arre.st and 
apoptosis of HeLa cells. Accordingly, HeLa cells, pretreated with NAC (0.1-1.0 mM) for 
1 h, were further treated with Allicin (0.3-3 iiM) for 24 h and the cell viability was 
measured by MTT assay. Our results showed that HeLa cells treated with Allicin (0.3. 
0.6, 1.5 and 3.0 faM) in the presence of NAC (0.1, 0.5 and I.O mM) recovered to normal 
viability pattern similar to control (difference was not significant) (Fig. 45. 46. 47). So. it 
can be concluded from this result that NAC sequestered the antiproliferative activity of 
Allicin in HeLa cells by replenishing intracellular GSH level. 
N-acet}'lcysteine (NAC) also Abrogated Allicin-Induced Cell Cycle Arrest and 
Apoptosis 
Our above results have clearly revealed that 3 \xM Allicin induced significant apoptosis 
(30.31%) in HeLa cells (Fig. 18, 19). However, pretreatment of the HeLa cultures with I 
mM NAC reduced the apoptosis induced by Allicin to 8.73% (Fig. 48). Likewise. 3 |.iM 
Allicin induced sig-;nificant Go/Gi arrest (64.5% cells in GQ/GI phase) (Fig. 15, 17). 
However, pretreatment of NAC (1 mM) completely abrogated the cell cycle arrest 
induced by Allicin and the percentage of Go/Gi cells in Allicin exposed cells recovered to 
a level similar to the control (41.7%) (Fig. 49). 
Allicin Suppressed the Expression of HPV E6 and E7 Protein 
HPV oncogenes E6 and E7 have been reported to be vital for carcinogenesis, progression. 
invasion and metastasis of cervical cancer (Munger and Howley, 2002). So in this study. 
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Figure 43: Effect of pretreatment of Buthionine sulfoximine (BSO) on cell viability 
of AUicin-treated HeLa cells: Cells were pretreated with or without 100 pM BSO for 24 
hour followed by 1,5 ^M Allicin for 24 h and cell viability was determined by MTT 
assay. NT denotes no treatment (Control). Data represent mean ± S.E.M of three 
independent experiments. p<0.001 was considered significant. 
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Figure 44: Effect of pretreatment of Buthionine sulfoximine (BSO) on cell viability 
of AJlicin-treated HeLa cells; Cells were pretreated with or without 100 nM BSO for 24 
hour followed by 3 ^M Allicin for 24 h and cell viability was determined by MTT assay. 
NT denotes no treatment (Control). Data represent mean ± S.E.M of three independent 
experiments. p<O.OGl was considered significant. 
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Figure 45: Effect of N-acetyl cysteine (NAC) on cell viability of Allicin-treated HeLa 
cells: Cells were treated with Allicin (0.3-3 |iiM) for 24 h in the absence or presence of 
0.1 mM N-acetyl cysteine and cell viability was measured by the MTT assay. NT denotes 
no treatment (Control). Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
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Figure 46: Effect of N-acetyl cysteine (NAC) on cell viability of Allicin-treated HeLa 
cells: Cells were tieated with Allicin (0.3-3 ^M) for 24 h in the absence or presence of 
0.5 mM N-acetyl cysteine and cell viability was measured by the MTT assay. NT denotes 
no treatment (Control). Data represent mean ± S.E.M. of tliree independent experiments. 
p<0.001 was considered significant. 
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Figure 47: Effect of N-acetyl cysteine (NAC) on cell viability of Allicin-treated HeLa 
cells: Cells were treated with Allicin (0.3-3 ^M) for 24 h in the absence or presence of 1 
mM N-acetyl cysteine and cell viability was measured by the MTT assay. NT denotes no 
treatment (Control). Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
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Figure 48: Effect of N-acetyl cysteine (NAC) on AUicin-induced apoptosis in HeLa 
cells: Cells with or without NAC pretreatment (1 mM) were incubated in absence or 
presence of 3 ^M AlHcin for 24 hour and stained with FITC-Annexin V and propidium 
iodide as described in Materials and Methods. Percent apoptosis was determined by a 
flow cytometer. NT denotes no treatment (Control). Data represent mean ± S.E.M of 
three independent experiments. p<0.001 was considered significant. 
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Figure 49: Effect of N-acetyl cysteine (NAC) on cell cycle distribution of Allicin-
treated HeLa cells: Cells with or without NAC pretreatment (1 mM) were incubated in 
absence or presence of Allicin (3 pM) for 24 hour and stained with propidium iodide in 
the presence of RNase A as described in Materials and Methods. NT denotes no 
treatment (Control). The data shown here are from a representative experiment repeated 
three times with almost similar results. 
we also examined the effect of Allicin on E6 and E7 oncoprotein expression by Western 
blot analysis which was performed after treating HPV 18 positive HeLa ceils with 1.5 
and 3 i^M Allicin for 24 h. Our results showed that HPV E6 and E7 protein expressions 
were significantly downregulated in HeLa cells after the treatment (Fig. 50). Since HPV 
E6 and E7 oncoproteins play important role in cervical carcinogenesis, downregulation of 
these proteins by Allicin indicated that it could be a promising chemotherapeutic agent in 
prevention of cervical carcinogenesis. 
Allicin Upregulated the Expression of p53 Tumor Suppressor Protein 
HPV E6 protein deregulate cell cycle control by neutralizing cellular p53 tumor 
suppressor protein (Munger and Howley, 2002; Mantovani and Banks. 2001; Scheffner 
and Whitaker, 2003). So in this study, we also investigated the effect of Allicin on the 
expressions of p53 protein by Western blot analysis which was carried out after treating 
HeLa cells with 1.5 and 3 |iM of Allicin for 24 h. Our results showed that p53 protein 
expression was significantly upregulated in HeLa cells after 24 h of treatment (Fig. 51). 
Thus, the result indicated that Allicin could restore the function of p53 by disrupting the 
E6/p53 pathway in cervical cancer cells. Since p53 simultaneously suppresses anti-
apoptotic Bcl-2 and activates apoptotic Bax, its increased expression and restoration of 
function could also assist in programmed cell death induced by Allicin in cervical cancer 
cells. 
Effect of Allicin on the Cell Viability of Monocytes 
Monocytes are the main effector cells of the immune system, and the regulation of their 
survival and apoptosis is essential for monocyte-involved immune responses. Allicin has 
been reported to have anti-allergic and anti-inflammatory activities, but its effect on 
monocytes has not yet been explored. In order to evaluate whether Allicin affects the 
viability of monocytes isolated from blood of cervical cancer patients, they were treated 
with varying concentrations of Allicin (0.3-3 yiM) and their survival was determined by 
MTT assay. Our results showed that Allicin reduced the survival of monocytes in a 
concentration and time dependent manner. Insignificant amount of reduction in viability 
of monocytes of about 7.88% of control was observed in the presence of 0.3 \iM Allicin 
after 24 h of treatment (Fig. 52). In the presence of 0.6 and 1.5 )iM allicin, monocyte 
exhibited about 25.59% and 41.67% reduction in viability respectively after 24 h 
105 
NT 1.5 |JM 3pM 
1 ^BHPIW^ • mBPP'^ n r V c I 
P-actin 
Figure 50: Downreguilation of HPV E6 and E7 Oncoprotein in Allicin-treated HeLa 
Cells: HeLa cells were treated with 1.5 and 3 ^M of Allicin for 24 hour. Protein (50 |a.g) 
from total cell lysates was subjected to SDS-PAGE and Western blotting using E6 and 
E7 antibodies. 
NT 1.5 |JM 3MM 
mmmmi ^«MMii' ) « • • » p53 
P-actin 
Figure 51: Upregulation of p53 Tumor Suppressor Protein in Allicin-treated HeLa 
Cells: HeLa cells were treated with 1.5 and 3 juM of Allicin for 24 hour. Protein (50 ^g) 
from total cell lysates was subjected to SDS-PAGE and Western blotting using p53 
antibodies. 
120 
O 
J3 100-1 
c 
o 
u 
- ^ 80 
(0 
o 
60 -o 
o 
c 
o 
M- 40 
(0 20 
NT 0.3 0.6 1.5 
Ailicin ((JM) 
Figure 52: Dose dependent reduction in viability of monocytes, isolated from blood 
of cervical cancer patients, treated with Ailicin (0.3-3 ^M) for 24 hour assessed by 
MTT assay: NT denotes no treatment (Control). Data represent mean ± S.E.M. of three 
independent experiments. p<0.001 was considered significant. 
(p<0.001). At 3 nM allicin, after 24 h, the rate of reduction reached 64.86% (p<0.001) 
(Fig. 52), At the dose of 0.3 nM Allicin, insignificant amount of decrease in survival 
(12.56%) was observed after 48 h of treatment. Allicin, at the dose of 0.6 |.LM, 1.5 i^ iM 
and 3 j^ M, showed marked reduction in survival of monocytes of about 31.66%) 
(p<0.001), 46.41% (p<0.001) and 71.77% (p<0.001) respectively after 48 h of treatment 
(Fig. 53). Thus it is obvious from this result that Allicin strongly reduced the viability of 
monocytes. Because the regulation of monocytic apoptosis has a great importance in the 
regulation of inflammation, this might be one of the mechanisms of Allicin's 
immunomodulatory effects. We, then, hypothesized that this marked reduction in 
monocyte viability is due to apoptosis and to confirm this we further investigated the 
activity of caspases in Allicin treated monocytes. 
Allicin-Induced Activation of Caspases during Apoptosis in Monocytes 
Since the activation different caspases in a cell is a hallmark of apoptosis, we determined 
the activities of caspases to ascertain our notion. Monocytes were treated with different 
doses of Allicin (0.3-3 |iM) for 24 and 48 h. Cytosolic proteins were extracted and 
assayed for caspase activities by incubation with a chromogenic substrate, LEHD-pNA 
(for caspase-9) or DEiVD-pNA (for caspase-3). Our results showed a significant induction 
of caspase-9 and -3 activities in monocytes after treatment of Allicin at 1.5 and 3 ^M 
concentrations (p<0.001) (Fig. 54, 55). Insignificant amount of caspase-9 and -3 activities 
were observed at 0.3 and 0.6 ^M concentration of Allicin after 24 and 48 h of treatment. 
The caspase activities were observed to be dose and time dependent and maximal at the 
dose of 3 pM Allicin after 24 and 48 h of treatment. Thus monocyte cultures treated with 
Allicin exhibited significantly higher activities of caspase-9 and -3, thereby indicating 
that the activation of caspases was associated with reduced cell survival and apoptotic 
death of Allicin-treated monocytes. 
Caspase Inhibitor Abolished Apoptosis in Monocytes Induced by Allicin 
The above results clearly indicate that caspase-9 and -3 proteases are activated in 
response to the apoptosis induced by Allicin. To determine whether the activation of 
caspases is required for the induction of cell death by Allicin, percent viabilily was 
determined in monocytes pretreated with cell permeable caspase inhibitor Z-VAD-FMK 
(general caspase inhibitor), followed by Allicin (3 \xM) for 24 h. Our result showed that 
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Figure 53: Dose dependent reduction in viability of monocytes, isolated from blood 
of cervical cancer patients, treated with Ailicin (0.3-3 |iM) for 48 hour assessed by 
MTT assay: NT denotes no treatment (Control). Data represent mean ± S.E.M. of three 
independent experiments. p<0.001 was considered significant. 
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Figure 54: Dose and time dependent activation of caspase-9 in AUicin-treated 
monocytes: Monocyites were treated with different concentrations of Allicin (0.3-3 i^M) 
for 24 and 48 h, harvested and lysed in lysis buffer. Enzymatic activity of caspase-9 was 
determined by incubation of 50 [xg of total protein with substrate LEHD-pNA for 2 h at 
37 °C. The release of p-NA was monitored spectrophotometrically at 405 nm. Data 
represent mean ± S.E.M. of three independent experiments. p<0.001 was considered 
significant. 
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Figure 55: Dose and time dependent activation of caspase-3 in Allicin-treated 
monocytes: Monocjles were treated with different concentrations of Allicin (0.3-3 ^M) 
for 24 and 48 h, har/ested and lysed in lysis buffer. Enzymatic activity of caspase-3 was 
determined by incubation of 50 ng of total protein with substrate DEVD-pNA for 2 h at 
37 °C. The release of p-NA was monitored spectrophotometrically at 405 nm. Data 
represent mean ± S.E.M. of three independent experiments. p<0.001 was considered 
significant. 
this caspase inhibitor abolished caspase activities and apoptosis induced by Allicin 
(p<0.001)(Fig. 56). 
Effect of Allicin on the Tumor Necrosis Factor-a (TNF-u) Expression in Monocytes 
Our above result on monocytes showed that Allicin could be a promising 
immunomodulatory compound. We further hypothesized that whether Allicin play some 
role in regulation of proinflammatory cytokines in monocytes. Consequently, we 
investigated the effect of Allicin on the expression of TNF-a secreted by monocyte 
culture. Our result showed time and dose dependent downregulation of TNF-a expression 
in monocytes treated with different doses of Allicin (0.3-3 (iM) for 24 and 48 h. Secreted 
TNF-a in culture supernatant of healthy individual monocytes was 7.41 pg/ml (p<0.00i, 
data not shown), whereas in monocytes isolated from blood of cervical cancer patient, 
devoid of any allicin, was 221.2 pg/ml (p<0.001). Thus, in comparison to healthy 
subjects, monocytes from cervical cancer patients exhibited a 29.85-fold augmented level 
of secreted TNF-a (Fig. 57). However, secreted TNF-a in culture supernatant of 
monocytes from cancer patients was suppressed to 195.2, 142.7, 98.2 (p<0.001) and 67.6 
pg/ml (p<0.00]) when cultures received 0.3, 0.6, 1.5 and 3 juM of Allicin for 24 h, 
respectively (Fig. 57). Similarly, secreted TNF-a in culture supernatant of monocytes 
from cancer patients was suppressed to 153.4, 126.1, 84.2 (p<0.00l) and 52.4 pg/ml 
(p<0.001) when cultures received 0.3, 0.6, 1.5 and 3 )iM of Allicin for 48 h, respectively 
(Fig. 58). These results showed that Allicin strongly inhibited the expression of secreted 
TNF-a in monocytes form cervical cancer patient. 
Effect of Allicin on the Interleukin-la (IL-la) Expression in Monocytes 
Subsequently, we investigated the effect of Allicin on the expression of IL-la secreted by 
monocyte culture. This result also showed time and dose dependent downregulation of 
IL-la expression in monocytes treated with different doses of Allicin (0.3-3 )iM) for 24 
and 48 h. Secreted IL-la in culture supernatant of healthy individual monocytes was 3.44 
pg/ml (p<0.001, data not shown), whereas in monocytes isolated from blood of cervical 
cancer patient, devoid of any allicin, was 50.44 pg/ml (p<0.001). Thus, in comparison to 
healthy subjects, monocytes from cervical cancer patients exhibited an augmented level 
of secreted IL-ia (Fig. 59). However, secreted IL-ia in culture supernatant of monocytes 
from cancer patients was suppressed to 46.22, 33.66, 26.34 (p<0.00l) and 14.77 pg/ml 
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Figure 56: Abrogation of Allicin-induced reduction in viability of monocytes by 
general caspase inhibitor (Z-VAD-FMK): Monocytes were pretreated for 2 h with 
general caspase inhibitor (Z-VAD-FMK) followed by 3 i^M of Allicin for 24 hour and 
cell viability was determined by MTT assay. Data represent mean ± S.E.M. of three 
independent experiments. p<0.001 was considered significant. 
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Figure 57: Effect on TNF-a expression in monocytes treated with Allicin for 24 
liour: Monocytes, isolated from blood of cervical cancer patients, were treated with 0.3-3 
HM of Allicin for 24 hour and amount of TNF-a secreted in culture medium was 
determined by TNF-a ELISA Kit. Data represent mean ± S.E.M. of three independent 
experiments. p<0.001 was considered significant. 
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Figure 58: Effect on TNF-o expression in monocytes treated with Allicin for 48 
hour: Monocytes, isolated from blood of cervical cancer patients, were treated with 0.3-3 
|iM of Allicin for 48 hour and amount of TNF-a secreted in culture medium was 
determined by TNF-a ELISA Kit. Data represent mean ± S.E.M. of three independent 
experiments. p<0.001 was considered significant. 
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Figure 59: Effect on IL-la expression in monocytes treated with Allicin for 24 hour: 
Monocytes, isolated from blood of cervical cancer patients, were treated with 0.3-3 \iM 
of Allicin for 24 hour and amount of IL-la secreted in culture medium was determined 
by IL-la ELISA Kit. Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
(p<0.001) when cultures received 0.3, 0.6, 1.5 and 3 [iM of Allicin for 24 h, respectively 
(Fig. 59). Similarly, secreted IL-la in culture supernatant of monocytes from cancer 
patients was suppressed to 37.13, 32.26, 21.51 (p<0.001) and 12.43 pg/ml (p<0.001) 
when cultures received 0.3, 0.6, 1.5 and 3 |aM of Allicin for 48 h, respectively (Fig. 60). 
These results showed that Allicin strongly inhibited the expression of secreted IL-lu in 
monocytes form cervical cancer patient. 
Effect of Allicin on the Interleukin-6 (IL-6) Expression in Monocytes 
We also investigated the effect of Allicin on the expression of IL-6 secreted by monocyte 
culture. This result also showed time and dose dependent downregulation of IL-6 
expression in monocytes treated with different doses of Allicin (0.3-3 jiM) for 24 and 48 
h. Secreted IL-6 in culture supernatant of healthy individual monocytes was 8.51 pg/ml 
(p<0.001, data not shown), whereas in monocytes isolated from blood of cervical cancer 
patient, devoid of any allicin, was 73.12 pg/ml (p<0.001). Thus, in comparison to healthy 
subjects, monocytes from cervical cancer patients exhibited an augmented level of 
secreted IL-6 (Fig. 61). However, secreted IL-6 in culture supernatant of monocytes from 
cancer patients was suppressed to 67.23, 44.32, 34.33 (p<0.001) and 19.23 pg/ml 
(p<0.001) when cultures received 0.3, 0.6, 1.5 and 3 |iM of Allicin for 24 h, respectively 
(Fig. 61). Similarly, secreted lL-6 in culture supernatant of monocytes from cancer 
patients was suppressed to 64.28, 41.18, 27.11 (p<0.001) and 15.37 pg/ml (p<0.001) 
when cultures received 0.3, 0.6, 1.5 and 3 (iM of Allicin for 48 h, respectively (Fig. 62). 
These results also showed that Allicin strongly inhibited the expression of secreted lL-6 
in monocytes form cervical cancer patient. Thus, in the current study, we clearly 
demonstrated that Allicin strongly induced the apoptosis of monocytes from cervical 
cancer patient, suppressed the expressions of proinflammatory cytokines TNF-a, IL-la 
and IL-6 in monocytes and consequently could act as a promising anti-inflammatory and 
immunomodulatory agent in cervical cancer. 
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Figure 60: Effect on IL-la expression in monocytes treated with Aliicin for 48 hour: 
Monocytes, isolated from blood of cervical cancer patients, were treated with 0.3-3 |iM 
of Aliicin for 48 hour and amount of IL-la secreted in culture medium was determined 
by IL-la ELISA Kit. Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
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Figure 61: Effect oni IL-6 expression in monocytes treated with Allicin for 24 hour: 
Monocytes, isolated from blood of cervical cancer patients, were treated with 0.3-3 ^M 
of Allicin for 24 hour and amount of IL-6 secreted in culture medium was determined by 
IL-6 ELISA Kit. Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
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Figure 62: Effect on IL-6 expression in monocytes treated with Allicin for 48 hour: 
Monocytes, isolated from blood of cervical cancer patients, were treated with 0.3-3 nM 
of Allicin for 48 hour and amount of IL-6 secreted in culture medium was determined by 
IL-6 ELISA Kit. Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
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Cervical cancer is the number one cancer in Indian women (Gajalalcshmi et al., 2001) 
with a five year survival rate of 47% in Kerala (Sankaranarayanan et al., 1995), 41% in 
Bangalore (Kumaraswamy et al., 1998) and 60% in Chennai (Gajalakshmi et al., 2000), 
posing a major public health problem. The standard first line treatment for invasive 
cervical cancer is usually cisplatin (Platinol) and 5-fluorouracil (5-FU, Adrucil, Efudex) 
used in combination and in addition to radiation. Recurrent and late stage cervical cancers 
are often treated with a combination of platinum, bleomycin, methotrexate, and 5-FU. 
Chemotherapy is administered intravenously, through injection, or in pill form and side 
effects often accompany treatment and may be severe; which can include nausea, 
vomiting, diarrhea, and leukopenia (low white blood cell count). Most of these side 
effects are a result of drug toxicity to healthy tissues such as skin, hair follicles, and 
epithelial cells that line the digestive tract and patient tumors can develop resistance to 
these therapies as well(Stewart and Viswanathan, 2006; Muggia et al., 2004 ). Hence, 
there is a need to develop alternate, safer, less toxic, and more specific therapies for 
uterine cervical cancer. 
Some of the most successful currently used anticancer drugs are extracts or derivatives of 
compounds from plants or other natural products. These include the advance class of 
drugs known as taxanes (Paclitaxel, Docetaxel) that come from the yew tree (Taxiis 
baccata), and the vinca alkaloids (Vincristine, Vinblastine, Vinorelbine) which are 
derivatives from the periwinkle plant {Catharanthus roseus). These compounds affect the 
growth of all rapidly dividing cells, whether normal or malignant, and like other drugs, 
are associated with significant toxicity and side effects. Millions of research dollars each 
year go to the discovery of new natural products with limited side effects that may be 
used as effective antitumor agents. Epidemiological observations and laboratory studies, 
both in cell culture and animal models have indicated anticarcinogenic potential of garlic 
and its organosulfur constituents, which has been traditionally used for varied human 
ailments around the world. 
Garlic {Allium sativum L.) is a widely consumed herb in foodstuffs and medicines. It has 
been reported to reduce chemically induced esophageal, skin, pulmonary, stomach, 
breast, uterine cervix, colon, mammary and lung tumor (Hussain et al, 1990; Hong et al, 
2000; Milner, 2001; Nakagawae^o/., 2001; Takezaki et al., 2001; limuro et al., 2002; Ku 
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et ah, 2002). The anticarcinogenic/antitumorgenic effects of garlic and its organosulfur 
compounds have been attributed not only to the modulation of the antioxidation and/or 
drug-metabolizing enzyme system, but also to the reduction of cell proliferation and 
induction of apoptosis in tumor cells (Dirsch et al, 1998; Kwon et al, 2002; Pinto et al., 
2001; Shirin et al., 2001; Sigounas et al., 1997; Ledezma et al., 2004; Knowles and 
Milner, 2001; Oommen et al., 2004; Robert et al., 2001; Wu et al., 2001, 2002; Milner, 
2001; Siegel et al., 2004; Tsao and Yin, 2001; Kwon et al., 2003). 
Allicin, the major component present in freshly crushed garlic, is one of the most 
biologically active compounds of garlic (Ali et al., 2000; Hasan et al., 2006; Hasan et al., 
2007). Allicin is formed from alliin by the action of allinase and gets metabolized rapidly 
into diallyl sulfide (DAS), diallyl disulfide (DADS), dialiyl trisulfide (DATS), Ajoene, S-
allyimercaptocysteine (SAMC), S-allylcysteine (SAC) and vinyl dithiines (Dirsch et al., 
1998; Hirsch et al, 2000; Sigounas et al, 1997; Sundaram and Milner, 1993; Welch et 
al., 1992). Allicin is readily permeable through phospholipid membranes aiding its 
biological activity, but its unstable nature raises the question whether all the effects of 
Allicin observed are due to Allicin itself or its metabolites (Hirsch et al., 2000; Miron et 
al., 2000). Indeed, its metabolites, SAMC (Sigounas et al., 1997; Pinto et al., 1997), 
DAS, DADS, DATS (Hageman et al., 1997; Sundaram and Milner, 1993), ajoene 
(Scharfenberg et al., 1990; Dirsch et al., 1998), and SAC (Welch et al., 1992), have been 
shown to possess an anticancer activity, which varies depending on the agent and the 
experimental model. There is evidence that Allicin is formed from its metabolite, DADS, 
in human liver microsomes indicating that Allicin may also be acting intracellularly 
(Teyssier e/flf/., 1999). 
Many changes occur in cancer cells as they become tumorigenic, including release from 
growth factor regulation, loss of contact inhibition, increased proteolysis, avoidance of 
immune surveillance, acquisition of immortality, promotion of angiogenesis and 
metastasis (Hartwell, 1997) and it is classically defined as uncontrolled cellular division. 
The cell cycle is controlled by the temporally and spatially fluctuating activities of 
protein complexes and its progression requires the regulation of different cyclins, cyclin-
dependent kinases (Cdks), Cdk inhibitors and dephosphorylation of several regulatory 
proteins (Murray and Hunt, 1993; Morgan, 1995; Molinari, 2000; Murray, 2004). 
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Cellular stresses may activate signal transduction pathways, referred to as checkpoints, 
which lead to cell cycle arrest and these checkpoints ensure completion of phase specific 
events and protect against genomic instability or, in cases where the damage is too 
severe, switch the cell fate to programmed cell death (Molinari, 2000; Murray, 2004). 
Many anticancer treatments initially cause perturbations in cell cycle progression and the 
interrupted phase depends on the genetic background of the cell as well as the mode of 
action of a given treatment. Earlier studies have shown that garlic-derived OSCs can 
suppress growth of cancer cells of different anatomical locations in association with cell 
cycle arrest (Knowles and Milner, 2000; Xiao et ai, 2005; Herman-Antosiewicz and 
Singh, 2005; Herman-Antosiewicz, 2007; Antosiewicz, 2006). Garlic-derived OSCs have 
also been shown to modulate a number of key elements in cellular signal transduction 
pathways linked to the apoptotic process (Hong et al, 2000; Nakagawa et al, 2001; Xiao 
et al, 2004; Xiao et al, 2006; Karmakar et al, imi; Kim et al, 2007). 
So, in the present study, first we investigated the effect of Allicin on HPV 18 positive 
cervical cancer HeLa cell line. Our results illustrated that Allicin strongly suppressed the 
proliferation of HeLa cells in a dose- and time-dependent manner. Furthermore, we also 
observed Allicin-induced cell cycle arrest in HeLa cells at GQ/GI phase along with a sub-
GQ/GI population suggesting that certain amount of cells underwent apoptosis which was 
further confirmed by the results of FITC-Annexin V Assay. Thus, antiproliferative action 
of Allicin in HeLa cells could be attributed to cell cycle arrest and apoptosis. Therefore, 
the above combined results demonstrated that Allicin treatment caused a significant 
decrease in the percentage of viable cell along with a concurrent induction of apoptosis in 
cervical cancer HeLa cells; however, the percentage of apoptotic cells did not coincide 
with the percent of viable cells. This difference in cell viability and apoptosis could be 
due to cell cycle arrest at GQ/GI phase induced by Allicin. 
Previous studies have already shown the effect of Allicin and its metabolites on cancer 
cell proliferation, cell cycle regulation and apoptosis (Sundaram and Milner, 1993; Zheng 
et al, 1997; Hirsch et al, 2000; Iciek et al, 2001). Allicin has been reported to induce 
growth inhibition, apoptosis and cell cycle arrest at G /^M phase in human promyelocytic 
leukemia-derived HL60 cells and human myelomonocytic U937 cells (Miron et al. 
2008). In vitro studies on human mammary MCF-7 cancer cells revealed that 
124 
antiproliferative activity of Allicin is accompanied by accumulation of cells in the 
regulatory checkpoints, GQ/GI and G2/M, of the cell cycle (Hirsch et al., 2000). Allicin 
can inhibit the cell proliferation of erythroleukemia cell lines, HL-60 and K562, and 
arrest their cell cycle at S phase (Zheng et al, 1997). Allicin can also exhibit the 
antiproliferation effect on human mammary (MCF-7), endometrial (Ishikawa) and colon 
(HT-29) cancer cells, and accumulate cells at the GQ/GI and G2/M phases of the cell cycle 
in MCF-7 cells (Hirsch et al, 2000), Interestingly, other ally sulfur compounds also 
cause similar effects (Knowles and Milner, 2001). Allicin metabolite DADS could 
significantly inhibit the proliferation of HepG2 cells (Icieke/o/., 2001). DAS, DADS and 
DATS significantly suppressed colon tumor cell proliferation (Knowles and Milner, 
1998). DADS significantly increased the cell cycle arrest at G2/M phase of human colon 
tumor cells (HCT-15) via the inhibition of Cdc2 (cyclin-dependent kinase 1, Cdkl) 
activity (Knowles and Milner, 1998). DADS also induced cell cycle arrest and apoptosis 
in human A549 lung carcinoma cells (Wu et al, 2005). DADS and DATS significantly 
modulated the expressions of cyclin and Cdks to induce J5 cells arrested at G2/M phase 
(Wu et al., 2004). Ajoene and Diallyl sulfide blocked HL-60 human myeloid leukemia 
cells at the G2/M phase (Dirsch et al, 1998; Zheng et al, 1997). Allicin has been shown 
to induce apoptosis in gastric cancer SGC-7901 cells and the cause of apoptosis was 
related to decreased telomerase activity, an enzyme which Allicin inhibits in a time- and 
dose- dependent manner (Sun and Wang, 2003). Allicin-induced apoptosis has also been 
reported in human cervical cancer SiHa cells and mouse fibroblast-like L-929 cells, 
manifested through the appearance of characteristic apoptotic morphological changes in 
apoptotic bodies, through DNA fragmentation, and activation of caspases-8, -9 and -3 
(Oommen et al, 2004). Allicin was also shown to induce apoptosis in human epithelial 
carcinoma through a caspase-independent pathway, mediated by the release of apoptotic-
inducing factor (AIF) from mitochondria and protein kinase A (PKA) activation (Park et 
al, 2005). 
Apoptosis plays a crucial role in the regulation of the development and homeostasis of 
multicellular organisms (Yan and Shi, 2005; Steller, 1995). Balance between cancer cell 
proliferation and spontaneous cell death via apoptosis has an important role in the 
regulation of cancer cell growth (Brown and Attardi, 2005; Makin and Hickman, 2000; 
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Thompson, 1995). Anticancer drugs also function by inducing cancer cell death via 
induction of apoptosis in sensitive cells (Roninson, 2003; Johnstone el ai, 2002; 
Kaufmann and Earnshaw, 2000; Chen et ai, 1996; Zhu et al., 1997). Apoptosis may be 
triggered by extracellular death signals, deprivation of survival signals, and genetic or 
toxicological damage (Brune, 2002). A common observation in response to these stimuli 
is the activation of caspases, a group of cysteine proteases that serve as main effectors of 
programmed cell death. There are two major pathways of caspase activation: ligand-
dependent or receptor-induced activation (extrinsic pathway), through death receptors 
such as Fas (CD95) or the members of tumor necrosis factor receptor (TNF-R) 
superfamily, and mitochondria-dependent activation (intrinsic pathway), via cytochrome 
c (cyt c) release from mitochondria induced by stress, irradiation, or inflammation 
(Budihardjo et al, 1999, Li et al, 1997). 
The mitochondrial apoptotic pathway (intrinsic pathway) is largely mediated through 
Bcl-2 family proteins, which include both proapoptotic members such as Bax, Bak and 
BMP3 that promote mitochondrial permeability and antiapoptotic members such as Bcl-2 
and Bcl-xL that inhibit their effects, or inhibit the mitochondrial release of cytochrome c 
(Korsmeyer et al, 1993; Antonsson et al, 1997). Another important component is the 
tumor suppressor protein p53, which simultaneously suppresses Bcl-2 and activates Bax. 
The ratio of Bax to Bcl-2 is critical to cell survival which determines whether a cell 
undergo apoptosis (Oltavi et al, 1993). Bcl-2 family members possess one or more of 
four Bcl-2 homology (BH) domains. The precise complement of these structural domains 
determines the pro or antiapoptotic activity of Bcl-2-related proteins (Tsujimoto, 1998). 
Family members that possess exclusively BH3 domains are proapoptotic, and have 
muhiple mechanisms of action. Some BH3-only proteins, such as Bad and Bik, promote 
the intrinsic death pathway by sequestering Bcl-2 and inhibiting its antiapoptotic effects 
by displacing Bid and Bim (Puthalakath et al, 1999; Letai et al, 2002). Bid and Bim can 
act directly to activate Bax, a multidomain proapoptotic Bcl-2 family member (Marani el 
al, 2002). In response to undefined apoptotic signals, Bax translocates to the 
mitochondria where it oligomerizes into a heteromeric protein channel. This putative Bax 
channel inserts into the outer mitochondrial membrane and releases apoptotic factors, 
such as cytochrome c (Wolter et al, 1997). Cytochrome c leakage supports the formation 
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of an apoptosome complex by binding to apoptotic protease activating factor-1 (Apaf-1), 
which activates the caspase-9 molecules (upon cleavage of the bound zymogen 
procaspases-9), which in turn activate caspase-3 (Korsmeyer, 1995; Vodovotz el al., 
2004) to initiate apoptosis. Caspases are synthesized as inactive proenzymes and their 
activation during apoptosis results in cleavage at specific aspartate cleavage sites (Cohen, 
1997; Thornberry et ai, 1997). While initiator caspases-8 and -9 undergo autocatalytic 
activation, executioner pro-caspase-3 is processed by initiator caspases. Caspase-3 is one 
of the key executioners of apoptosis, being responsible either partially or totally for the 
proteolytic cleavage of many key proteins, such as the nuclear enzyme PARP, followed 
by DNA fragmentation (Enari et al., 1998; Nagata, 2000). 
In the current study, keeping in mind the previous reports on garlic and its organosulfur 
compounds, we further explored the involvement of mitochondrial apoptotic pathway in 
Allicin-induced apoptosis in HeLa cells. Our Western blot results showed that Allicin 
induced the mitochondrial release of cytochrome c in the cytosol. Moreover, Allicin 
treated HeLa cells also exhibited an augmented caspase-9 and -3 activities which were 
found to be dose dependent. Likewise, Western blot results also showed cleavage and 
activation of procaspase-9 and -3 which further confirmed our finding of enhanced 
caspase-9 and -3 activities. Pretreating HeLa cells with caspase inhibitors Z-VAD-FMK, 
Z-DEVD-FMK (caspase-9 inhibitor) and Z-LEHD-FMK (caspase-3 inhibitor) completely 
abrogated Allicin-induced caspase activation and cell proliferation. Furthermore, we also 
demonstrated Allicin-induced PARP cleavage in HeLa cells and cleaved product of 89 
KDa was found to be evident in Western blot. Similarly, results of Western blot analysis 
also revealed an upregulated Bax and downregulated Bcl-2 protein expressions in 
Allicin-treated HeLa cells. Therefore, our above combined results established the 
contribution of mitochondrial or intrinsic pathway in Allicin-induced apoptosis. 
The majority of garlic-derived compounds activate the so called intrinsic or 
mitochondria-mediated pathway in the execution of apoptosis, which involves loss of 
mitochondrial membrane potential and release of apoptogenic molecules from the 
mitochondria to the cytosol (Thornberry and Lazebnick, 1998; Hengartner, 2000). Garlic-
derived OSCs are believed to trigger apoptosis by modulating the levels of Bcl-2 
proteins. Allicin has been reported to induce apoptosis through mitochondrial pathway 
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followed by significant release of cytochrome c and activation of caspase-9 and -3 in 
human promyelocytic leukemia-derived HL60 cells and human myelomonocytic U937 
cells (Miron et al., 2008). PARP cleavage has been reported in human mammary (MCF-
7) cancer cells during Allicin-induced apoptosis (Hirsch et al, 2000). DAS or DADS 
treatment increased the ratio of Bax/Bcl-2 in SH-SY5Y neuroblastoma cells, as well as in 
H460 and HI299 lung cancer cells compared with untreated controls (Hong et al, 2000; 
Karmakar et al, 2007). A time-dependent upregulation of Bax protein level and 
concomitant downregulation of Bcl-xL protein level was observed in DADS treated 
MDA-MB-231 breast cancer cell line (Nakagawa et al, 2001). The Z-ajoene-induced 
apoptosis in HL-60 cells was associated with caspase-mediated cleavage of Bcl-2 (Li et 
al, 2002). The DATS induced apoptosis in prostate cancer cells correlates with a 
decrease in Bcl-2 level as well as with hyperphosphorylation of this protein, which 
reduces Bcl-2/Bax interaction and activates the mitochondrial pathway of apoptosis (Xiao 
et al, 2004). The DATS-induced apoptosis in LNCaP cells correlated with a modest 
increase in protein levels of pro-apoptotic Bcl-2 family members Bax and Bak (Kim el 
al, 2007). 
The mitochondrial apoptotic pathway (intrinsic pathway) is also regulated by the 
mitochondrial permeability transition pore (uiPTP) (Hirsch et al, 1997). The mPTP is 
thought to be a large protein complex composed of the voltage-dependent anion channel 
(VDAC), the adenine nucleotide translocator (ANT), and cyclophilin D (Martinou et al, 
1999). The components of the mPTP are associated with the mitochondrial inner 
membrane and form a pore that is permeable to low molecular weight (<1.5 KDa) solutes 
and ions, ultimately leading to mitochondrial membrane depolarization and swelling of 
the mitochondrial matrix (Zamzami and Kroemer, 2001) causing cell death. mPTP 
opening also acts as an initiating event to trigger Bax translocation to mitochondria, 
ultimately leading to cytochrome c release and caspase activation (Precht et al, 2005). 
Cyclosporin A (CsA) is an inhibitor of cyclophilin D and blocks the formation of the 
mPTP and prevents its opening which could lead to abrogation of mitochondrial 
membrane depolarization and Bax translocation to mitochondria. This ultimately 
suppresses release of cytochrome c from mitochondria and thus caspase activation which 
play important role in apoptosis. Therefore, in the current study, the effect of CsA 
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pretreatment on Allicin-induced suppression of proliferation and apoptosis of HeLa cells 
was also investigated. Our results showed that CsA pretreatment of HeLa cells inhibited 
Allicin-induced growth suppression and cell death, corroborating the central role of 
mitochondria in the apoptotic process induced by Allicin. Furthermore, Alticin induced a 
cell cycle arrest at GQ/GI in HeLa cells. Upon CsA pretreatment, the percentages of cells 
at GQ/GI remain unchanged. So, it can be deduced from this result that the effect of 
Allicin on cell cycle arrest was independent of its proapoptotic activity. Furthermore, the 
above effect of CsA on HeLa cells suggested the involvement of mPTPs in Allicin-
induced apoptosis. A recent report has demonstrated that CsA pretreatment of human 
promyelocytic leukemia-derived HL60 cells inhibited Allicin-induced cell death (Miron 
et ai, 2008). 
Glutathione (GSH), cysteine and accessible free sulfhydryl (-SH) groups of various 
proteins and peptides are rapidly oxidized by Allicin to their respective Allyl disulfide 
derivatives (Rabinkov, 2000; Rabinkov, 1998). The mixed disulfide formed is less active 
than Allicin, yet it can easily react with free -SH in thiol-disulfide exchange reactions, 
and produce, at the end of a series of reactions, the oxidized form of glutathione (GSSG), 
the oxidized form of cysteine (cystine) and glutathiolated S-proteins. Glutathione is the 
major regulator of the thiol-disulfide redox state of living cells (Gilbert, 1990; Powis, 
1995; Sies, 1999; Moran et al, 2001). Alterations in cellular free thiols have already been 
described as a key event in the generation of apoptosis (Meister, 1995; Lash, 2006). 
In the present study, the effect of Allicin on cellular GSH content and total free thiol (-
SH) content of cytosol and mitochondria was also examined. Our results showed that 
Allicin induced an initial drop in GSH levels that was followed by a regeneration process, 
occurring several hours after treatment. This may be due to decreased feedback inhibition 
of GSH biosynthetic enzymes such as y-glutamylcysteine synthetase (7-GCS) by GSH 
(Lash, 2006). In addition, Allicin also caused GSH depletion concomitantly in the cytosol 
and mitochondria in HeLa cells. The rate of free -SH depletion from the cytosol and the 
mitochondria was similar, indicating that Allicin penetrated the mitochondria and the cell 
membrane equally well and reacted with free -SH in both compartments. Furthermore, in 
BSO-pretreated cells, there was no recovery of GSH after its Allicin-induced depletion, 
as BSO is a direct inhibitor of y-GCS. Since BSO-induced depletion of GSH levels 
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caused neither mitochondrial permeability transition nor apoptosis (no effect on cell 
survival), it is likely that BSO treatment depletes GSH mainly from the cytosol, whereas 
Allicin induced depletion of mitochondrial GSH trigger the apoptotic process. 
Previous studies have already shown that Allicin strongly depleted the cytosolic and 
mitochondrial glutathione level, which plays very important role in maintaining the 
cellular and mitochondrial redox potential, and thus sensitized the cells to undergo 
apoptosis (Hirsch et al, 2000; Miron et ah, 2008). The following Allicin-induced 
apoptotic scenario can be deduced from this study: Allicin penetrates the cells and readily 
reacts with any exposed -SH present in its vicinity. As GSH is the most abundant thiol 
molecule in the cytosol and the mitochondria, it is the main target for Allicin reaction. 
The reaction with glutathione leads to an immediate change in the ratio GSH/GSSG. The 
increased concentration of GSSG and the depletion of GSH bring about a decrease in the 
cellular reduction potential state. Concomitantly, mitochondrial damage occurs, its 
enzymatic activity decreases and the cytochrome c is released to the cytosol. Upon its 
release, cytochrome c participates in the activation of the caspase-9, followed by 
activation of caspase-3. 
N-acetylcysteine's (NAC) primary function in vivo is to supply cysteine necessary for 
GSH synthesis and replenishment (Zafarullah et al, 2003). It can also reduce disulphide 
bonds in proteins (Ziment, 1988; Harada etal, 2004) and scavenge free radicals (Aruoma 
et ah, 1989). The direct antioxidant activity of NAC has been proposed primarily based 
on data from in vitro studies, where NAC has been shown to reduce oxidant-induced cell 
damage and cell death by apoptosis (Zafarullah et al, 2003). Results of the present study 
demonstrated that simultaneous treatment of HeLa cells with NAC and Allicin abrogated 
the antiproliferative and apoptotic activity of Allicin. Furthermore, the cell cycle arrest 
induced by Allicin at GQ/GI phase was also shown to be abolished by NAC. The results 
observed could be due to NAC's key role to provide cysteine for GSH synthesis and 
replenishment depleted by Allicin. In other words, NAC could play an important role in 
maintaining cellular redox environment destroyed by Allicin. Additionally, NAC could 
also sequester the harmful activity by competing with GSH for the reaction with Allicin. 
Previous reports have confirmed this observation that NAC could alter the 
antiproliferative and apoptotic activity of garlic organosulfur compounds, NAC has been 
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reported to eliminate the growth inhibitory effect of Allicin in human promyelocytic 
leukemia-derived HL60 cells and human myelomonocytic U937 cells (Miron et al., 
2008). DADS-induced cell cycle arrest and apoptosis in human A549 lung carcinoma 
cells has also been reported to be abrogated by pretreatment of NAC (Wu el al., 2005). 
HPV oncoproteins E6 and E7 can disturb cell cycle regulation and impede apoptosis 
through binding to tv/o tumor suppressor proteins, p53 and pRb, respectively which 
results in cellular immortalization and transformation (Munger and Howley, 2002; 
Mantovani and Banks, 2001). The p53 tumor suppressor gene is critically involved in cell 
cycle regulation, DNA repair, and programmed cell death and RB and its family regulate 
the activity of E2F transcription factors, which control transcription of various genes 
required for cell cycle progression. The HPV E6 protein binds to p53, promoting its 
degradation through the ubiquitin pathway and thus abrogates its function and E7 protein 
binds to hypophosphorylated members of RB (retinoblastoma) family, resulting in their 
destabilization and the disruption of RB-E2F repressor complexes (Ferenczy and Franco, 
2002; Gonzalez et al, 2001; Scheffner and Whitaker, 2003). 
Most striking finding of this current study is that Allicin strongly suppressed the 
expressions of HPV18 E6 and E7 oncoproteins in cervical cancer HeLa cells. This 
downregulation of E6 and E7 expressions could result in cessation of cervical cancer cell 
growth. However, the underlying mechanism of the suppression of E6 and E7 
oncoproteins of HPV by Allicin is not known and needs further extensive research. 
Furthermore, the expression of p53 tumor suppressor protein in Allicin treated HeLa cells 
was also found to be upregulated. In other words, Allicin could restore the function of 
p53 and disrupt the E6/p53 pathway which plays a vital role in cervical carcinogenesis. 
Since p53 simultaneously suppresses anti-apoptotic Bcl-2 and activates apoptotic Bax, its 
increased expression and restoration of function could also assist in programmed cell 
death induced by Allicin in cervical cancer cells. 
Monocytes play an important role in the initiation, development, and outcome of the 
immune response (van Furth, 1981; Meuret, 1981; Muller, 2001; Lee et al., 2002). 
Immune responses and inflammatory reactions mediated by monocytes are regulated not 
only positively by cellular recruitment, proliferation, and cross-talk, but also negatively 
by apoptosis of monocytes (Savill, 1997; Kiener et al, 1997). Monocytes generated in 
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the bone marrow circulate in the bloodstream for a few days, after which they are 
programmed to undergo apoptosis in the absence of specific survival signals. Several 
inflammatory cytokines, such as GM-CSF, TNF-a, and IL-ip have been reported to 
antagonize this spontaneous apoptosis of monocytes (Mangan et ah, 1992; Mangan and 
Wahl, 1991; Mangan et ai, 1991). LPS, a cell wall component of gram-negative bacteria, 
also has the potential to prevent monocytic apoptosis (Mangan et ai, 1991). On the other 
hand, several reports have demonstrated that anti-inflammatory cytokines, such as IL-4 or 
IL-10, and glucocorticoids, such as dexamethasone, promote the apoptosis of monocytes 
(Mangan et ai, 1992; Schmidt et ai, 1999; Estaquier and Ameisen, 1997). Therefore, the 
homeostasis and apoptotic processes of monocytes were regulated both positively and 
negatively by multiple stimulations, and this regulation has been postulated to play a 
pivotal role in the monocytes-related inflammatory responses. Strikingly, findings of the 
current study demonstrated that Allicin strongly induced apoptosis in monocytes of 
cervical cancer patients. Because the regulation of monocytic apoptosis has a great 
importance in the regulation of inflammation, this might be one of the mechanisms of 
AJlicin's anti-inflammatory effects. 
Previous studies have shown that several proinflammatory cytokines (IL-la, lL-6, or 
TNF-a) stimulate proliferation of carcinoma cell lines derived from several different 
tissues including cervix (Ito et ai, 1993; Wu et ai, 1993; Sugarman et al, 1986; Lewis et 
al., 1987, Wei et al, 2003). Thus, these proinflammatory cytokines might act as paracrine 
or autocrine growth factors in promoting malignant progression of cervical cancer. 
Surprisingly, results of the present study showed an augmented expression of 
proinflammatory cytokines TNF-a, IL-la and IL-6 in monocytes from cervical cancer 
patients. Furthermore, expressions of these proinflammatory cytokines in monocytes 
were shown to be suppressed by Allicin treatment. So, our above results indicated that 
suppression of proinflammatory cytokines such as TNF-a, IL-la and IL-6 by Allicin 
could alter the local microenvironment of cervical tumor leading to malignant 
progression. 
Other biological pathways that might be implicated in anticancer approaches are related 
with the immune and the inflammatory system. Since both are strongly interdependent, 
organosulfur compounds affect both of them. Accordingly, garlic contents were described 
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to possess immunomodulatory and anti-inflammatory properties, by modulating 
lipopolysaccharide (LPS)-induced cytokine levels e.g. decrease of proinflammatory 
interleukin (IL)-ip and tumor necrosis factor (TNF-a) in human blood (Keiss el al. 
2003), which resulted moreover in a reduction of the activity of the transcription factor 
NF-KB, which is strongly linked with inflammatory diseases like cancers (Aggarwal and 
Shishodia, 2004; Delhalle et al, 2004), in human embryonic kidney (HEK 293) cells, 
when exposed to the treated blood (Keiss et al, 2003). 
Anti-inflammatory effects were also observed by prevention of a radiotherapy-induced 
up-regulation of the intercellular adhesion molecuIe-1 (lCAM-1) by Allicin (Son et al, 
2006), or by a decrease of the level of cyclooxygenase-2 (COX-2), an enzyme 
responsible for the biosynthesis of prostaglandins and known to be induced in several 
cancers. The latter effect appeared to be correlated with an anti-neoplastic activity in vitro 
(Elango et al, 2004). In addition, stimulation of the immune defense (lymphocytes) by 
Allicin was demonstrated in vitro and supposed to be contributing to the compounds anti-
tumoral potency in mice (Patya et al, 2004). Furthermore, apart from interactions with 
the immune system or inflammatory processes, induction of differentiation of human 
leukemia cells (HL-60) was shown by garlic and onion oils (Seki et al, 2000). 
In summary, the above combined results of the present study established that Allicin, an 
organosulfur compound of garlic {Allium sativum), has a potent antiproliferative and 
apoptotic properties against cervical cancer HeLa cell line. Allicin-induced growth 
inhibitory action in HeLa cells involved the cell cycle arrest and apoptosis involved the 
activation of caspase-9 and -3 as well as release of cytochrome c from mitochondria, 
downregulation of antiapoptotic Bcl-2 and upregulation of apoptotic Bax and p53. 
Interestingly, Allicin also suppressed the expression of HPV E6 and E7 oncoproteins 
implicated in cervical carcinogenesis. In addition, Allicin also induced apoptosis and 
suppressed the augmented expression of inflammatory cytokines TNF-a, IL-la and lL-6 
in monocytes of cervical cancer patients. Thus, it could be concluded that in view of the 
above antiproliferative, apoptotic and anti-inflammatory properties, Allicin could be a 
promising chemotherapeutic agent in prevention of cervical cancer. 
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